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PREFACE
The National Agricultural Biotechnology Council (NABC) was established in
1988 with the following objectives:
• to represent the leadership of major, not-for-profit agricultural research
and teaching institutions,
• to provide an open forum for attendees of all points of view, to speak on,
to listen to, and to learn about major issues of agricultural biotechnology,
• to sponsor an annual meeting covering broadly based interests and key
issues, and to publish a proceedings report,
• to promote dialogue and search for options for policy makers on
agricultural biotechnology issues, and
• to produce and disseminate other documents on agricultural biotechnol-
ogy and agricultural research.
The NABC strives to identify and consider in open forum the major issues in
agricultural biotechnology. Past annual meetings have focused on sustainable
agriculture (1989), food safety and nutritional quality (1990), societal aspects
(1991), animal biotech (1992), risk (1993), the public good (1994), discovery,
access and ownership of genes (1995), novel products and new partnerships
(1996), challenged environments (1997), gene escape and pest resistance
(1998), impacts of biotech and industrial consolidation on world food security
and sustainability (1999), and the biobased economy and agricultural expan-
sion into health, energy, chemicals, and materials (2000). Thus NABC provides
all stakeholders—representatives of academia, government, industry, public-
interest groups, farming, etc.—the opportunity to come together to speak,
to listen, and to learn. Its membership includes thirty-six leading not-for-profit
agricultural research and educational institutions in the United States and
Canada.
Almost all—if not all—Americans and Canadians have consumed foods and
beverages (some of which are represented on the front cover) produced from
crops and enzymes modified by biotechnological processes. Fermentatively
produced chymosins are now used to produce 80 to 90% of cheeses, and about
one third of corn and two thirds of soybean crops in the United States have
been modified by molecular processes (“genetically modified” or GM). Accord-
ingly, in 2001 NABC’s annual meeting focused on the consumer and GM foods.
Titled High Anxiety and Biotechnology: Who’s Buying, Who’s Not, and Why?, it was
held in Chicago, May 22–24, and was hosted jointly by the University of Illinois
at Urbana-Champaign and Iowa State University. The meeting covered the
safety, ethical, marketing, and environmental issues that influence the accep-
tance of agricultural and food biotechnology by consumers. Some 220 people
registered, with the clear consensus that the meeting was a great success. A new
debating format was used for the workshop sessions that encouraged the
exchange of views; participants came away with a broader understanding of
opposition viewpoints and a heightened appreciation of subtle, perceived flaws
inherent in their own stated positions.
This report contains an overview of the 2001 meeting, a summary of the
workshop debates, and the plenary presentations. Transcripts are included of
discussion sessions that followed the presentations, and preliminary results are
presented from a survey (on information assessment) in which the participants
were invited to participate.
In 1999 and 2000, the popular media frequently published stories that
questioned the human and environmental safety of GM crops. By the end of
2001 these stories were infrequent, and were becoming neutral to favorable to
agbiotech [1]. As far as environmental aspects of biotechnology are concerned,
two sets of research studies published in 2001 should help to allay the fears of
many. Crawley et al. [2] reported a long-term study of four transgenic crops—
oilseed rape, corn, sugar beet, and potato, modified for insect and herbicide
resistance—grown in twelve different natural habitats for ten years. All popula-
tions of rape, corn, and sugar beet were extinct at all sites within four years of
sowing; potato survived at one site for ten years, but none of the survivors was
genetically modified. In the second set of studies [3–5] pollen from corn engi-
neered for insect resistance with genes from the bacterium Bacillus thuringiensis
(Bt) was found to have negligible effects on the larvae of monarch butterflies.
(The only transgenic corn pollen that consistently affected the larvae was from
Cry1Ab event 176 hybrids that, during the 2001 season, accounted for <2% of
corn planted. These hybrids are being withdrawn from sale.)
A Congressional Briefing was held in the Russell Senate Building, Washing-
ton, DC, on April 20, 2001. Michael J. Burke, NABC Chair, William F. Brown
(University of Florida), and Ralph W.F. Hardy described the results and implica-
tions of NABC’s twelfth annual meeting, organized by the University of Florida
and held in Orlando in May 2000. Copies of NABC Report 12, The Biobased
Economy of the Twenty-First Century: Agriculture Expanding into Health, Energy,
Chemicals, and Materials were distributed. A similar Congressional Briefing
is planned—at which this volume will be disseminated—to share the outcomes
from High Anxiety and Biotechnology: Who’s Buying, Who’s Not, and Why?.
The 2002 NABC annual meeting will be hosted by the University of
Minnesota, St. Paul, MN, titled Foods For Health: Potential, Perspectives,
and Policy. It will be held May 19–21 at the Radisson Hotel Metrodome
(www.coafes.umn.edu/nabc2002). Participants will have the opportunity for
discourse and debate on current and future aspects of the marriage of agricul-
ture and medicine, and the potential for agricultural science and technology to
directly benefit human health beyond the realms of food, feed, and fiber.
Allan Eaglesham Steven G. Pueppke Ralph W.F. Hardy
NABC Executive Director Associate Dean for Research, NABC President
University of Illinois
at Urbana-Champaign
[1] Editorial (2001) Genetically modified maize is not that bad for monarchs.
The Economist September 65.
[2] Crawley MJ et al. (2001) Transgenic crops in natural habitats. Nature 409
682–683.
[3] Hellmich RL et al. (2001) Monarch larvae sensitivity to Bacillus
thuringiensis-purified proteins and pollen. Proceedings of the National
Academy of Sciences 98 11925–11930.
[4] Stanley-Horn DE et al. (2001) Assessing the impact of Cry1Ab-expressing
corn pollen on monarch butterfly larvae in field studies. Proceedings of
the National Academy of Sciences 98 11931–11936.
[5] Sears MK et al. (2001) Impact of Bt corn pollen on monarch butterfly
populations: A risk assessment. Proceedings of the National Academy of
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High Anxiety and Biotechnology:
Who’s Buying, Who’s Not, and Why?—
An Overview
STEVEN G. PUEPPKE
University of Illinois
Urbana, IL
The topic of NABC’s annual meeting, held in Chicago on May 22–24, 2001, was
“High Anxiety and Biotechnology: Who’s Buying, Who’s Not, and Why?” The
organizers had some anxiety of their own when they realized that the meeting
was a likely target for anti-GMO protestors, and these groups did appear on the
first day of the conference. But all was peaceful, and the street theater even did
us a favor by attracting the media. NABC 2001 participants provided several
media interviews, which were broadcast both locally and on an agricultural
television network.
The meeting used an optical metaphor to represent the divergent viewpoints
of participants in the public GMO debate. Each plenary session examined the
subject as focused through a different kind of lens. This centered the GMO
debate on the context of its participants and emphasized that not all judge the
issue from a single vantage point.
LESSONS TO LEARN FROM
Five plenary speakers set the stage and established perspective for the meeting.
Michael Jacobson from the Center for Science in the Public Interest, pointed
out the potential benefits of agricultural biotechnology, not just for farmers, but
also for consumers and the environment. He reminded the audience that public
outcry has brought biotechnology to a crossroads, and he cautioned against
extreme views on either side. Those who claim that all applications of
agricultural biotechnology are bad fall into one kind of trap, but those who
assert that biotechnology will provide all the answers fall into another. Jacobson
believes that objective parties, including universities and state and federal
agencies, ought to be doing more research on behalf of agricultural producers.
Napoleon Juanillo from the University of Illinois pointed out gaps between
the way that scientists tell their story and the expectations of the public.
Researchers avoid eloquence and speak plainly. They are cautious, hesitant to
extrapolate, and generally unprepared to deliver sound bites. Increasingly,
though, the public is interested in the subjective and in nuance. Is agricultural
biotechnology moral? Is it fair, or does it exploit? Does it cause society to lose
control? People expect these issues to be addressed, and it is especially difficult
for scientists to do so.
We heard about pasteurization as a case study in new technology and the
complications that surround technological change. Joseph Hotchkiss from
Cornell University surprised many in the audience by reminding us that the
technology of heating milk to kill bacteria—a benign process by today’s
standards—was vigorously resisted in the late nineteenth and early twentieth
centuries. As a consequence, infant mortality remained high for decades after
the invention of a process to make milk safe. This historical lesson was
sobering, especially to those who view biotechnology as an important tool to
combat world hunger.
Nancy Millis from the University of Melbourne challenged participants with
a thoughtful analysis of risk and its management. Who decides which risks are
acceptable and which are not? She reminded us that scientists were allowed to
make these decisions in the past, but that society now demands a voice in the
process. One of her key take-home messages is that perceptions of hazard must
be taken seriously. Australia’s experience with GM crops provided several
examples of governmental activities to inform both growers and the general
public.
C. S. Prakash from Tuskegee University told the story of agricultural
biotechnology and its historical roots. The continuum of agricultural
improvements over the centuries—beginning with simple selection and now
involving biotechnology—represents a success story and a source of pride for
many in the audience. But it is difficult for the public to appreciate either the
historical context or the future potential for agricultural biotechnology. Instead,
people want the unattainable: zero risk. Consumer perception of risk with foods
is no different from that with any other kind of change, but this fact is small
comfort for those seeking to educate the general public.
INFLUENCING THE CONSUMER LENS
Session II helped us to understand how consumer attitudes can be influenced.
Kerry Smith from North Carolina State University provided lessons on the basis
of his experience with health risks. One of these, radon gas, can seep into home
basements and represents an involuntary risk. If local governments want people
to monitor for this gas, impersonal campaigns with notices and posters are
ineffective. But as soon as community leaders become involved in educational
efforts, citizens begin to respond. The message for biotechnology: Continuous,
personalized involvement can make a difference. Efforts to educate on the
hazards of smoking provide another perspective: Be honest, build trust, and be
aware of the fact that people become very concerned when the results of the
choices they make are irreversible.
Mark Sagoff from the University of Maryland showed us evidence that food
processors deliberately and broadly offer food as fantasy, with liberal use of
natural in advertising. This was an important message to those who sometimes
feel that consumers are conditioned to fantasize only about the products of
biotechnology. Sagoff convulsed the audience with colorful Shakespearean
imagery of the concept of natural.
DIVERGENT LENSES OF STAKEHOLDERS
The most all-encompassing session emphasized the rich diversity of partici-
pants in the agricultural biotechnology debate. Dave Erickson, a northwest
Illinois farmer, gave us a poignant first-person account of agricultural
biotechnology from the viewpoint of a midwestern producer of corn and
soybean. This perspective is often overlooked by consumers and by those
interested in trade and public policy. To farmers, though, biotechnology is
primarily a management tool that will be accepted if it makes economic sense.
Anatole Krattiger from bioDevelopments LLC considered the potential for
biotechnology to solve problems in the developing world, but with several
unique perspectives on globalization. One is the sheer speed with which the
technology has been advanced by the private sector and adopted in the
developed world. This has caught scientists off guard and mystified some of
those interested in improving the human situation. Application of agricultural
biotechnology to the developing world has challenged our concepts of
intellectual property and the perceived role of public research establishments
dedicated to fighting hunger. Krattiger advocates a novel “privic” approach that
involves both the private and public sectors.
Tony Van der haegen’s after-dinner keynote address offered a view from the
European Union, one that underscored the importance of food safety to
European consumers who enjoy abundant food supplies and thus the luxury to
make food choices. We were reminded that Americans must understand the
psychological undercurrents to the debate in Europe. Europeans are more
cautious about new technology and the influence of large corporations. And,
unlike Americans, they have recently experienced food and health scandals
involving mad cow disease and tainted blood supplies that have eroded trust in
scientists and regulators. Lack of understanding between the United States and
Europe has already disrupted trade. Ongoing thorny debates about regulatory
approval and labeling are not likely to be settled in the near future. However,
Van der haegen projected that Europe will eventually accept biotechnology-
based foods.
Dirk-Arie Toet from Nestlé gave us a personalized and industry view from the
European standpoint. Although Americans often view the European situation
pessimistically, Toet pointed out that politicians are again speaking publicly
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about biotechnology. He summarized plans for a new European framework for
discussions, particularly as they apply to tracing and labeling.
Gary Comstock from Iowa State University, who sometimes used audience
members as examples in thought games, helped us to organize our ethical
thoughts about agricultural biotechnology. The audience learned to distinguish
factual assertions from value-laden, normative assertions—and extrinsic
objections to the introduction of biotechnology from intrinsic objections that
the process itself is in some way harmful.
Susan Harlander from BIOrational Consultants was unable to attend the
meeting. Bruce Chassy from the University of Illinois summarized her
perspective from the standpoint of the food industry. On the one hand, the
United States Food and Drug Administration considers GM crops to be
“substantially equivalent” to their traditional counterparts. This means that
they can be managed simply as commodities in this country. On the other hand,
various sorts of labeling are required in many other countries, and so food
companies doing business worldwide must comply with various sorts of
regulations. Consequently, food companies have removed GM ingredients in
countries with mandatory labeling requirements. These conflicts have led to
turmoil in the marketplace. Harlander pleads for harmonization of the
regulatory process across international boundaries.
At the final lunch-time session, Stanley Abramson from Arent Fox Kintner
Plotkin & Kahn, PLLC, in Washington, DC, shared his recommendations for
improving product stewardship and federal regulations.
FINAL REMARKS
NABC 2001 was not just about plenary sessions. As a prelude to the traditional
annual conference workshops, we were treated to a rollicking great debate that
was moderated by NABC President Ralph Hardy. Featured were two unnamed
members of the organizing committee. One was in white lab coat, scrolling
really bad slides and pontificating about technology. The other, who was deeply
buried under a fright wig, took the role of protestor. The dialogue ran its
expected course and ended with hotel security “escorting” the activist from
the room.
Tom Hoban’s “Hot Topics and Hot Hors D’Oeuvres” provided another change
of pace. Tom shared some of his research data on consumer perceptions of
biotechnology and then invited meeting participants to comment. The
atmosphere was informal and cozy, the subject matter was challenging, and the
wine and food worked their magic. This session ended, not when Tom sat
down, but when the hotel staff turned off the lights.
“High Anxiety,” which attracted more than 200 scientists and leaders in the
agricultural and food arenas, was organized by the University of Illinois and
Iowa State University. The annual NABC meeting always attracts a diversity of
speakers and speaking styles, but rarely have the participants had so much fun,
mixing laughter with challenging thoughts on agricultural biotechnology.
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The Great Agricultural Biotechnology
Debates: Outcomes from the Workshops
MARY ANN LILA SMITH
University of Illinois,
Urbana, IL
COLIN SCANES
Iowa State University,
Ames, IA
In order to thoroughly examine the conflicting issues and arguments that
fuel controversies about agricultural biotechnology in the food system, the
workshop sessions were constructed in a modified “debate” format. The
overriding intent was to ensure that the workshops were not just cerebral
exercises, but would result in strong connections among participants, and
thought-provoking, useful take-home outcomes. The debates were engineered
in order to:
• engage conference participants as active players in a deliberately fast-paced
process of discovery, and
• compel conference participants to critically and thoroughly evaluate rival
viewpoints.
Accordingly, upon entering the workshop-breakout rooms, participants were
assigned to a particular framework position, and were called upon to rapidly
absorb, adopt, and rigorously defend a stance perhaps contrary to their own
deeply ingrained beliefs.
The topic resolution for the debates was: Be it resolved: that GM technology is
a sound and safe innovation, and should be permitted in the food chain without
restrictions. Up until this point in the conference, attendees had heard a variety
of viewpoints on the issues. Now, they were required to actively advocate and
defend a particular position in multi-dimensional arguments that closely
paralleled those currently ongoing internationally in the media, and even on
the streets in front of the conference venue.
Because so many of the opposing pro and con arguments about GM food
crops are at cross-purposes, debate participants found that irrefutable
arguments and decisive winners were not easy to identify. Although relatively
well versed in the issues, frequently they scrambled to counter opinions voiced
by the opposing team, and realized that some lines of reasoning, especially
those with emotional undertones, were difficult to refute. Therefore, it is not
surprising that the general public has a difficult time sorting out the facts
surrounding GM issues.
The Great Debate workshop format promoted productive, concentrated
interaction, and facilitated appreciation for diverse perspectives. The scenario
presented here may be adapted for use in classrooms or other assemblies to
foster intensive exchange of viewpoints.
THE SET-UP
The debate-format workshops were prefaced by presentation of a mock debate
(Appendix I, page 229), which introduced the conferees to the extremes of
viewpoints both from the pro-GM and from the anti-GM camps. The moderator
introduced the resolution, and the mock debate followed with arguments from
a land grant university professor, an advocate of GM technology, that were
countered by a European prince/gentleman organic farmer strongly opposed to
genetic engineering, followed by arguments from a pro-biotechnology industry
representative countered by an anti-biotechnology radical protestor from a
consumer advocacy group.
Although deliberately exaggerated in tone and content, the mock debate
introduced the rules of engagement for the workshops to come, and provided
a preview of the typical point/counterpoint order of argumentation in
traditional debates.
Next, the conferees were divided into four workshop-breakout sessions
(twenty-five to thirty participants per group). At least two trained debate
coaches staffed each breakout session.
Once participants entered a breakout room, they were asked to count, in
turn, one through six. All who had called out number one were asked to form a
group in one corner of the room, all those who called number two assembled in
another part of the room, etc. Via this procedure, the attendees were arbitrarily
divided into teams, the composition of each likely represented a broad
spectrum of viewpoints. This process occurred simultaneously in each of the
four breakout session rooms, with four to six teams assembled in each room.
Debate coaches then assigned each team one of the following identities:
• pro-GM university scientists
• anti-GM militant environmental “green” group (anti-multinational
companies)
• pro-GM large corporate US/multinational biotechnology company
representatives
• anti-GM consumer advocate group in the European Community
• pro-GM farmers in the developing world
• anti-GM organic farmers in the US
• pro-GM US regulatory agency
• anti-GM government regulatory agency (non-US)
• pro-GM politician (you pick the country)
• anti-GM politician (you pick the country)
Individual group members did not have the opportunity to select a preferred
position on the GM issue.
Each team selected a captain, who usually served also as recorder. During the
remainder of this session, each team identified a ‘top-ten’ list of arguments in
favor (or opposed, depending on their assigned identity) to the stated debate
resolution, Be it resolved: that GM technology is a sound and safe innovation,
and should be permitted in the food chain without restrictions.
Because participants were randomly assigned to possibly unfamiliar
positions, the debate organizers had collected a broad selection of written
position papers and other statements that were displayed in each breakout
session room. A table was laid out with an eclectic selection of actual current
literature materials including Website position statements from consumer
activist groups, white-paper statements from pro-GM authorities, industry
public relations statements, newspaper stories on GM issues, political
statements, etc. Team members were encouraged to peruse this array of pro and
con arguments surrounding the GM controversy as they assembled arguments
to support their positions. Teams were allotted only 15 minutes to compile their
top ten lists, and the debate coaches offered assistance and encouragement to
any teams that were floundering for ideas. With only a brief period of time to
formulate arguments, intensive, cooperative effort was necessary, thus building
camaraderie.
Each team captain listed the top-ten arguments (in abbreviated outline form)
on large buff sheets posted on the walls. The captains explained the items to the
broader audience; discussion ensued and suggestions of potentially stronger
arguments were entertained.
For the remaining 10 to 15 minutes of this first session, each pro-GM team
exchanged their top-ten list with their counterpart anti-GM team, and vice
versa. The teams reconvened to develop counterpoint arguments to refute their
opponents’ arguments. The coaches collected all of the pro and con and rebuttal
arguments, and held them until the afternoon workshop sessions.
THE DEBATES
The second workshop-breakout session was initiated by having the coaches
quiz the participants about which positions had seemed most difficult to defend
or rebut during the morning session. This brief discussion session helped to
prepare the teams for the debate scenario.
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Each team designated two spokespersons, and abbreviated debates were
staged between the pro and con teams. Teams were introduced to the following
‘Rules of Debate,’ which were posted on large buff paper sheets to facilitate
order during the debate exercise:
1. First pro-GM constructive speech: affirm the resolution, explain the
position, and provide a plan for adopting and embracing GM in the food
system. (3 min)
2. Cross-examination by the first anti-GM spokesperson (Q&A): attempt to
refute the arguments of the first speaker, and show the audience that you
are a truth seeker. (2 min)
3. First anti-GM constructive speech and rebuttal: turn the tide in favor of
your position by explaining why the plan of the pro side would be
disastrous, and/or offer an alternative plan. (3 min)
4. Cross-examination by the first pro-GM spokesperson. (2 min)
5. Second pro-GM constructive speech and rebuttal. (3 min)
6. Cross-examination by the second anti-GM spokesperson. (2 min)
7. Second anti-GM constructive speech and rebuttal. (3 min)
8. Cross-examination by the second pro-GM spokesperson. (2 min)
At least two debates (four teams) were conducted in each session, at the
finish of which the audience voted on which side “won,” and arguments that
were perceived as “turning points” were discussed. Pitfalls that inhibited
serious resolution of opposing viewpoints were documented. Cases where the
arguments did not seem to address the same points also were noted.
THE OUTCOMES
By general consensus, the debates were thought-provoking and productive,
because the debate teams put concerted effort into preparing and delivering
strong and persuasive arguments. Team spokespersons, even those assigned to
positions contrary to their own opinions, provided well constructed, impas-
sioned short speeches. Rebuttals were made with little hesitation, again even
when the participants were playing roles diametrically opposed to personal
convictions. Clearly, the participants were well informed about biotech issues.
Since the workshops were strictly timed, the participants were thrust into the
task of actively defending their assigned positions and quickly formulating the
strongest possible arguments. In most scenarios, within a team of five or six
participants, only one or two were elected to provide the formal speeches and
rebuttals during the debates. In other cases, all team members were free to ask
questions during cross-examination, which amplified the scrutiny of, and the
challenge for, the representative speaker in opposition.
As the debates progressed, the intensity of the arguments escalated. When a
designated team spokesperson had the chance to refute an argument voiced by
the opposition, (s)he frequently did so with passion. This competitive spirit
often engendered the development of stronger counter-arguments. Nuances and
hidden perspectives behind each position were brought to light. Participants
reported that they came away with new appreciation for the wealth of
information and complexity behind opposition viewpoints, which, in some
cases, they had previously viewed as one-dimensional.
A synopsis of primary arguments and position statements from the pro and
con camps is provided below.
The coaches agreed that the presentations staged in their breakout sessions
provided mixes of opinions on GM products in the marketplace that spanned
the range from rational to irrational. One coach commented, “Our role
diminished the moment the groups understood the task in hand. They jumped
right into it, and came up with good arguments for their positions; every
individual on each team threw in ideas and perspectives, so we had an excellent
mix of people who were not afraid to participate.”
What were the hardest points to refute? Participants found it difficult to
defend their stance against ‘the moral high ground’ of a zealous opponent.
Interestingly, this particular strategy was used on both sides of the issue. While
it was frequently argued that GM technology is “immoral, unethical, and
against nature to cross species barriers,” others contended that it is “immoral
and unethical” to deny the benefits of GM crop improvements to impoverished
farmers or undernourished children in a global context, or to fail to embrace
the opportunity for reduced pesticide exposure, or decreased environmental
impact.
Another coach commented that some of the participants were “sobered” by
the fact that they were most swayed by the con arguments. In fact, most of the
coaches acknowledged that many of the arguments, pro and con, were most
difficult to refute when based on fears and emotional issues: “It is relatively
easy to create a fear and more difficult to allay one, because of the complexity of
the subject matter.” One coach noted that he was not sure there were any clear
winners in his breakout session, which illustrated that “gray is the color of
choice for biotechnology and food.”
Participants came away with new appreciation for the
wealth of information and complexity behind opposition
viewpoints, which, in some cases, they had previously
viewed as one-dimensional.
Smith and Scanes
Coaches observed that a few debaters “did not always play it straight.” There
were cases where “fallacious arguments, including begging the question,
creating a straw man, argumentum ad hominem, and emotional appeals” were
substituted for substantive factual materials. In a couple of instances, debate
teams spent more time on form (disruptive behavior) than on content. For
example, a spokesmen for an ‘environmental advocacy group’ noted that his
opposing spokesman had ridiculed his position and failed to take him
seriously—an observation with which the other participants concurred.
In summary, some of the most difficult issues to resolve concerned the
approval/regulatory process, labeling, and, as noted previously, moral and
ethical issues.
Approval/regulatory process Based on available data, teams were unable to verify
to what extent GMOs are required to undergo regulatory approval in the United
States. Pro-biotech literature emphasizes that GM is perhaps the most highly
scrutinized technology in recent history. The European press argues that the
approval process in the United States is shrouded in mystery, and the
interconnections among the three major regulatory agencies (the Environmen-
tal Protection Agency, Food and Drug Administration, and United States
Department of Agriculture) are unclear and without transparency. Further,
there was a perception that safety data on which approvals are based may have
been compiled by industry and held by private companies.
Labeling Neither side of the issue was able to address to what extent labeling
policy is consistent with United States law, practice, or longstanding guidelines.
Opponents argued that labeling policy in the United States is out of synchrony
with those of the rest of the world, e.g., the EU views labeling as the first step as
a matter of policy. The apparent contradiction was noted with regard to
“substantial equivalence ” of a GM product on one hand and the ability to
patent it on the other.
Moral and ethical issues Religious and moral beliefs were among the most
strongly held, but proponents and detractors were repeatedly chastised when
they “tried to impose their views on everyone else.” Opponents should not be
forced to consume GM products, whereas advocates should not attempt to force
the world to accept the technology without choice. When an opposition team
debater claimed, “I’m scared! I want to know my risks!”, the fears could not be
alleviated with data, statistics, or probabilities.
Pro-GM scientists were faced with the challenge of credibility: “Why should
we trust you? Originally you told us that DDT was safe.” Anti-GM teams found
it difficult to counter accusations of being “against progress” and “against free
enterprise.” These arguments implied that the precautionary position is
shortsighted, especially when challenged with illustrations of past fears over
pasteurization, microwave ovens, and vaccination. An agreeable compromise
between caution and progress was not easy to reach.
Interestingly, the participants saw clear parallels between their GM debates,
and emotion-charged disputes over unrelated issues such as Creationism vs.
Evolution. It was especially clear that science-based opinions were frequently
insufficient against ideological arguments or moral/emotional concerns. One
spokesperson, an industry representative from the private sector, had endured
the “pesticide wars” in the seventies; he felt that those years were worse in
terms of being in an uncomfortable position and representing an industry that
was constantly attacked.
TAKE-HOME MESSAGE
What was the take-home message of the Great Debate workshop sessions? In
order to be effective advocates for what we believe in, in order to readily defend
our position, it is essential that we thoroughly appreciate all the nuances and
complexities of the contrary view. The participants came away with a broader
understanding of opposition viewpoints and a broadened appreciation of subtle,
perceived flaws inherent in their own stated positions.
A compilation of pro and con arguments voiced in the role-playing debates in
response to the resolution is presented below. Similar or linked arguments are
grouped under subject categories.
Many of these points were made in the heat of open discussion and are not
necessarily factual. Their inclusion here should not be interpreted as an
endorsement by the NABC.
Religious and moral beliefs were among the most strongly
held, but proponents and detractors were repeatedly
chastised when they “tried to impose their views on
everyone else.”
In order to be effective advocates for what we believe in, in
order to readily defend our position, it is essential that we
thoroughly appreciate all the nuances and complexities of
the contrary view.
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• GM products are embraced by
farmers because of benefits, i.e.,
increased efficiency, increased
yields, decreased pesticide costs,
improved quality of commodities.
• Biotechnology can be used to
produce food on marginal land, i.e.,
dry areas, saline and acid soils; this
is particularly important for
developing countries.
• What aspect of quality has been
improved for the consumer? It
seems that only farmers and
producers are benefiting.
• So far, there have been no consumer
benefits despite a lot of talk; all
benefits are to US producers
• Excess food is already produced in
the US and EU. Land that is
marginal should not be used.
• Growing GM crops means environ-
mentally friendly reduction in
pesticide usage on the farm.
• Less impact on the environment,
e.g., less tillage required, less
contamination of groundwater, less
erosion of soil.
• Reduced off-target drift = better
relations with neighbors.
• Extensive evaluation of Bt corn does
not support initial findings of
adverse impact on monarch
butterflies.
• Less exposure to pesticides,
– benefits medical system,
– better water quality.
• Lessens negative impact on
beneficial insects.
• GM crops may induce pesticide
resistance in insects, which means
we will need all the pesticides
anyway.
• Monarch butterflies illustrate a
definite negative environmental
impact.
• GM crops increase genetic diversity/
biodiversity.
• GM crops may decrease biodiversity.
• Stronger drive towards monoculture.
Environmental Concerns
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
• The GM process is precise—known
genes and proteins.
• Pollen-flow issue is being addressed
to ensure pollen will not be able to
reproduce. Organic growers may
need to develop their own seed
sources and testing procedures.
• Data show reductions in use of
environmental toxins.
• Reduced energy (petrochemical)
use.
• GM crops contaminate organic
agriculture.
• Organic farmers lose certification
because of pollen drift.
• No data are available showing
environmental impacts.
• Environmental pollution—
superweeds, salmon, toxins.
• Genes used are already present in
the environment.
• New GM crops are being developed
to prevent pollen drift / gene flow.
• Ecological concerns—gene transfer
damage to wild species.
• Gene drifting.
• Agribusiness is best equipped to
scale-up research and development.
• No other agricultural processes
(e.g. the method of slaughtering
animals) are labeled and neither
should this process.
• Consumer choice must be
preserved (GM ingredients should
be labeled, traceable).
• There is a danger of induced
resistance in pests (threat to organic
farming).
• GM crops will lead to fundamental
restructuring of global agriculture.
• GM crops can produce food on
marginal lands (dry regions, saline
and acid soils).
• Marginal lands should not be
exploited.
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Environmental Concerns (continued)
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
US Regulations/Trust in Government
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
• The process is as safe or safer than
conventional crop improvement.
• GM foods are scrutinized more
rigorously than conventional foods.
• GM technology has earned third-
party endorsements (AMA, NAS,
FDA, USDA, etc.).
• Has there been enough testing?
Where is the scientific literature?
Where is the third-party testing?
• A neutral third party should do
the testing.
• If a product is substantially
equivalent, labeling has no point.
To give total information on a label
would be both confusing and
counterproductive.
• Labeling should be mandatory.
What is being hidden by com-
panies who are reluctant to label?
• The concept of substantial
equivalence is inappropriate since
GMOs by definition are not
equivalent.
• Farmers are adversely affected by
any requirement to segregate a
crop—such would be an ill-advised
regulation.
• Legal liability is of great concern.
• Safeguards are already in place to
protect the environment and the
consumer through the legal system.
• GM is proven by 13+ years of
testing.
• US consumers do not want further
regulations and restrictions.
• There has been equivalent or greater
testing than for non-GM food.
• Government has misinformed us in
the past: mad cow and hoof and
mouth diseases in Europe. Pre-
market review has been voluntary
only, not mandatory.
• Segregate GM from other crops.
• Poor public health history.
• If the current approval system is
supposedly effective, what
happened with StarLink™?
• Testing of all commodities should
be required (and defined by law).
• There have been no public-health
issues to date.
• Extensive testing and regulation is
done, even more than for most non-
GM food products.
• Vertical integration is an on-going
economic process regardless of the
science.
• USDA requirements are adhered to.
• Trace-back-to-origin systems should
be set in place.
• Post-market surveillance should be
required.
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
Health and Safety
• Human health will be improved due
to lower incidence and levels of
toxins (including aflatoxins),
carcinogens, and allergens
• Bt proteins are toxic to insects;
how do we know that there
will be no long-term effects on
humans?
• How do we know that there will be
no changes that will elevate
production of toxins?
• Dr. Pusztai’s interpretations of data
were found to be faulty by a review
panel.
• GM is far more precise than
conventional breeding and
selection.
• Pharmaceuticals produced by GM
methods are well accepted—why
not food?
• Higher quality, “cleaner,” more
uniform products; nutritional
benefits.
• Known allergens are not used.
• Antibiotic markers are no longer
used in GMO development.
• GM with breeding will increase
nutritional quality of food.
• The Brazil-nut/soybean episode
shows that industry takes the
responsible self-regulating course
when required.
• Arpad Pusztai’s potato-feeding
experiment shows how dangerous
GM is.
• Mark Lappe’s soybean analysis
paper shows GMOs have lower
isoflavone content.
• We have co-evolved with our food
supply and GMOs introduce
unnatural new proteins.
• Antibiotic resistance markers may
transform our cells or those of gut
bacteria.
• StarLink™ proves we cannot
regulate these things.
• We have no way of telling what will
be an allergen.
• The Brazil-nut protein in soybeans
proves how dangerous the
technology can be.
• We cannot anticipate new health
hazards that could arise from these
unknown crops.
• Safety is uncertain, especially long
term.
• GM benefits the American
consumer. Without it we could
not get out-of-season produce.
Free-trade channels are
desirable.
• Producers/farmers have an
improved quality of life/efficiency.
• Threatens the way of life of small-
farm communities.
• Poor public health history (mad
cow, hoof and mouth diseases in
Europe).
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Research Issues
• Biotech offers more control of the
product and its consequences.
• There is an exact characterization of
inserted genes.
• Safety has been tested and proven.
• Pleiotropic effects are tested in the
laboratory and in field trials over
5–7 years.
• This is a new technology and we are
dealing with living organisms.
There may be unforeseen
consequences. Science has not
always been right, e.g. mad cow
disease.
• Not enough research has been
conducted.
• There have been no long-term
studies.
• Delaying science will result in
reduced capacity to meet future
challenges.
• Pesticide resistance may build up
over time.
• No fixed protocols have been
established.
• There have been no studies in
humans.
• GM is the quickest way to add
value.
• Academia was doing this research
long before the large corporations
had a profit stake. Corporate
funding is necessary to finance
university research.
• Corporate research information has
not been available to the public.
• Corporate profit trumps public
health.
• Biotech companies exert undue
influence in setting public research
agenda.
• Data favoring biotech products have
been produced by industry, not by
unbiased scientists.
• Data are not published in peer-
reviewed journals; data are limited
or lack substance; peer-review is
biased; scientists are untrustworthy
(especially in industry).
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
• In the long term, more food can be
produced from a relatively constant
area of arable land to feed an
increasing population.
• The potential exists for a major
contribution to alleviating world
hunger. We cannot take the risk
of not developing this technology.
The impact has been small so far;
products to decrease world hunger
are still being developed.
• Food choice is plentiful in the US
and Europe, but not in many other
parts of world, and biotech can
help.
• Most critics of GM are well fed, as
are their children; they may feel
differently if hungry, as are many in
developing nations.
• GM is not needed to “feed the
world.” Why not control popula-
tion? There is no clear-cut evidence
of increased yields with GM crops.
• Currently there is a global excess of
food—the issue is one of distribu-
tion—golden rice is not an answer
to world health / hunger.
Moral and Ethical Issues
• Hybrids and past and current
farming practices have for years
been based on manipulating Mother
Nature.
• GM is against God and nature; a
perversion of Mother Nature.
• GM is immoral.
• Given the benefits of biotechnology
it would be criminal not to progress
and bring its advantages to our
world.
• A moratorium should be estab-
lished.
• The precautionary principle should
be followed; do not approve until
certain.
• Religious and moral convictions
should not be imposed.
• Religious and moral issues must be
addressed.
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
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• Intellectual property rights and
protection provides more incentive
to enable products to be brought to
market.
General Considerations
• Corporate power is driving the
technology.
• Terminator + Developing World
damage from multinationals.
• Domination / control by multina-
tionals.
• Profit-driven research funding.
• Industry is buying credibility.
• Focus is share holders, profits.
• Industry donates only unprofitable
technologies.
• Public pressure is forcing
transparency.
• Industry is selectively transparent—
GM-producing companies do not
want us to know they make
pesticides.
• Biotech a conspiracy—ecompassing
large companies and government
agencies
• GM will benefit small-farm
communities.
• Ordinary farmers do not see
advantage; benefits accrue only to
corporations.
• Potential liability for farmers.
• Threatens small-farm communities.
• Hurts small family farms; local
production is important—eat
locally, shop daily.
• GM contributes to medical,
industrial and environmental
advances.
• Unforeseeable risk: plant it, cannot
sell it.
• Intellectual property issues—
patenting life is wrong.
• Decreased cultural / local identity.
• GMOs are not needed.
• Farmers will become serfs to large
corporations.
Arguments in Favor of the Resolution
(pro-GM)
Arguments Opposed to the Resolution
(anti-GM)
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I am grateful for the opportunity to participate in this important meeting. It
comes at a time of great controversy over biotechnology, and I hope that the
audience and speakers can identify some areas of agreement.
For those of you who are not familiar with the Center for Science in the
Public Interest, it is a nonprofit consumer-advocacy organization that, since
1971, has focused on food safety and nutrition. Our activities have touched
most Americans lives, because in 1990 we led the efforts to win passage of laws
mandating the Nutrition Facts food label and a federal definition of “organically
grown” foods. We are supported largely by the 850,000 subscribers to our
Nutrition Action Healthletter, along with foundation grants. We do not accept
funding from government or industry.
Though CSPI sometimes has been accused of being anti-everything in the
world of food, from fettucine Alfredo to olestra to McDonald’s french fries, we
have a decidedly middle position on genetically engineered foods. We believe
that, if used properly, engineered crops could greatly benefit farmers,
consumers, and the environment. They hold the promise of increased yields,
reduced use of pesticides, lower costs, and better nutrition. Indeed, some of
those benefits already have been partly realized. But, if misused, biotech foods
could cause great harm.
Biotechnology is reaching a crossroads, where public opposition may become
so great that no farmer, food manufacturer, or retailer will want to market a
food with biotech ingredients. The biotech industry, by and large, has insisted
that genetically engineered foods are sufficiently regulated and perfectly safe.
That posture simply is not flying in the age of StarLink™ corn, mad cow
disease, and the Internet.
Critics are generating many questions about biotechnology, ranging from
accusations of potential health and ecological catastrophes to monopolization
of the seed industry by a few companies. Currently, genetically engineered
crops benefit primarily the seed and chemical companies and farmers, not
consumers. When benefits are enjoyed by one party, but possible risks are
borne by another, it is a formula for suspicion. In such an environment, it
behooves those who hope to realize the potential benefits of biotechnology to
address valid concerns, debunk red herrings, and build long-term public
confidence. One key step would be to establish strict rules to protect the
environment and ensure safety and choice to consumers.
Before I address the concerns, let me emphasize that farmers, the environ-
ment, and environmentalists should draw some measure of satisfaction from
existing benefits of genetically engineered crops and the absence of known
health and environmental problems.
• The widespread use of Bt cotton has dramatically reduced the use of
organophosphate pesticides. According to the National Center for Food
and Agriculture Policy, Bt cotton in 1999 resulted in 2.7 million pounds
less use of chemical insecticides and 15 million fewer applications of
insecticides. Cotton production increased by 260 million pounds per year,
and net revenues increased by an estimated $99 million. That is a
tremendous boon to farmers and presumably to non-target species,
including insects and the birds and other organisms that feed on them.
• Herbicide-tolerant soybeans reduced weed-control costs by $216 million in
1999, and reduced herbicide applications by 19 million. Although biotech
soybeans have led to a great increase in the use of glyphosate herbicides,
those herbicides appear to be much safer than some that they replace. No-
till farming, which herbicide-tolerant crops encourage, should reduce soil
erosion.
• Bt corn saved an estimated 66 million bushels of corn from European corn
borer in 1999. Also, Bt corn should have lower levels both of insect
damage and of some mycotoxins.
• Genetically engineered papayas provide Hawaiian farmers an effective new
means of coping with the papaya ringspot virus, which has been
decimating crops.
Bt cotton in 1999 resulted in 2.7 million pounds less
use of chemical insecticides and 15 million fewer
applications of insecticides.
Other crops could be providing similar benefits:
• Bt sweet corn and potatoes could dramatically reduce insecticide use.
• Apples resistant to fire-blight bacteria could benefit farmers in the
Northeast.
• Herbicide-tolerant sugar beets could reduce soil erosion.
However, farmers and processors are unwilling to plant or accept those crops
for fear of consumer backlash.
SAFETY CONCERNS
From the point of view of the consumer, the key question about biotech foods is,
“Are they safe?” Many consumers are leery because they do not know what
biotech foods are, and the term “genetically modified” sounds scary.
To date, of course, biotech foods have not caused any known health problems
whatsoever. Though still in its infancy, biotechnology’s record of safety is
reassuring. To be honest, though, it probably would be impossible to identify
many long-term problems, such as immunotoxicity, carcinogenicity, or
neurotoxicity, with current testing procedures.
One of the obvious concerns is whether engineered foods might cause
allergic reactions. Known allergens are easy to identify. However, if a protein to
which people have had only limited exposure were introduced into foods, one
could not state definitively that it would not cause any allergic reactions.
Another concern is that levels of naturally occurring toxins in plants might
be increased. Again, known toxins are easy to assay. But it is not inconceivable
that a genetically engineered food would display a novel toxicity, such as by
activating a “silent” gene or unexpectedly altering a metabolic pathway. Finally,
some scientists have speculated that there is a very small risk that transgenic
foods could cause a catastrophe: anything from being carcinogenic to
introducing prions causing something like Creutzfeldt-Jakob disease. While
speculative, those concerns indicate the need for a rigorous, but not suffocating,
regulatory scheme, including appropriate testing standards.
Herbicide-tolerant soybeans reduced weed-control costs by
$216 million in 1999, and reduced herbicide applications
by 19 million.
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ECOLOGICAL CONCERNS
While consumers may focus on safety, transgenic crops raise diverse environ-
mental questions. Whether it is the effect of Bt corn on monarch butterflies and
other non-target organisms, the spread of genetically engineered characteristics
to wild relatives, or the development of pesticide resistance in insects or weeds,
GM crops deserve the closest scrutiny. After all, the self-propagating nature of
living organisms—be they fish or wheat—means that once a problem occurs, it
might be uncontrollable. The United States Department of Agriculture (USDA)
and the Environmental Protection Agency (EPA) are responsible for anticipat-
ing and preventing environmental problems caused by GM crops. But serious
questions have been raised about the rigor of those agencies’ scrutiny and
judgment. For example, last year a committee of the National Academy of
Sciences (NAS) identified numerous ways in which the system should be
strengthened. And last March an EPA Science Advisory Panel concluded that
data requirements for the effects of Bt corn on non-target insects were not
complete, leading the EPA to ask companies for new studies.
The USDA recently established an Advisory Committee on Agricultural
Biotechnology to provide independent advice on environmental concerns, and
commissioned the NAS to conduct an ongoing review of its (USDA’s) regulatory
process. Those committees should help guide the USDA cautiously into the
future and increase public confidence in agricultural biotechnology.
REGULATION – SAFETY
Most Americans, I believe, are open to biotechnology, but want assurances that
the foods are safe and that crops and other organisms will not adversely affect
the environment. We need to upgrade the regulatory system to respond to these
concerns.
The Food and Drug Administration (FDA) has long considered genetically
engineered plants to be “substantially equivalent” to conventional varieties,
relying upon a voluntary consultation process to address any safety concerns.
The Food and Drug Administration (FDA) has long
considered genetically engineered plants to be “substan-
tially equivalent” to conventional varieties, relying upon a
voluntary consultation process to address any safety
concerns. Although that process has not resulted in any
health concerns, it invites criticism.
Although that process has not resulted in any health concerns, it invites
criticism. After all, the process largely transpires behind closed doors and does
not result in formal approval. In contrast, the FDA has a mandatory, albeit
secret, process for approving transgenic animals—such as genetically
engineered fish—and the EPA has a mandatory, relatively open, process for
evaluating transgenic pest-protected plants, such as Bt corn. The USDA, too,
has a relatively open process for considering whether new crops may adversely
affect agriculture.
The FDA recently proposed a mandatory review process to replace its current
voluntary system for evaluating GM crops. Importantly, the new process would
ensure that all new food crops are scrutinized. Also, the new process would be
open to public scrutiny, with most company documents being placed on the
public record. However, because the FDA has not provided formal safety-testing
guidelines, and because companies propose safety tests to the FDA, the process
gives the appearance of being driven by industry’s decisions. Moreover, the new
review process still would not result in formal approval. Instead, the FDA
would say, “We have no further questions.” While that approach might not
result in any safety questions, it would still invite the accurate criticism that
transgenic crops are not formally approved in the United States, and that,
unnecessarily, diminishes public confidence.
Because the FDA has been unwilling to argue that it has the authority to
formally approve all biotech foods, Congress should pass a law to mandate that
it does so. New legislation would distinguish transgenic organisms from
existing categories, such as “generally recognized as safe” substances, incidental
additives, or food additives. Last year, Congressman Dennis Kucinich and
Senator Richard Durbin introduced different bills to establish a formal approval
process. Those bills provide good starting points for debate. Passage of such
legislation could reduce public controversy.
New legislation should require each proposed new GM crop or animal to be
supported by a petition to the FDA. Importantly, such petitions would be public
documents, enabling any concerned party to scrutinize the data and provide
input to the agency. The end point would be the publication of a formal
approval in the Federal Register. That notice would explain the agency’s
thinking and respond to any concerns submitted by outsiders to the agency.
In contrast, the FDA has a mandatory, albeit secret,
process for approving transgenic animals—such as
genetically engineered fish
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Although food and seed companies support “mandatory consultations,”
currently they object to a formal approval process. They contend that the FDA
could take years to make decisions. That problem might be soluble simply by
requiring that a decision be made within a specified period of time. If necessary,
user fees or ordinary appropriations could provide the FDA with adequate
staffing to make timely decisions. Industry also fears that legislation on biotech
approvals might be saddled with all sorts of amendments. Frankly, I fear the
same thing: that industry would use the bill as a vehicle for achieving other
goals. I would hope, though, that voluntary agreements and astute management
of the bills would restrict the content to a mandatory approval process.
Representative Kucinich’s bill incorporates several other sensible measures. It
would ban common or severe allergens from biotech foods, phase out
antibiotic-resistance marker genes, and have the NAS’s Institute of Medicine
evaluate FDA’s system for evaluating biotech foods. One question that should be
studied carefully, as the NAS recommended last year, is whether sub-chronic or
chronic toxicity animal-feeding tests should be conducted on transgenic foods.
New legislation also should fund research at the National Institutes of Health or
the FDA to develop better means of predicting allergenicity.
The StarLink™ episode revealed two additional problems. First, farmers and
seed producers apparently lack the ability to ensure that corn—or other
crops—grown for feed will not appear in food. Hence, as Kraft Foods and
others have recommended, the FDA and EPA should not approve biotech crops
for animal feed if they are not also approved for human food. Second, the FDA
and USDA lack the authority to recall products, engineered or not. Senators
Tom Harkin and Byron Dorgan have introduced legislation to give those
agencies recall authority, but that bill has not moved through Congress.
Those all are simple, sensible steps that the biotech and food-manufacturing
industries should be able to accept and, indeed, to support.
REGULATION – LABELING
The second component of an improved regulatory scheme concerns the labeling
of genetically engineered foods. Concerns about labeling range from those
about allergies to ethics to the environment.
In response to environmental groups, the European Union, Australia and
several other countries are requiring labeling of foods containing genetically
engineered ingredients. The FDA says that it is not obligated to require foods
containing biotech ingredients to state “Contains Genetically Engineered
The FDA and EPA should not approve biotech crops for
animal feed if they are not also approved for human food.
Ingredients,” or “GM,” somewhere on the label. Instead, the FDA recently
defined a voluntary labeling scheme that it believes will be useful to consumers.
It has described situations in which terms like “does not contain genetically
engineered ingredients” may be used on labels. Consumers concerned about
GM foods would then have a choice. I hope that the FDA will anticipate future
developments by providing guidance to ensure that labels claiming that a
transgenic product offers benefits—such as “reduces the use of pesticides” or
“increases nutritional value”—are honest. Overall, the FDA’s labeling guidance
represents a small improvement, but does not satisfy those who want
mandatory labeling. And even the FDA admits that very few foods, other than
those grown organically, will sprout labels.
Some critics hope that GM labeling will be the kiss of death for engineered
foods and agricultural biotechnology. But it may be that the public is simply not
going to have confidence in biotechnology if companies are not more open
about their use of transgenic ingredients. Indeed, the FDA’s own focus-group
research revealed intense feelings around the marketing of genetically
engineered foods without special labeling.
To better understand the public’s interest in biotech labeling and how
consumers might react to it, CSPI recently commissioned a national telephone
survey of about 1,000 American adults.
First, two questions found that 62% to 70% of people say they would like
engineered foods to be labeled. Those percentages, of course, are similar to
many previous surveys indicating fairly broad support for biotech labeling.
We wanted to get beyond that first question and understand attitudes about
labeling in greater detail.
The survey found that as the amount of the engineered ingredients in a food
decreased, so does the desire for labeling. If labeling were required, 61% of
those surveyed said that a whole food, such as a tomato, should be labeled. If a
major ingredient, such as the wheat in Wheaties, was engineered, 53% said that
that should be labeled. The percentage favoring labeling dropped to 42% for a
minor ingredient, such as corn starch in a frozen dinner and to 38% for a food
Some critics hope that GM labeling will be the kiss of
death for engineered foods and agricultural biotechnology.
But it may be that the public is simply not going to have
confidence in biotechnology if companies are not more
open about their use of transgenic ingredients.
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containing soy oil that does not contain any other engineered material. Thus, if
labeling were required, well under half of people wanted labeling when only
small amounts of, or no, genetically modified material was present.
One thing about surveys that ask whether people want more information is
that people indicate a desire for just about any piece of information about food
production. Thus, based on two questions in our survey, 76% wanted labels to
disclose the spraying of pesticides, and 66% wanted information on genetic
engineering. But 43% wanted label statements on foods grown with practices
that cause soil erosion, and 40% wanted the use of hybrid corn to be disclosed.
It could be that most Americans know little about food production and are
suspicious of any process or term they do not understand. One may interpret
our survey as indicating that 40%, not 0%, should be considered the baseline
when asking people if they want something on labels about growing practices.
Another question gave people four choices and asked them which one they
would add to food labels, if they could add just one. Almost twice as many
people, 31%, wanted labeling for pesticide residues as genetic engineering, 17%.
Considerably fewer people, 8%, wanted imported wheat to be labeled, and
7% wanted processing contaminants to be declared.
Several questions indicate that support for labeling is not as deep as appears
at first glance. We asked people how much extra they would pay for their
family’s food to have labels declare that foods were genetically engineered.
About 50% of the people whose top labeling priority was genetic engineering,
or who said that engineered foods should be labeled, would pay either nothing
or only $10 per year for that labeling. One in four respondents said they would
pay $50 per year or more for labeling. A small group of consumers, 12%, would
pay $250 a year or more to get labeling; those are the hard-core proponents of
labeling. Thus, although most consumers may desire labeling of GM foods,
relatively few appear willing to pay additional costs for that information. Of
course, some people might want labeling, but feel that someone else — namely
the food and seed industries — should bear the costs.
To better inform the public and decision makers, an agency like USDA’s
Economic Research Service should estimate the costs of different forms of GM
labeling.
We next explored how people interpret label statements. About one-third of
respondents believed that foods labeled “contains genetically engineered
ingredients” are less safe or not as good as foods without labels. There was little
difference if the term “biotechnology” was used instead of “genetically
engineered.” Conversely, about one-third of respondents believed that foods
labeled “does not contain genetically engineered ingredients” are better than
foods without such a label. Thus, if, as appears to be the case, there is no
difference in safety or quality between conventional and GM crops, many
consumers apparently would be deceived by labels that state “genetically
engineered” or “not genetically engineered.”
Those perceptions about safety, quality, or other matters carried over into
buying behavior. Only about 40% of respondents said they would buy foods
made with genetically engineered ingredients. It did not matter whether the
foods were transgenic fruits and vegetables or processed foods that contained
only minor ingredients that came from engineered crops. Clearly, considering
the public’s current views, no food manufacturer would market foods
containing engineered ingredients if they had to put a statement on the label.
We also asked people if they would buy foods bearing other labels.
Interestingly, while only 43% of the respondents said they would buy foods
labeled “genetically engineered,” about the same percentage said they would
buy foods labeled as having been sprayed with pesticides, treated with plant
hormones, or made from hybrid corn. Apparently, people have apprehensions
about any unusual and suspicious-sounding statements on labels.
One thing our survey did not examine is the reaction to different kinds of
labels. We left to the imagination of the respondents the prominence of the GM
label on food packages. It would be worth exploring how differently people
might perceive the term “contains genetically engineered ingredients” on the
front of the package, the term “genetically engineered” embedded within the
ingredient statement, and a small “GM” symbol somewhere on the front of the
package. Our only finding in this area was that when GM labels stated “reduces
pesticide use,” the percentage of people who thought those foods were safer
jumped from 7% to 21%. Still, about 30% of people continued to believe that
the GM food was not as safe as other foods that might have been sprayed with
pesticides.
If foods are to be labeled, Congress should give the FDA a clear mandate,
because the FDA will not require such labeling on its own. In any case, though,
whether label statements are mandatory or voluntary, such statements should
not lead people to think that a food made with genetically engineered
ingredients is inferior, or that a food made without genetically engineered
ingredients is superior.
Labeling is a “catch-22” problem for industry. As long as engineered foods are
not labeled, people will contend that the public’s right to know is being short-
changed and will criticize government and companies for hiding that
information. If engineered foods were labeled, many people would not buy
them, and so companies, not wanting to lose sales, will not market engineered
foods with a label. Considering how negatively the public views the term
“genetically engineered,” I think that industry needs to be candid with
consumers about the benefits and pitfalls of the technology. The food industry
could lessen suspicions if it mounted a full-scale advertising campaign
depicting hundreds of packaged and restaurant foods that contain ingredients
from engineered crops. Those ads could explain the apparent safety and the
environmental benefits, while acknowledging that safety can never be assured
with absolute certainty.
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REGULATION – ENVIRONMENT
Probably the most likely problems concerning biotech products pertain not to
consumer health but to ecological disruption. One major concern is that while
the EPA stipulates that certain crops, such as Bt corn, be accompanied by
refuges of conventional crops, no agency polices and enforces such critically
important requirements. That must be corrected. Also, the NAS report on pest-
protected plants made numerous specific recommendations, ranging from
regulating viral coat proteins under the Federal Insecticide Fungicide and
Rodenticide Act (FIFRA) to improving inter-agency coordination. All of those
recommendations should be implemented.
The USDA is charged with ensuring that new crops do not become pests. But
experience suggests that environmental reviews by the Animal and Plant Health
Inspection Service (APHIS) have underestimated the potential for significant
problems resulting from Bt corn’s impacts on lepidopterans, from the weediness
potential of herbicide-tolerant canola and virus-protected squash, and from the
need for pest-resistance-management planning for Bt crops.
Despite the millions of acres planted with GM crops, APHIS has never
prepared a full environmental impact statement (EIS) for any of the GM crops
that it has approved. Full EISs would have led to better analysis and mitigation
for any remaining questions.
To summarize: now is the time, while agricultural biotechnology is still
young, for Congress and regulatory agencies to create the framework that
would maximize the safe use of these products, bolster public confidence in
them, and allow all of humankind to benefit from their enormous potential.
OTHER CONCERNS ABOUT AGRICULTURAL BIOTECHNOLOGY
Aside from effects on the public’s health and the ecosystem, agricultural
biotechnology raises many other concerns. While it is impossible to explore
each of these matters in detail, I will touch on various measures that would
boost public confidence and help ensure that biotechnology is used wisely and
productively.
Underlying many of the attacks on biotechnology is the question of whether
a handful of giant companies will soon control the world’s major crops and the
technology itself. The briar patch of patent rights that affects Golden Rice
exemplifies the extent to which private industry (and, in some cases,
universities) has gained control over the technology. Also, it is clear that
commercial interests focus on the largest and most profitable crops in the
developed world—and then only on applications that are profitable—rather
than those the primary purpose of which is to protect the environment.
To bring the greatest benefits to the most people, it is essential that the
industrial nations sponsor more basic and applied research to ensure that new
methods and products are in the public domain. Government-sponsored
research also should address the needs of small farmers, consumers, and the
environment, as well as the so-called minor crops, which may not be so minor
to the people who grow and eat them, whether in the industrial or developing
world. To ease the regulatory-cost burden for small businesses, universities, and
researchers, government could waive certain fees. For example, the USDA’s
current IR-4 program, which helps register certain low-profit uses of pesticides,
could be expanded to support “orphan” biotech applications. Furthermore, we
need to expand aid programs to train scientists in developing countries, fund
research stations, and help those nations build a regulatory structure to
anticipate and prevent possible problems. In some of those countries, the need
for careful regulation is particularly acute, because ancestral cultivars grow side
by side with commercial varieties, making it difficult to prevent gene pollution
of the traditional genotypes.
Organic farmers in the United States have justifiable fears that pollen from
biotech farms will pollute their crops, possibly rendering them non-organic
under the law. If an organic farmer saved his or her seed from year to year, it is
easy to see how even 1% contamination per year by neighboring biotech crops
would soon significantly decrease the purity of the seed. While the definition of
“organic” does not specify allowable contamination levels, anything over a few
percent would certainly begin to jeopardize the premium that organic food
commands. Organic farmers also fear that insects will develop resistance to Bt
toxin. While that concern was always present due to the use of that natural
insecticide by organic farmers themselves, the widespread planting of Bt corn
and cotton increases tremendously the possibility that pests will become
resistant. I do not pretend to have the solutions to these tough problems, but
they deserve careful attention. Buffer zones, compensation by seed companies,
and other measures should be developed to protect the integrity of organic
foods, without raising their prices even further.
BEYOND BIOTECHNOLOGY
Let me conclude by noting that many critics of biotechnology are opposed to
any and all of its applications, apparently regardless of its benefits. Advocates
should not fall into a similar trap of thinking that biotechnology is the answer,
regardless of the question. Genetic engineering is not the only tool in the
agricultural toolbox. Conventional breeding and non-transgenic applications
To bring the greatest benefits to the most people, it is
essential that the industrial nations sponsor more basic
and applied research to ensure that new methods and
products are in the public domain.
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of biotechnology offer tremendous opportunity. We should also note that
production agriculture, biotech or not, suffers from real problems. Many
farmers are losing money and declaring bankruptcy. Many more would, were
it not for huge government bailouts. Both advocates and critics of genetic
engineering should recognize that the wisest course of action would be
simultaneously to follow several paths to satisfy our food needs, making use
of genetic engineering, conventional methods, and organic or sustainable
approaches. Many farmers are discovering that sustainable agriculture,
including organic farming—based on smaller farms, diverse crops, and natural
means of pest control—may be just as profitable, or even more so. Their input
costs may be lower, while their crops may command premium prices in the
marketplace.
There are no big chemical or seed companies or government subsidies to
support this approach to agriculture. Hence, my final recommendation would
be for agricultural schools, the USDA, and state departments of agriculture to
conduct more research and provide greater technical and financial assistance to
farmers who want to get off the agribusiness treadmill.
Q: You mentioned the organic farmers and risks of contaminations. They
have indicated only 100% organic, or zero percent contamination, is acceptable.
Is it reasonable to think that anyone in today’s agricultural environment in the
United States can produce soybeans that are zero percent transgenic?
A: It may be possible in some areas of the country to produce 100% non-
transgenic soy, but organic food does not have to be 100% organic. The Food
and Drug Administration and the United States Department of Agriculture have
called for an identity preservation system, with affidavits and so on, indicating
that the intent of the farmer and the food system is to keep these products as
pure as possible, but the government is not insisting that they be 100% organic
with regard to pesticides or transgenics or other contamination. Food will not
be declared non-organic if one kernel of Bt corn is in the crop.
Many critics of biotechnology are opposed to any and all
of its applications, apparently regardless of its benefits.
Advocates should not fall into a similar trap of thinking
that biotechnology is the answer, regardless of the ques-
tion. Genetic engineering is not the only tool in the
agricultural toolbox.
Q: To what degree would you say previous interactions of consumers . . .
[inaudible]
A: I think the bigger factors in consumer perceptions are the very effective
criticisms by the opponents, who have created symbols that are very easy to
understand: a dead monarch butterfly, for instance, or the term frankenfood,
which are powerful means of communication. The advocates of biotechnology
have not developed equally effective symbols—“fewer farmers poisoned by
pesticides” for example. Proponents have not waged an effective campaign to
educate the public. It amazes me that so few are talking about the benefits from
reducing insecticide use, or herbicide use. The critics cannot bear to acknowl-
edge that there are some benefits from biotech foods, even though these people
are critical of pesticide use—they’ve been campaigning against them since
Rachel Carson was around. So, the critics aren’t talking about it, and, on the
other hand, the companies can’t talk about it because some of them make
pesticides. For these companies, it is not a plus for pesticide sales to go through
the floor. And the trade associations, which represent industry’s lowest common
denominator, cannot talk about these benefits. Somebody must contribute to
the debate facts that demonstrate benefits to the public at large, maybe not as
consumers, but out of concern for the environment. This is needed in Europe
also. The advocates of biotechnology, the companies, the professors, consumer
groups, etc., need to go to Europe and talk about how Europeans’ insistence on
non-biotech crops means that the American ecosystem will be more polluted,
that more farmers will be harmed, and that more non-target insects and other
species will be killed.
Q: With reference to your remarks on sustainability, were you implying that
there is no role for genetic engineering in sustainable agriculture?
A: No. Genetic engineering can contribute to sustainability. Twenty years
from now, organic farmers may be clamoring for genetically engineered crops
that are beneficial and safe, and fit into their systems; they are not inconsistent.
Q: A key problem in Europe is that organic agriculture is striving for 100%
zero tolerance of genetic engineering. Don’t you think that organic agriculture
has to come to terms with the fact that genetic engineering is part of agricul-
ture, therefore they have to find a way to accommodate a threshold as they are
doing for pesticides and herbicides?
A: They don’t have to. If you are against genetic engineering, you’ll want zero
tolerance. It’s a political decision. In the United States, a decision has been
made that the test for organically grown foods will not be chemical; instead, it
will be a paper trail. The government has not indicated a percentage, neither
0.1% nor 5%. The assumption is that it is a small fraction, and court cases may
be needed at some point to decide what the percentage will be. The government
has said minimal contamination—a little is okay.
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Q: Something we have learned in the food industry is that you can sell an
advantage that is directly linked to the product, but it is difficult to sell
advantages that are far upstream in the process. You mentioned that the biotech
industry has failed to draw attention to decreased pesticide use. In my opinion,
even if they produce pesticides and GM crops that are resistant to these
pesticides, if the biotech industry is unable or unwilling to articulate these
advantages it will be extremely difficult to change the minds of the consumer.
A: Yes, it is pathetic that the industry itself can’t do it. It could be that’s life
and we will not have genetically engineered foods for a period of years. The
biotech industry needs to wake up. Companies like Monsanto that don’t market
most chemicals—obviously they market Roundup—that are adversely affected,
need to speak out, and maybe the academic community and regulators need to
talk to them and try to knock some sense into their heads. But ultimately, the
technology may be lost for some years, or its use will be restricted to feed grains
or fiber crops, like cotton, that don’t enter the food chain.
Q: Does the CSPI provide informational hand-outs or brochures on educating
the public on issues such as labeling?
A: We are just beginning to do this. We have had a couple of articles in our
newsletter, the Nutrition Action Healthletter, which reaches 800,000 people, and
we have had a couple of op-ed articles in the Wall Street Journal and other
newspapers. We are beginning to reach out to the public via the usual Website,
but it has to be much bigger than CSPI alone. We are hoping to serve as a
nucleus around which groups that have a reasonable attitude may coalesce and
call for sensible regulation of genetically engineered crops, portraying them
neither as evil nor as a panacea. The big money lies with the food industry and
the seed and chemical companies, and any mass-media efforts must come from
them. If they are unwilling to mount a significant effort, they may see their
market shrivel. The academic community could speak out more clearly,
particularly in regard to calls for a better regulatory system. The public has had
sufficient reassurances from professors who consult for the biotech companies
and are less than totally believable—but they would have greater credibility if
they called for tighter regulatory controls. Especially people at the University of
Illinois because Senator Durban is very influential and very sensible.
Frames for Public Discourse on
Biotechnology
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University of Illinois
Urbana, IL
In the past five years, science-based food-safety issues have been a staple of
daily news in the United States as well as in other parts of the world. Develop-
ing news on mad cow and foot-and-mouth diseases from Europe, furor over
golden rice in Southeast Asia, and the continuing coverage of the risks and
benefits of agricultural biotechnology have vigorously put science and the
scientist in the public arena. As the lenses of the public are trained increasingly
on science and the scientist, it becomes inevitable, then, for the scientist to
also have the public very much in mind.
In the evolving interaction involving the public, the mass media, and
scientists, it is reasonable to expect some convergence in the discourse on
biotechnology. However, what we have witnessed so far seems to show
increasing divergence. Although public-opinion studies in the United States
do not exhibit the anti-biotechnology phenomenon that we hear about, the
movement against biotechnology has certainly gained momentum in other parts
of the world. This is particularly true in Europe and parts of Asia, where public
opinion about biotechnology has been unfavorable and public suspicions of
GMOs and institutional regulatory agencies and industry have remained
unabated.
Indeed, we would not be here today if it were not for the intriguing question
as to why agricultural biotechnology has become a lightning rod for conflicting
public discourses. Although I am not a scientist and can comment only from
within the limits of my training and scholarly reflections, I would like to proffer
some insights that relate to the communication dimension of this phenomenon.
In reexamining the divergent opinions expressed in public discourses over
biotechnology, I thought it best to go back to the basic question: Who are the
actors and from what contextual frames do they see agricultural biotechnology
as they further their agendas in the public sphere?
Clearly the actors involved are scientists, the mass media, and involved
publics. It also is obvious that each of these actors brings to the discourse a
way of knowing and presenting truth and knowledge, a peculiar rhetorical and
epistemological style, and a set of values and meanings that cannot be removed
from history and immediate experiences. Whether or not they are, in our view,
protagonists or antagonists in the biotech debate would also depend on the
frame that we ourselves use in examining the unfolding events of agricultural
biotechnology.
THE SCIENTIFIC FRAME AND THE TRANSFORMATION OF
SCIENTIFIC DISCOURSE
In order to understand the manner of scientific discourse or talk, a look back in
history might help. As we all know, the Scientific Revolution was characterized
by a denunciation of scholasticism and the use of rhetoric in investigating
nature. In order to dissociate itself from the moralizing and personalizing types
of discourse, science had to seek other ways of presenting information. The
imperative to have a distinctive discourse for science was particularly
underscored in Thomas Sprat’s History of the Royal Society, which admonished
its members to separate the knowledge of Nature from the colors of rhetoric,
the devices of fancy, or the delightful deceit of fables. Robert Hooke, in his draft
preamble to the original statutes of the Royal Society of London, specifically
argued that scientists should have nothing to do with “Rhetoric.” During a
scientific congress in Italy in 1839, Grand Duke Leopold II even remarked that
one of the forbidden topics would be “eloquence.” These admonitions reflected
the need to have a scientific discourse that was characterized by logic and
analysis, the direct evidence of the phenomena, the results of observations,
stripped of all charms of fancy. In this context, scientists were conduits through
which nature spoke directly, across the great divide between the independent,
outer world of phenomena and the subjective, inner world of the observer
(Gross, 1990; Fahnestock, 1998).
These distinctive marks of scientific discourse continue to be evident in
contemporary science. Then, as now, the imperative has always been for a close,
clinical, naked, natural way of speaking, almost mathematical plainness. It
reflects both the values and social structure of science, which is entrenched in
the tradition of peer review and careful evaluation and scrutiny (Martin and
Veel, 1998; Priest, 1999). It implies a degree of separation between science and
society, with the former as the fountainhead of all new empirical knowledge.
The autonomy of science was seldom contested. Knowledge, per se, is devoid
of ethical content or moral value. It is the society, at large, that deems as good
or bad (or both) the uses of knowledge and understanding, and even pure
information, depending on the social, historical, and cultural contexts, and on
the prevailing human and social values of the times (Brown, 1998).
Thus, when modern scientists communicate, we note cautious attempts to
establish the validity of the observations they report, emphasis on methodology,
and importance given to tables, figures, photographs, and all other representa-
tions that can solidify the claim for the physical evidence generated. It is a type
of discourse that can be characterized as “forensic” or “empiricist” in that it is
largely based from observable characteristics of the natural world, aided by
actuarial, toxicological, epidemiological, or probabilistic risk analyses and risk
assessment. Using this rhetorical style, scientists simply restate the results of
scientific research and suggest that risk can be calculated with precision. To
deviate from this process is to negate the epistemological underpinnings and
moorings of the scientific enterprise. When scientists communicate with their
peers through papers, reports, or conferences, they reaffirm this built-in ethos
of empiricism and try to hold back from any celebratory discussion of the
significance or relevance of the work. The audience is left to infer and spell out
the relevance of the study for a particular context (Sera and Shea, 1991; Priest,
1999).
But what happens when scientists shift to another type of discourse? The
problem, I believe, begins when the scientific discourse slides from the forensic
or empiricist style to what I would call the “celebratory” style. Communicating
scientific reports and findings in ways that would make sense to the larger, non-
scientific (lay) audience requires that the scientific information be adjusted to
meet the lay audience’s already held values and assumptions. This celebratory
scientific discourse veers towards explicating the value and significance of
scientific discoveries for lay audiences. It focuses on the breakthroughs,
advances, contributions, applications, and benefits of scientific discoveries. It
tries to contextualize science. The increasing importance of “context” shifts the
discourse of science from the more traditional, established scientific search for
truth to the more pragmatic discourse of “science that works.” Indeed, there is
a change from a discourse of methods and processes to a discourse that gives a
final answer (Fahnestock, 1999).
In the case of agricultural biotechnology, celebratory scientific discourses
may extrapolate, for example, the social benefits of biotechnology in terms of
It can be argued that, in the era of three-second sound
bytes and diminishing attention span of media audiences,
such creative catch-phrases that herald scientific accom-
plishments and potential social benefits may just be the
proper counterpoint to other equally mind-grabbing sound
bytes such as “frankenfood” and “terminator genes.”
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solving world hunger and even poverty in developing countries. The term
“golden rice” for the genetically modified rice grain that contains beta-carotene
is an example of a celebratory connotation for science. One scientific
organization is even more effusive by referring to the so-called “golden rice” as
the “grain of hope.” It can be argued that, in the era of three-second sound
bytes and diminishing attention span of media audiences, such creative catch-
phrases that herald scientific accomplishments and potential social benefits
may just be the proper counterpoint to other equally mind-grabbing sound
bytes such as “frankenfood” and “terminator genes.” Perhaps, scientists should
fight fire with fire. While this strategy may be convenient, what the public gets
at the end of the day, however, is simply a clash of sound bytes and more
confusion.
Ironically, in an effort to make scientific discoveries relevant and appealing to
the lay audience, celebratory scientific discourse all but foregoes some of the
exacting standards of empiricism that have gained respect for science and
entrenched its institutional role in society. Thus, it has been noted that
celebratory scientific discourses tend to pay less attention to caveats, contradic-
tory evidence, and qualifications that are highlighted in forensic or empiricist
discourses. By downplaying scientific uncertainty, it alludes to greater certainty
of scientific results for public consumption (Brown, 1998).
However, as it inevitably moves closer towards the arena of debate over what
constitutes the common good and what is socially beneficial, it opens itself up
also to a wide range of questions engendered by a different set of frames of
public discourse for which science may not have the answer.
THE LAY AUDIENCE’S FRAME: MORAL AND SOCIETAL MEANINGS AND
THE DEMANDS FOR CERTAINTY
In my opinion, the lay audience’s contention over biotechnology is neither
about the science per se nor the content of forensic-empiricist discourses on
biotechnology. For how then can we explain continuing public expectations for
definitive answers or their needs for certainty, from science, even if these are
rather unrealistic demands? These expectations could only suggest that, in the
eyes of the public, science is still a repository of answers to many of the
problems that beset the human condition. I would like to offer an analogy,
despite its obvious limitation. This relationship between scientists and the
public is almost akin to the principle of the separation between church and
state. The church is respected as a purveyor of profound reflections on matters
of morality, ethics, and conscience. The public expects that. But it is altogether
a different discourse if the church dictates to the state as to what is moral and
ethical. It weakens the state.
Hence, in the public discourse of biotechnology, conflict arises when science
begins to be perceived as precluding public judgments and playing a decisive
role in setting directions, policies, and regulations on food production and
food-safety standards. There is evidence that negative public reaction to
agricultural biotechnology is driven to some extent by uneasiness over
regulatory and risk-management policies that are solely based on technical risk
analyses and risk assessment. This process is seen as disenfranchising other
discourses that embody particular values and meanings vis-à-vis biotechnology.
In the eyes of the public, it weakens the democratic nature of the public sphere
that is supposed to engage a wide spectrum of participants and discourses. The
conflict may very well be about the process of envisioning the common good
and the best way to attain it (Gilbert and Mulkay, 1984; Webber, 1990; Gregory
and Miller, 1998).
Scientific assertions evidently have a rightful niche in the public sphere.
Celebratory scientific discourses on the wonders and socio-economic benefits
of biotechnology have, in fact, been used as a rhetorical tool in several
marketing or public information campaigns. In a functioning public sphere,
however, these scientific claims must be evaluated side by side with other
assertions, each carrying a frame of meanings, priorities, and values. This may
be the reason why we do not see a blanket rejection of biotechnology. There is,
in fact, disparity in public choices and levels of support for biotechnology.
Public-opinion surveys indicate more support for the use of biotechnology for
medical or pharmaceutical purposes than for the use of biotechnology in the
production of food.
What, then, are these frames of meanings and values that inform non-
scientific or lay discourses of biotechnology? These frames pertain to (a) ethics
and morality, (b) control, (c) fairness, (d) familiarity, and (e) trust in institu-
tions that regulate biotechnology. These frames are essentially reflective of
Professor Peter Sandman’s categorization of the more than twenty factors that
influence public perceptions and opinions about risk-related issues. Using some
of these categories, let me outline the typical arguments that characterize lay
discourses of biotechnology (Juanillo, 2001).
Ethics and Morality Lay discourses tend to liberally equate “ethics” with
“moral concerns.” Hence, if the application of a technology and related
instances is unethical, it is also consequently considered morally wrong.
Public support for a technology is largely contingent on its perceived moral
acceptability. Studies indicate that moral acceptability is a strong predictor of
support for biotechnology and that moral concerns outweigh questions of risk
and utility. The emphasis on ethics has even swayed institutional structures. In
France, forums on ethics in biotechnology have been institutionalized with the
creation of National Consultative Ethics Committee (de Cheveigné et al.,
1999).
In general, lay discourses about the ethics and morality of biotechnology are
informed by naturalistic or ecocentric worldviews, which see humans as only a
part of nature. They manifest deeply held existential ideas about humankind
and our relationship with nature. Fundamental to the ethical-moral question of
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biotechnology is the guiding principle among many that nature is pure, and “all
that is natural is valuable and good in itself.” Thus, an action is right “when it
tends to preserve the integrity, stability, and beauty of the biotic community
(and) … wrong when it tends otherwise (MacLean, 1995). Hence, biotechnol-
ogy is intrinsically wrong because it is seen as tampering with nature and as
contrary to the very essence of humanity and its position in nature.
This particular discourse on biotechnology becomes even more complex
when framed in a religious perspective. “Playing God” has been a familiar
accusation against biotechnology and a basis for not a few impassioned public
objections.
Interestingly, however, nationwide surveys conducted in Austria, the United
Kingdom, Australia, Germany, Japan, and the Netherlands generally show less
ethical opposition to genetic engineering for medical, pharmaceutical, or
therapeutic applications than to applications in food production and agricul-
ture. Genetic testing and medicines are deemed useful, morally acceptable, and
to be encouraged, but genetic manipulation of food crops and animals is
considered morally unacceptable.
Control Perceived loss of control over the effects of biotechnology on human
health and the environment has been a recurring theme. For example,
biotechnology opponents cite the threat to the independence of small farmers
and the consumers’ right to know and choose. People ask how broad public
interests can be served in light of the growing concentration of ownership of
food resources in a handful of multinational companies, particularly their
control over key aspects of food growth, production, and marketing. There are
concerns over the move toward agricultural research being predominantly
influenced and funded by the very companies that stand to benefit most from
genetically modified crop technology.
There is widespread perception that the genetic engineering industry seeks to
industrialize agriculture even further and to intensify farmers’ dependence
upon industrial inputs abetted by a system of intellectual property rights, which
legally inhibits the rights of farmers to reproduce, share, and replant seeds
(Altieri, 1999).
Opponents also express fears about similar effects of agricultural biotech-
nology in developing countries, opening up the debate once more on the
dependency that technology creates on the research and manufacturing
capacities of developed economies. They believe that agricultural biotech-
nology will exacerbate the marginalization of small and resource-poor farmers
since the technology is under corporate control, protected by patents,
expensive, and inappropriate to the needs and circumstances of indigenous
people. There is a perceived threat of total “corporatization” of farming, of
unfairly burdening the farmers of developing countries who would become
dependent on corporate genetically engineered seeds, despite being unable to
afford them (Altieri, 1999).
Fairness Public debates over genetically modified foods have also centered on
the technology’s role in exacerbating social inequities. Concerned groups both
in developed and in developing societies, for example, see current intellectual
property rights as devices for perpetuating, rather than alleviating, entrenched
discrepancies between rich and poor countries (Jasanoff, 1999).
Non-government organizations also have decried the limited flow of
information and resulting lack of transparency as a result of the patent system
in developed countries. Existing patent systems allow biotechnology industries
to protect the product as well as the process, and therefore to limit the flow of
technical information. Procedures and policies have yet to be established in
order to promote access to these technologies. As a consequence, the public
perceives that the whole biotechnology business is shrouded in secrecy,
conjuring up images of technology as an instrument of social control.
Stringent regulations in developed countries on the release of genetically
modified organisms or their products also are seen as making developing
countries particularly vulnerable to uncontained on-site applications of
biotechnology as these countries do not yet have the necessary regulatory
policies. Current guidelines governing the release of genetically modified
organisms do not include provisions governing the testing and application of
organisms in other countries, particularly in the developing world. This
situation provides opportunity for the biotechnology industry to test new
products or locate their production facilities in developing countries that are ill-
prepared to respond due to the lack of national safety policies, effective
regulatory mechanisms, technical know-how, and institutional accountability.
The perception that developing countries are being “exploited” by companies
who profit from the use of indigenous biological resources has triggered anti-
biopiracy awareness campaigns by non-government organizations worldwide.
There are serious concerns that these companies are being granted patents for
products and technologies that make use of these indigenous genetic materials,
plants, and other biological resources (Altieri, 1999).
Voluntariness An exposure to risk that is perceived as involuntary is regarded
as more threatening than when an individual has a choice over personal
exposure (Frewer et al., 1997). Consumer food choices are informed by the
general feeling of well-being and satisfaction associated with products that have
been chosen voluntarily, guided in part by an array of cultural, ethnic, and
religious motivations.
The negative attitude of consumers towards biotechnology products appears
to emanate from the perception that food and dietary risks are personal choices
and ought not to be imposed on them by corporations. Much of the opposition
revolves around upholding the consumer’s autonomy and right to be informed
through mandatory labeling and disclosure of any salient nutritional differences
or new production methods in foods. In the United States, public-opinion
surveys continue to demonstrate that consumers want labeling. A Gallup poll
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conducted in September, 1999, showed that even though a bare majority of
Americans believe that biotech foods are safe, most are willing to pay more
to have labels that distinguish between gene-altered food and conventional
produce. Sixty-eight percent of the respondents said they would pay more for
labeled foods whereas 29% would not.
Moreover, as a reaction to this perceived threat, Europe and a growing
number of developing countries have proposed a Biosafety Protocol that would
require exporters of “living modified organisms” to notify the importing nation
in advance, giving that nation a chance to reject the shipment. Agricultural
commodities would be included because they contain seeds that can be
presumably planted or can escape into the environment.
Familiarity and Tradition Agriculture has been closely associated with
land-based farming where small communities have cultivated crops and
domesticated animals for consumption and commerce. In the United States,
powerful images of agriculture and the virtues of harmonious agrarian life
persist even as the modern farm has lost much of its folk character. The village
and the countryside are still perceived as the stronghold of primal American
values: a sense of human values, neighborliness, respect for family, moral
stewardship of the land, and a bastion of democracy and religion.
Opposition to the application of biotechnology in food production and
agriculture emanates partly from the belief that it destabilizes the firmly rooted
cultural archetypes and the deep symbolism associated with agrarian culture.
Many environmental and sustainable agriculture groups view transgenic food as
a symbol of the assault on traditional sources of food. Decreasing familiarity
with their food and its origin and composition engenders such anxiety. The
benefits of using biotechnology on food and crops seem far-fetched and
superfluous, bear no immediate impact on individual well-being, and lack
personal relevance.
Trust and Credibility Central to the public discourse on the risks and benefits
of biotechnology is the issue of trust and perceived credibility of societal
institutions such as regulatory agencies, life-science companies, and private
research organizations. Communication between the public and proponents of
biotechnology breaks down, perhaps irreparably, when the public perceives that
the proponents are not telling the truth about the risks of biotechnology or are
not sufficiently prepared to handle the potential risks of the technology. Public
expectations about the competence of societal institutions involved in
biotechnology are often based on the institutional track record or on the basis
of how these institutions have handled food-related crises in the past.
The level of public trust in institutions and sources of information and how
the public perceives risk work in tandem. This ongoing public suspicion of self-
interest mars the relationship between the public and the governmental
regulatory agencies and private food companies in debates over the risks and
benefits of biotechnology. As public trust in institutions declines, the public
perceives the hazards of biotechnology to be greater, and public trust in
advocacy groups increases.
The Eurobarometer surveys conducted by the European Commission in 1996
on public perceptions of biotechnology show that public authorities, adminis-
trative institutions, and industry are least trusted to tell the truth about
biotechnology, and are perceived to be least reliable to regulate biotechnology.
Non-government entities such as consumer organizations and environmental
groups are most widely trusted, followed by school- and university-based
experts. Trust, however, is issue-specific. Those in the medical profession, for
example, are most widely trusted for introducing genes into animals to produce
organs for human transplants. There also is more trust in the providers of
biotechnologies for medicinal or therapeutic use than in those involved in
biotechnologies for food production (Durant et al., 1998).
A study I conducted in Southeast Asia (the Philippines, Singapore, and
Thailand) on public perceptions of food safety manifests similar trends.
Results of the survey show that life-science and food companies and govern-
ment regulatory agencies rank lowest as trusted sources of information on
food-related risks including biotechnology. University scientists rank first in
all three countries, followed closely by non-government organizations such
as consumer-advocacy and environmental groups and the mass media. Life-
science and food companies and government regulatory agencies are perceived
as being most biased in releasing information and most likely to withhold
information on food-related risks. Moreover, the public perceives university
scientists to be much more concerned about public health and safety with
regard to biotechnology issues than are government agencies or life-science
and food companies.
THE MASS MEDIA DISCOURSE: FOCUSING ON THE FRAMES THAT SELL
Turning now to the mediator of scientific and lay discourses on biotechnology,
I believe that there is no doubt about the critical role of the mass media. Studies
have pointed out the possible role of the mass media as influencing the rise
and fall of social issues in the public agenda. Whether rejected, accepted, or
modified, the comments by definers of scientific issues in news accounts have
become points of departure for personal conversations. The lay public’s
understanding of science and technology issues and its evaluation of techno-
logical risks stem more from a reliance on a broader, more popular vocabulary
of risks and benefits provided by the mass media than on the traditional risk
analysis and assessments given by experts. Risks do not just emerge as issues
for the public according to their intrinsic importance, but rather in interaction
with social processes such as the manner by which the mass media frame,
construct, or define risks. Media effects are manifested especially in issues that
lie outside the individual’s personal experience, and for which the mass media
are the only frames of reference.
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Do reports in the popular media reflect scientific discourses or lay dis-
courses? Tentative findings from my content analysis of the New York Times for
the period 1998 through 2000 show that nearly 30% of the content is devoted
to scientific discourses, in both celebratory and forensic styles. Evidently, much
of the coverage focused on social dimensions of agricultural biotechnology,
particularly on issues pertaining to control and fairness, trust and credibility,
and voluntariness. Lesser coverage was devoted to issues of tradition and
familiarity and ethics and morals.
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Q: Should scientists change their mode of address and move to a more
celebratory style when dealing with the public?
A: Some communications research is being conducted by the Environmental
Protection Agency (EPA) on the merits and demerits of using narrative
discourses over more empirical, or more forensic, discourses. But the real
challenge will be implementing the EPA findings in outreach programs or
seeing them in action through information campaigns, and that has yet to be
evaluated.
Q: Recently when I gave an introductory talk on genetically modified foods,
one of the audience members asked me the question: “If you were to be offered
only genetically modified foods for one year, would you accept it or not?” In
terms of your framework—celebratory versus forensic—as an academician,
what answer should I have given to that question?
A: As an academician, I don’t have answers to very practical questions such as
this. I think I work best as an observer. The real challenge is in evaluating
communications strategies applied in outreach and extension programs. As of
now, I have not seen any solid evaluations or findings of which strategies work
best. Suffice it to say that certainly we know that when scientists try to
celebrate, to take pride in, their own work, and to allot meaning to their
discoveries, something else happens. It is a totally different framework—one of
values and meanings—in which it is fair game for everyone to accuse you of
something else. I think the public expects the scientist simply to talk about
findings as empirically as possible, which is the reason that there is solid
recognition for the role of scientists in society. It is something else when the
scientist steps into the arena of value and meanings.
Q: Several surveys have shown that people trust in those with academic and
scientific knowledge, but they get most of their frontline information from the
media. I think it would be to the benefit of the consumer to hear from
scientists, because they do respect the empirical point of view. On the other
hand, we really do have to think about putting things into terms that the
consumer can understand and hear what the consumer is really asking,
fundamentally: is the food safe? That’s what the consumer wants to know.
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A: Albert Gunther, at the University of Wisconsin, has stated the following
in response to the strategy question of what should be said to the consumer:
when interviewed, the scientist usually begins in an empiricist mode, but then
switches to a celebratory mode, which is when the mass media interprets
and reinterprets and puts new meaning into what the scientist has said. It
is a complex communication dynamic, and I don’t think you can fault the
scientist for not answering the question—certainly the mediators of the
information from the scientist to the consumer play an important role. We
still have to come up with an examination of how the mass media tinker with
information from scientists. Who knows, rather than being actually celebratory,
added meaning may be injected by the mediator to cloud the fundamental
issue: is the food safe?
Q: The issue of celebratory science and communication is interesting. We are
seeing increasingly more of this, particularly in the genomics area in which the
identification of genes for specific diseases is leading to expectations for cures.
As funders of the scientific enterprise, we are increasingly being called upon to
be accountable. Do you see this as an increasing problem likely to erode the
public’s confidence in scientists? And do we as members of the scientific
community need to exercise control to decide what is a biologically significant
correlation—is it 20%, is it 80%? Do we need to set some thresholds for press
releases?
A: I think this is a trend. Once you start celebrating science, it is difficult to
change course. We must recognize that at some point the discourse will be
empiricist and it will eventually slide to celebratory. I think the challenge for
the scientist is, how best can you come up with communication strategies—
remember when you engage in celebratory discourse you subject yourself to
social criticism, which is an arena of public meanings, values and priorities that
you put into your communication. Whereas, with an empiricist approach, you
control the discourse. Therefore, I think that your concern about scientists
exercising more control of the information that they release, whether
celebratory or empirical, has to be seriously considered particularly by science
communicators and educators. Inasmuch as there are checks and balances in
empiricist discourse—through peer reviews and conferences—the same should
happen in celebratory discourses. And we have to be careful about whether or
not we are educating the public appropriately. If you choose to call golden rice
the “grain of hope” you open yourself up to criticism—you enter a discourse
that is not totally yours. It calls for a different way of thinking. However,
henceforth it will be impossible to concentrate on empiricist discourses; some
scientists will fight fire with fire. When Michael Jacobson asked what is the best
way to herald some of the benefits of agricultural biotechnology, he was asking
what is the best way of celebrating it.
Lambasting Louis: Lessons from Pasteurization
JOSEPH H. HOTCHKISS
Cornell University
Ithaca, NY
Despite extensive lay, regulatory, political, and scientific discussions and
reviews of recombinant DNA technology (i.e. biotechnology) and its application
to food and agriculture, worldwide opposition remains. Human and environ-
mental safety and socio-economic concerns have been discussed and debated in
rational and scientific detail, yet opposition remains fervent. Is this opposition
due, somehow, to the unique nature of biotechnology, or should it be expected
with any new technology, especially when applied to food, agriculture, and the
environment? Or is there a general distrust of new technologies that are not
widely understood and for which there is little direct individual experience or
for which the benefits seem obscure? If it is, at least in part, due to a general
distrust of technology, how might we better plan for such debates? It may be
useful to look back at past controversies.
Providing food has always been one of the major applications of basic
science. It should not be surprising that one of the foremost applications of
advances in biology has been food, along with medicine. One hundred and
thirty-five years ago, Louis Pasteur and others were also making striking
discoveries in basic biology leading to the field of microbiology. Major
discoveries over the past three decades have, likewise, led to biotechnology.
The application of Pasteur’s discoveries to food and agriculture was controver-
sial, just as the application of biotechnology is today.
LOUIS PASTEUR
Pasteur did not discover microorganisms. He made the immensely important
observation that they were not a consequence of disease, decay, and putrefac-
tion—as was the common scientific opinion at the time—but were, in fact,
the causes of these problems, and that eliminating them could eliminate the
problem. This knowledge led to revolutionary changes in medicine and food
preservation, not the least of which was the understanding that relatively mild
heating kills microorganisms and substantially improves the safety and quality
of foods without destroying desirable nutritional and sensory characteristics.
The process of heating perishable foods to make them safer and last longer
while retaining nutritional and eating quality was, as we all know, named after
Pasteur. As a good Frenchman, he applied his discovery to the preservation of
that most important beverage: wine. According to McCulloch (1936), in order
to “prove” the effectiveness of his process, Pasteur shipped a cargo of
pasteurized wine around the world in 1868 on the French frigate, La Sybile,
“without spoilage of a single bottle.” Pasteur later applied his mild heating
method to beer preservation, but there is no evidence that he applied it to milk.
It can be reasonably argued that pasteurization ranks, along with mass
immunization and water purification, as among the most significant develop-
ments in public heath during the early twentieth century. Nevertheless, in spite
of overwhelming evidence that pasteurization was beneficial, there was fervent
opposition in the late nineteenth and early twentieth centuries. This opposition
delayed widespread implementation for 30 years or more, and undoubtedly
resulted in the unnecessary loss of thousands of lives (Pirtle, 1926). Opposition
was so strong that some companies pasteurized milk in secret (McCulloch,
1936).
The early scientific work on pasteurization and microbial thermal death and
the many time-temperature recommendations for several pathogenic organisms
associated with milk have been reviewed (Westhoff, 1978; Holsinger et al.,
1997). For many years there was no consensus on the time-temperature
combination to inactivate the major milk-born threat, Mycobacterium
tuberculosis. Values ranged from 50 to 100∞C for 1 min to 6 h. North (1921)
pointed out that thirty-one different heating recommendations were made
between 1890 and 1920. Pasteurization times and temperatures were not based
on rigorous thermal death studies, but generally on the “complete” destruction
of M. tuberculosis as measured by infectivity.
The current time-temperature requirements for pasteurization were set in the
1950s, based on “complete destruction” of Coxilla burnetti (Q fever) in milk
containing 100,000 infectious guinea-pig doses. This organism cannot be
enumerated directly, therefore, studies were based on number of infectious
doses in laboratory animals (Enright et al., 1957). This approach to thermal
death might not withstand current scientific scrutiny were it not for pasteurized
milk’s safety over the past four decades. Scientific uncertainty about the most
appropriate time-temperature combination for milk remains even today, and
current research may determine that there is need for further adjustment (Grant
et al., 2001). Pasteurization and biotechnology, like other applications of
science, share a degree of scientific uncertainty.
PASTEURIZATION DEFINED
Modern pasteurization is the application of sufficient heat to a product for a
period of time in order to destroy pathogenic microorganisms, yet leave the
product acceptable from sensory and nutritional standpoints (Lewis and
Heppell, 2000). This latter point distinguishes pasteurization from other heat-
based processes that destroy microorganisms at the expense of product
acceptability. We now know that microorganisms generally die in a logarithmic
fashion when exposed to heat (Figure 1). One log cycle reduction in survivors
gives a 90% reduction in numbers. The time required to complete this 90%
reduction, the “D” value, is dependent on the specific organism and the
temperature to which it is heated, as well as on the medium in which it is
heated. This means that total microbial destruction is not possible, only that
some number of log-cycle reductions (D values) can be achieved and that
authorities must decide how many log reductions are required to adequately
protect public heath. Typically, food products are subjected to sufficient heating
for a period of time to give reductions of five to twelve D values. Thus,
pasteurization is not a guarantee of absolute safety, but a matter of risk
reduction. Some degree of risk must be accepted. Statistically, pasteurization
leaves behind some number of pathogenic organisms. Again, this is similar to
biotechnology, which also carries inherent hazards for which we must be
willing to accept some degree of risk.
Figure 1. Thermal death-rate curve for Pseudomonas fluorescens in milk
at 50°C. One D value equals the time to give a 1-log (ten-fold) reduction
in survivors, in this case 12.8 min.
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Microorganisms differ greatly in their sensitivity to heat, and, thus, the
combination of time and temperature that is sufficient to kill one species may
have little effect on others. Pasteurization, like biotechnology, is not a single
entity, but has been developed into a complex group of related technologies.
The appropriate heat treatment depends on the desired outcome and product.
MILK IN THE NINETEENTH CENTURY
Today, we think of milk as one of the safest foods available, and guard its
integrity and wholesomeness with near-religious fervor. But this has not always
been so. In the nineteenth century, in the words of Stenn (1980): milk “was
as deadly as Socrates’ hemlock.” It was one of the very few animal foods that
was almost universally consumed without heating or refrigeration, and was
less of a health risk when consumed within a few hours of collection. But, as
cities grew larger in the industrial revolution of the mid-1800s with mass
immigration to the United States, the time and distance between collection
and consumption increased. In the early 1800s, dairy cows were commonly
found within residential areas of American and European cities. As the cities
grew, dairy farming became more rural and milk transportation took longer,
hence the term “milk run” became synonymous with frequent stops as made
by trains of the latter half of the nineteenth century. Rosenau (1912) pointed
out that urbanization increased the time between collection and consumption
from a few hours to more than forty-eight without refrigeration. Given the
nature of milk as a microbial growth medium, one can only imagine the
microbial condition of raw milk kept at ambient temperature for two days.
Then, as today, milk was seen as important in infant nutrition and, as
such, it held a special place in the hierarchy of foods. It was surrounded with
superstitions such as the belief that thunder was responsible for curdling, as
the following demonstrates (Belcher, 1903):
The prevailing belief that a thunderstorm is the cause of milk souring is
one instance of misunderstanding. The fact that it is easy to purchase
milk which will not sour during a thunderstorm should suggest to the
consumer that there must be some other reason. And the reason is the
presence of lactic acid forming bacteria in milk. It is not disputed that
milk sours during a thunderstorm, but the cause is not the
thunderstorm itself, but certain conditions accompanying it, which
are favorable to the action of lactic acid bacteria. (emphasis added)
In the latter half of the nineteenth century, scientists who followed Pasteur
began to investigate the microbiology of milk and its possible relationship to
human disease, especially to the scourge of the day: tuberculosis. In the United
States, the yearly death rate from this disease in the early twentieth century was
160,000 and, of a population of 90 million, about 6 million could expect to die
from it. Typhoid fever claimed 25,000 per year (Rosenau, 1912). These and
other often-fatal infectious diseases including gastroenteritis, scarlet fever, cow
pox, milk sickness, diphtheria, septic sore throat, Malta fever, foot and mouth
disease, anthrax, contagious abortion, and rabies were, at least partially, linked
to raw milk.
In 1886, Soxhlet described a heating apparatus for pasteurizing milk at
home, and, in 1889, the Prussian-born physician Abraham Jacobi (the first
professor of pediatrics in the United States) brought Soxhlet’s ideas to this
country with the goal of improving the health of infants. Later, he and Henry
Koplix (a pediatrician in New York City) became convinced that pasteurization
would save children’s lives. Later work by M.J. Rosenau of Harvard Medical
School and C.E. North, among others, began to define the thermal death of
bacteria in milk.
In the nineteenth century, high infant mortality was considered a fact of life.
Rates, both in the United States and Europe were, by today’s standards,
unfathomable. The United States census of 1900 found infant mortality rates as
high as 40% (North, 1921). In Baltimore alone, 3,000 infant (<5 years of age)
deaths per year were reported (Knox, 1906). One third of all deaths were of
infants. In 1905, infant deaths totaled >105,000, of which 39,000 resulted from
diarrhea (Hygienic Laboratory, 1909). In 1920, infant mortality rates were
seventy-two to 203 per 1,000 infants in twelve major cities in the United States
(North, 1921). The current rate is <0.8%.
Undoubtedly, this high death rate had multiple causes, but careful epidemio-
logical studies were not undertaken. Studies in the United States and Europe,
however, suggested that diet was a particularly important source of fatal
infections. Savage (1912) reviewed the compelling evidence that milk caused
significant numbers of infectious-disease cases. The high rates of death due to
diarrhea, and increases in deaths in warm months, also provided clues. Studies
in England compared death rates of “suckled” infants to those fed “cow’s milk
only” (Tables 1–3). Breast-fed infants died at a rate of 6.2% compared to 36%
for those fed only cow’s milk. This difference was even greater when only the
first 3 months of life were considered. While we now know that breast milk has
many advantages, such as passing on immuno-stimulants, they are not great
enough to explain these differences. The evidence that milk was a transmitter of
diseases such as tuberculosis, typhoid fever, scarlet fever, and “septic sore
throat” was, even by the epidemiological standards of the day, incontrovertible.
In the nineteenth century, high infant mortality was
considered a fact of life. Rates, both in the United States
and Europe were, by today’s standards, unfathomable.
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TABLE 1. RELATIONSHIP BETWEEN MILK SOURCE AND INFANT
MORTALITY FROM DIARRHEA IN BRIGHTON, ENGLAND, 1903–1905
[CENSUS OF 10,308 HOUSEHOLDS (SAVAGE, 1912)].
Age at death (months)
0–3 3–6 6–9 9–12
—————— (% infant mortality) ——————
Breast only 1.9 1.3 — —
Bovine only 92 69 25 22
Unknown 2 4 2 2
TABLE 2. FRACTION OF 1-YEAR-OLD INFANTS DYING FROM
DIARRHEAa WHEN FED DIFFERENT MILK SOURCESIN BRIGHTON,
ENGLAND, 1903–1905 (SAVAGE, 1912).
Milk source Percent
Breast only 6.5
Bovine only 36
Condensed 30
Unknown 8
a121 of 1,259 infants died in the first year of life.
TABLE 3. INFANT (<1 YEAR) MORTALITY IN THE SUMMER MONTHS FED
DIFFERENT MILK SOURCESIN BRIGHTON, ENGLAND, 1903–1905
(SAVAGE 1912).
Milk source Percent
Store milk 19
Condensed 20
“Good bottled” 9
Central distributed milk 3
“Best bottled” 0
Breast only 0
Milk source
Knowing what we now know about diseases, there is little doubt that milk
was a very dangerous food in the late nineteenth and early twentieth centuries.
As late as 1942, G.S. Wilson reviewed the broad range of infectious diseases
transmitted through milk, and pointed out that they caused thousands of
deaths in Great Britain annually, and concluded that milk was “probably the
most dangerous article in our dietary” (Wilson, 1942). In an article titled
“White Poison,” Atkins (1992) reviewed milk quality in London at the
beginning of the twentieth century, and concluded that E. coli counts were more
than 1 million per milliliter. Current standards in the United States require
fewer than ten coliform (fecal) bacteria per milliliter. Stenn (1980) estimated
that residents of Berlin, Germany consumed 300 pounds of “cow dung” daily in
their milk due to the poorly hygienic conditions in which dairy cows were kept.
Scarlet fever was widespread, and transmitted via the milk supply (Wilson,
1986). It is not surprising that a cartoonist of the day portrayed milk as a
harbinger of death (Figure 2).
Figure 2. “I drink to the general death of the whole table.”
(This cartoon won a prize from the American Medical Association, ca. 1910.)
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Some of the most compelling evidence for the dangers of raw milk came from
New York City and the work of Nathan Straus, a wealthy principal owner of
Macy’s department store. Reportedly, he lost a child and was convinced it was
due to milk. Although he had no scientific training, he became interested in the
thermal treatment of milk after meeting Jacobi, and installed a pasteurization
unit in 1897 on Randall’s Island at the city’s asylum for children. The mortality
rate in 1897 at the asylum was an astounding 44%. After the introduction of
pasteurized milk in 1898, the rate dropped to 20% and further dropped to
16.5% by 1904 (Straus, 1917). The introduction of pasteurization was the only
major change during this period.
The success at Randall’s Island convinced Straus that he could save more
children’s lives through milk pasteurization, so, between 1899 and 1910, he set
up depots across the city to dispense free or low-cost pasteurized milk to
families with infants. While it is impossible to know the precise impact of milk
pasteurization, the infant mortality rate fell from 12 to 3.8 per 1,000 between
1893 and 1916. The then-commissioner of health in New York City stated that
there could be “little doubt” that the major factor in this reduction was “the
compulsory pasteurization of milk” (Straus, 1917).
Some in the young field of public health believed that raw milk was a carrier
of disease and that pasteurization offered a solution. In discussing the causes of
“food poisoning” Jordan (1917) pointed out that “of all foods, milk is the most
likely to convey disease,” and “the amount of illness traceable to milk far
exceeds that ascribable to any other food.” Knox (1906) found that 30% of the
10,000 deaths per year in Baltimore in the early years of the twentieth century
were of infants under 5 years, and concluded that 1,000 of these infant deaths
were due to milk consumption.
The headlines of the day were likewise critical of the milk supply. Nearly
every week the New York Times carried articles on the hazards of milk
(Figure 3). Headlines such as “Public Health and Infected Milk” appeared
as early as 1873.
As we now know, pasteurization is effective at controlling pathogenic bacteria
to the point that milk is now one of the safest of all foods. According to the
Centers for Disease Control and Prevention in Atlanta (CDC, 2000), between
1993 and 1997 only 207 of 86,058 (0.2%) were confirmed food-disease cases—
and no deaths—were traced to milk. It is likely that some, if not most, of these
cases were related to the still legal practice of selling raw milk, which, in recent
years, has been implicated in outbreaks of human disease (Steele, 2000).
RESISTANCE TO PASTEURIZATION
For decades, strong and adamant opposition succeeded in stalling moves to
make pasteurization mandatory in many parts of Europe and in North America.
The opposition came from almost all quarters, including the medical commu-
nity, the dairy industry, dairy technologists, and the milk-consuming public.
Wing (1897) advised that the use of pasteurization was an “open” question and
that “official” herd inspection was a better safeguard than pasteurization or
sterilization. He advised that the main culprit in milk-borne disease was the
dairyman “who is careless in regard to the cleansing of his utensils.” Bailey
(1909) described pasteurization in terms of contemporary agricultural practices
in the Cyclopedia of American Agriculture, but suggested that it be used only
when outbreaks of contagious disease were attributable to milk.
Opposition was based on four general arguments (Wilson, 1942):
• It was reasoned that milk pasteurization was deceptive and not needed if
milk was properly handled. Pasteurization would mask low-quality milk,
conceal evidence of dirt and filth, remove any incentive to produce clean
milk and cull diseased animals, and legalize ineffective dairy practices. The
efficiency and effectiveness of pasteurization was questioned based on
observations that in some cases it appeared to work well and in others not
at all. These differences, no doubt, resulted from differences in recom-
mended time-temperatures. Although the precise times and temperatures
were not known with certainty, there was sufficient understanding of the
technology to broadly implement pasteurization (Kilbourne, 1916).
Equipment to heat-process milk was widely available by 1901, when
Monrad (1901) described in detail the technology to pasteurize, cool, and
ship milk.
• The agricultural industry in particular worried that pasteurization would
disrupt the economic status quo. There was fear that mandatory
pasteurization would place the cost of milk beyond the means of too many
Americans, and would put small producers out of business. Only the large
companies would be able to afford the process. Milk was already too
expensive for many, and was consumed in greater amounts by the wealthy
Figure 3. Selected headlines from the New York Times concerning milk and
disease 1873–1920.
• Public Health And Infected Milk, September 10, 1873.
• Milk—Pure and Impure, July 21, 1874.
• Milk as a Spreader of Disease, Editorial, October 25, 1878.
• Milk—Cow with Rabies: Milk Sold on Staten Island, June 14, 1887.
• Milk, A Source of Disease, April 20, 1890.
• Cattle—Tuberculosis Contracted from Diseased Milk, March 3, 1894.
• Milk—Disease Transmitted: Pasteurization Urged” May 24, 1896.
• Milk—Deaths Due to Milk, August 19. 1903.
• Coblenz—E.L. James Says Death Rate of Children Under 5 Has Increased
in Last 6 Years and that Milk is Lacking, January 8, 1919.
• Diphtheria—2 Deaths, Traceable to Milk, Occur in Greenwich, March 4,
1920.
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(who suffered the ill effects of the raw product). The sentiment was
asserted that people have a “right” to drink raw milk if they wish.
• One of the most common arguments against pasteurization was that it
adversely affected milk composition and its organoleptic properties. It was
said to “ruin” the flavor and “take the life out of milk.” It must be
remembered that milk then, as today, held a special place as a food.
• Ironically, the most vehement opposition may have been from the medical
community who argued that pasteurization would diminish the health
benefits associated with milk, particularly in infants. The concern was that
pasteurization would destroy the nutrients. Understanding of human
nutrition was just beginning in the early part of the twentieth century. One
focus was on milk’s “anti-scurvy” properties of milk.
The exact nature of scurvy and its relationship to vitamin C was largely
unknown, but physicians had made the observation that raw milk could have
anti-scurvy activity that was lost upon heating. Hess (1920) suggested that
whereas milk heated in the home was not adversely affected, commercial
pasteurization would destroy the anti-scurvy activity. We now know that raw
milk contains a small amount of vitamin C (<2% of the current RDA per
serving) and that excessive heating can reduce this low level. It is possible that
even this small amount would be sufficient to ward off scurvy in an infant
whose total intake of vitamin C was borderline.
Another health-related objection was connected to tuberculosis. It was clear
that this was an infectious disease, but its precise cause and vehicles were not
understood. Cattle also suffered from tuberculosis, but there were differences
between the organisms infecting humans and cattle. Some suggested that
bovine tuberculosis was not transmittable to humans and, therefore, milk could
not be a vehicle. Some suggested that exposure to bovine tuberculosis had a
protective effect on humans.
Other objections were less scientific. It was suggested that pasteurization
interfered with nature, that infants failed to thrive on pasteurized milk, and that
pasteurization would give a false sense of security because bacteria grew rapidly
when added to pasteurized milk. These objections came not only from the
fringe, but often from mainstream science. Comments on pasteurization by
McCollum (1918) in a nutrition text are illustrative:
Milk which has been pasteurized at 165°(F) is more liable to induce scurvy than
either boiled milk, or milk which has been pasteurized at lower temperatures, as
140–145° for thirty minutes. The most satisfactory explanation for these results seems
to be found in the bacteriological condition of the milks treated in the various ways
described. . . . These results strongly support the view that there is a bacteriological
factor involved in the causation of scurvy, and emphasizes the importance of securing
clean milk, and of having it so handled as to insure its delivery in a good bacteriologi-
cal condition.
Hess (1920) agreed:
It has become increasingly evident that in the course of pasteurization milk loses an
important measure of antiscorbutic vitamine [sic].
Proponents of pasteurization countered these objections by arguing, as did
Savage (1912) in England and Rosenau (1912) in the United States, that milk
was the cause of significant human disease and that pasteurization would make
it safer. Savage (1912) argued that four strong lines of evidence linked milk to
disease:
The incidence is upon those who drink a particular supply of milk (disease outbreaks
are traceable to specific milk supplies).
Outbreaks are explosive in nature (large numbers of outbreaks occur simulta-
neously).
Incidence falls upon the milk-consuming part of the community (segments that tend
to consume more milk have higher disease incidence, and milk consumption and
disease correlate with economic status).
Milk drinkers in particular houses are attacked (milk consumers have a higher
incidence than non-consumers living in the same household).
In 1909, the United States Hygienic Laboratory published a collection of
papers on the relationship between milk and the public health, by epidemiolo-
gists, bacteriologists, dairy chemists, sanitarians, and dairy-processing
specialists (Hygienic Laboratory, 1909): the cost in lives from milk-borne
disease was immense and the answer readily available. Yet, broad implementa-
tion was decades away.
In 1909, the United States Hygienic Laboratory published
a collection of papers on the relationship between milk and
the public health, by epidemiologists, bacteriologists, dairy
chemists, sanitarians, and dairy-processing specialists
(Hygienic Laboratory, 1909): the cost in lives from milk-
borne disease was immense and the answer readily
available. Yet, broad implementation was decades away.
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Opposition to pasteurization exists today, disseminated on the Internet. Dr.
Regan Golob, writing for the Dynamite Company, tells people that pasteuriza-
tion “kills” milk. The “Milk Quiz” at the “Not Milk” Web-site indicates that the
main reason for pasteurization is to “fool you.” Proclaimed nutritionist Aajonus
Vonderplanitz and a raw-milk farmer tells Internet surfers that “the bacteria-
phobia has no empirical basis” and that there have been no clinical studies to
prove or disprove the “theory” that pathogens in milk can cause disease in
humans.
PARALLELS BETWEEN THEN AND NOW
There are several parallels with the debate over biotechnology, and the solutions
discussed in the early 1900s seem quite applicable today. In 1912, Rosenau
debated what should be done about the opposition to pasteurization or, as he
put it in his book, “The Milk Question.” He called for patience, public and
professional education, and cooperation between commercial, government, and
scientific communities, and that all should let the “facts speak for themselves.”
Interestingly, he promoted the comparison of milk with other health issues such
as water treatment, which apparently generated no opposition. This suggestion
is similar to the contemporary view that technologies should be viewed in light
of the magnitude of risk associated with implementation (or not). Decades
later, Hill addressed strategies to deal with the still-strong opposition to
pasteurization (Hill and San, 1947). He argued for the importance of public
education on pasteurization and that scientists should strongly repudiate
misinformation. He also counseled that facts overcome falsehoods, that credible
authorities should speak out on the issues and present factual information
based on unbiased research, and he admonished scientists to acknowledge
imperfections and shortcomings.
These approaches do not seem much different from those proposed today,
but there are notable instances where they appear to have been ignored. It is
also instructive to note that the opposition to new technologies is not a new
phenomenon associated solely with recombinant DNA technology. Recent
examples range from food additives, coloring, and pesticides, to irradiation and
packaging. It seems that opposition to technology in agriculture and especially
consumer foods will occur no matter what the technology.
What lessons and strategies can scientists and technologists gain from this
history? The most obvious is that controversy and opposition are likely to
develop in response to the implementation (not discovery) of any new
technology used in food and agriculture. Anticipation and planning should
accompany technological development, and not be a reactive response. When
controversy is not anticipated and planned for, technologists and scientists are
forced into the position of reacting to the debate as framed by others, rather
than being framers of the debate.
It is also instructive to note that the opposition to new
technologies is not a new phenomenon associated solely
with recombinant DNA technology. Recent examples range
from food additives, coloring, and pesticides, to irradiation
and packaging. It seems that opposition to technology in
agriculture and especially consumer foods will occur no
matter what the technology.
The controversy surrounding pasteurization also points to the importance
of the media. For more than 40 years, the press has been generally in favor of
pasteurization. It is important to educate the media early in the development
stage and not to delay until implementation. Perhaps because of his experience
in the retail business, Straus seemed to understand the importance of the press.
While it is essential that scientists educate themselves and their colleagues
about new technologies, they cannot dismiss the importance of the broader
audience. Professional societies with interests in food, agricultural, environ-
mental, and health issues have produced a number of excellent overviews of,
and discussion-pieces on, biotechnology, and have issued rational position
papers (e.g. IFT, 2000). And several professional groups have been producing
educational documents, technical summaries, and detailed reports for nearly
a decade. The American Dietetics Association and the American Medical
Association, among others, have also developed reports and positions on
agriculture-related biotechnology. These publications are especially useful for
educating groups with direct interest in the technology and with sufficient
background to grasp the underlying science.
Unfortunately, these efforts are at times “preaching to the choir” in that
they target groups willing to listen and to learn and to evaluate new technolo-
gies on their merit, and may miss lay audiences. This latter constituency may
have little interest in the technical details—whereas most educational materials
consist almost entirely of technical explanations—and be more interested in
the broader implications. Among the most important questions for consumers
are: Who benefits? Who is at risk? What will it cost? Who oversees the
technology? What are the health and environmental risks? Powell (2000)
pointed out the importance of understanding the audience’s concerns in
communication of risk to lay groups.
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There is little evidence that those who developed and promoted pasteuriza-
tion understood these lessons any more in 1901 than modern promoters of
biotechnology do today. If influential groups (e.g. the press, see Figure 4)
who are likely to oppose technology were considered early in the development
process, rather only after controversy has erupted, implementation might
involve a less arduous route. Strategies for early engagement of influential lay
interests might foster easier transition from basic discovery to practical
implementation.
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Q: Was pasteurization accepted differently in different countries, and are
there lessons to be learnt from that?
A: It was controversial both in Europe and in the United States, but possibly
less so in Europe, even as recently as post World War II. Since pasteurization
makes milk last longer, it received a boost after the war. However, it remained
controversial, certainly in the United Kingdom, whence comes much of my
information.
SOME FACTS ABOUT MILK
Germ changes and contamination of milk
Information important to women…
House wives and mothers should be versed in milk lore—modified milk
sterilization and pasteurization…
…the prolific source of danger which is harbored in this fluid…
…severe epidemics of typhoid fever…owing their existence to the common
source of tainted milk…
…it is no imperative that milk must be contaminated…
They (British and Americans), continue to drink milk…without protection
from infection. It is true but strange that every savage nation on the globe that
uses milk... has some form of protection.
Milk as used in large cities is a very different article from that used by
primitive man. It is seldom perfectly fresh, pretty sure adulterated, and almost
always dirty.
Until we are assured of absolute purity, we should resort to protection. Science
has unmistakenly established the importance of this.
Figure 4. New York Times headline and excerpted article, September 22, 1895.
Q: Considering that the concept of pasteurization was so hard to sell, against
the reality of the high rates of infant mortality, what are your thoughts
regarding biotechnology, the benefits of which are less obvious to the public?
A: Clearly, it is a harder sell. However, mind-set is important. People had
always expected their children to die. Even educated individuals said that this
was the way of the world. Many thought that infants died because they had
“poor constitution.” I don’t know exactly what that was, but it was regarded in
terms of it being better that they died. It is ironic that a lay person, Nathan
Straus, raised this issue, rather than the medical community. With respect to
biotechnology, people who are bringing it to practical use must tell the lay
public why they are doing it, what it will do, who will benefit, and they must
admit that profits are involved. It should have been stated much more forcefully
that children were dying and that there was good evidence that it could be
stopped by pasteurization.
Q: Have you considered writing this story for, say, the New York Times
magazine or the Atlantic Monthly to obtain broad communication of this
message to encourage people to draw their own conclusions as to where we
are today?
A: That is an interesting question. Particularly on a lay level, I think there
is an important lesson that technology in general should be judged by what it
can and cannot do, and what its risks and benefits are.
With respect to biotechnology, people who are bringing
it to practical use must tell the lay public why they are
doing it, what it will do, who will benefit, and they must
admit that profits are involved. It should have been stated
much more forcefully that children were dying and that
there was good evidence that it could be stopped by
pasteurization.
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Q: Were the business interests in pasteurization similar to or different from
the business interests that underpin biotechnology?
A: Nathan Straus died poor, broken because the authorities made him shut
down all of his pasteurization plants. He was Jewish, and had hoped to take the
technology to what is now Israel. He made no money for this, and, in fact, lost
most of his fortune in trying to promote it. Opposition to pasteurization came,
in part, from the entrenched dairy industry—farmers and processors—which
is different from the situation today. On the other hand, some companies
did promote pasteurization, primarily Borden Foods, in Syracuse, New York.
Louis Pasteur began to understand pasteurization in 1865, however,
violent opposition exists even today, as evidenced by what can be found on
the Internet.
Q: Cheese is made with unpasteurized milk in Switzerland. I eat it when
I can get it, because it is so good. I eat it knowing that there is some risk. One
of your slides mentioned the “right” to consume unpasteurized milk. Do you
agree with that, and are their parallels with people declaring that it is their right
to choose GM foods or to avoid them?
A: Cheese is a poor analogy in that, if it is aged more than 60 days, the risk
is substantially reduced. There is on-going argument on this issue between
Europe and the United States. In the United States, all cheeses under 60 days
of age have to be made from pasteurized milk. On the question of the right to
drink “raw” milk, I think it is a societal question. Drinking such milk, and
possibly eating such cheese, is to play food-poisoning roulette. As a society,
where do we draw the line on what we protect ourselves from? In general,
where the risk is high and technology exists to reduce that risk, we as a
society should apply that technology. Where the risk is low, I believe that
the technology again should be applied—but that is subjective and will be
interpreted differently by different people. We have decided that the risk from
unpasteurized milk is high. Roughly two-thirds of the states have made it
illegal to sell it. Each case should be looked at in terms of risk versus benefit,
and as a society that is why we elect supposedly very smart people to make
such decisions for us. That brings some smiles.
Q: In your coverage of opposition to pasteurization you mentioned small-
scale producers. Do you see a time when a similar issue will apply to
biotechnology?
A: Yes I do, not for technological reasons, but for marketing reasons. We at
Cornell put the gene-gun into a Winnebago and drove it around the state and
let high-school students genetically modify plants. In other words, it is not a
centralized technology, although it is centralized as a business. When I’m in
Europe, I tell people that they should protest the fact that biotech is broadening
the gap between the rich and the poor, and that biotech is not being applied
where it is needed most: in the developing world.
An Agricultural Response to the
Feeding Frenzy
NANCY F. MILLIS
University of Melbourne
Melbourne, Australia
The ancestors of our agricultural plants and animals were subjected to stresses
that selected among populations for fitness to survive in particular environ-
ments. But, for our purposes, survival was not enough—we wanted other
properties as well, such as more starch, oil or protein in the seed, shorter stalk,
more protein in the leaves. We selected parents with these properties, bred from
them, and ruthlessly culled any inferior offspring. So, slowly, randomly, the
genome of the population was nudged towards wanted goals. Obviously, this
so-called selective line breeding was restricted to organisms where crosses
produced fertile offspring. This severely restricted the pool of genes from which
useful properties could be drawn.
In the middle of the last century, opportunities for improvements came from
unnatural techniques like protoplast fusion, where cells of related, but
incompatible, species were fused as protoplants and then regenerated into
whole plants. Other sources of variation were developed using somoclonal
variation, embryo rescue, and mutagenesis. By altering the genome, these
techniques have added considerably to the range of agriculturally useful plants
and animals. These new cultivars and animals have been readily accepted by
farmers, and consumers now demand the improvements so achieved—who
wants stringy beans, small, tough, high-tannin apples, bitter lettuce, or
poisonous potatoes?
The first transgenic plant was developed In 1982, but it was a further 13
years before transgenic crops were grown on any significant area. Currently,
that area is estimated at over 50 million ha in the west, with further significant,
but unknown, areas in China. In Canada 55% of the canola is GM, the United
States has extensive areas of GM cotton, corn, soya and canola. Argentina’s soya
crop is 95% GM, and a third of Australia’s cotton crop is GM. The European
Union, however, has shown considerable reluctance to accept GM crops,
particularly in certain countries, e.g. Denmark, Austria and Switzerland;
Belgium, the United Kingdom and France are prepared to consider them,
provided appropriate supervision is in place.
WHY IS OPPOSITION TO GM CROPS SO HEATED?
It is clear that the reasons for the fuss must be addressed by farmers who
adopt the technology with the intention ultimately of selling their produce.
Consumers’ perceptions are vital. The scientists may make and use the
constructs, identify potential hazards and, with the regulators, assess risks and
suggest appropriate management strategies, but they are often not well disposed
to empathize with the perceived risks held by various sectors of the general
public. This brings me to concerns I have observed in the debate about GM
crops destined for the food supply. But, first I want to talk about risk and
various ideas related to it.
RISK ANALYSIS, ACCEPTABLE RISK, PERCEIVED RISK,
MANAGING RISK
For me, risk analysis is the combination of some identified hazard or harm and
the probability that that harm will come to pass. This is linked to consider-
ations of the seriousness of the identified harm. Risk management follows from
the information just listed, as it leads to devising ways to eliminate, minimize,
or control serious harm. I believe we should not use the concept of acceptable
risk, as it immediately raises unanswerable questions:
• Acceptable to whom?
• Who decides what that level of risk will be?
The concept is value-laden and, accordingly, the level of risk chosen tends
towards zero, as the only acceptable risk. This fails to recognize that effort spent
in risk reduction may be misapplied if, to be acceptable, risk must be zero or
Consumers’ perceptions are vital. The scientists may make
and use the constructs, identify potential hazards and,
with the regulators, assess risks and suggest appropriate
management strategies, but they are often not well
disposed to empathize with the perceived risks held by
various sectors of the general public.
close to it. Effort in risk reduction is best spent after comparing the seriousness
of the identified risks associated with an activity, and then putting effort into
reducing the most serious—in other words, managing the risk in a cost-effective
fashion.
When risk assessment of gene technology began in the 1970s, it was very
much the autonomous domain of science and technology. Science methodology
was applied to identifying hazards and quantifying risk. Social implications
received scant attention, and the scientific and social sectors of the community
engaged in name-calling; this fueled mistrust of science among the general
public and a dismissive “irresponsible” label was applied by scientists.
From 1980 onwards, attitudes changed, and it is more widely appreciated
that science and technology are also socially constructed and must interact with
the public, companies, and farmers. Scientists must recognize that there are
issues unrelated to science that are very significant to some sectors of the
community that ultimately will buy (or not buy) GM products depending on
whether they feel comfortable and consulted about the process of surveillance
and regulation. The way in which surveillance and regulation was established
made those with concerns for social issues feel powerless. Scientists and
regulators must recognize that the resulting stand-off is counter-productive, and
take time to meet with the stakeholders and explain in plain terms the process
of surveillance and risk assessment, how it works, and how a reasonable
accommodation can be reached between differing positions.
CONCERNS ABOUT GM AGRICULTURAL CROPS
It may be helpful to recognize the types of concerns held by the community.
They can be placed in two broad classes. One consists of concerns stemming
from personal beliefs, moral values, religious convictions, lifestyle preference,
and method of food production, or from socio-economic concerns about
multinational companies that own the patents on many of the genes and
processes, and make the chemicals associated with the use of some of them, for
example GM plants with herbicide resistance. Others simply do not trust
scientists. It is important to note that these concerns are not connected with
any risk of the GM crop to the worker, the farmer or the environment, nor with
claims of efficacy. The other class of concerns relates to hazards identified as
possible outcomes from growing the GM organism.
It is not acceptable for GM advocates to dismiss the first class of concerns as
inconsequential, any more than it is appropriate for GM opponents to deny
others access to a technology that they perceive as beneficial. It is a dangerous
path to develop regulations based on the religious beliefs or lifestyle preferences
of particular sectors of the community. It is, however, possible to offer choice.
In the case of GM foods and food ingredients, labeling will give those who do
not wish to eat such foods the option to avoid them. Moral, religious or ethnic
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issues cannot be readily addressed by legislation, but those who oppose GM
technology on these grounds must be prepared to accept the differing views of
others. Similarly, with small-scale cottage agriculture/organic farming, those
advocating these methods must recognize the escalating demands for food from
the world’s increasing population, and by populations currently undernour-
ished. This requires us to be responsible in adopting every tool at our disposal
to increase productivity, reduce predators in crops, competition from weeds,
disease infestation and post-harvest losses. We know that the planet has no new
land suitable for agriculture, but gene technology may enable marginal land to
become productive by designing plants to tolerate high salinity, or with the
ability to complete their life cycle in areas with a very short growing season.
One could ask whether it is ethical to deny such possibilities.
ADDRESSING IDENTIFIED HAZARDS
Scientists must be seen to address honestly any hazards that might be associated
with transgenic plants. A list of some of these follows:
• Crop plants might become weeds.
• Herbicide-resistance genes might pass to related weeds.
• Growing herbicide-resistant crops might result in greater use of herbicides.
• Plants carrying genes for a pesticide could result in insects becoming
resistant more rapidly because of continuous selective pressure.
• Genes for pesticides could pass to weeds and encourage their growth, since
they would not then be eaten by pests.
• Transgenic plants may cross with free-living relatives and thus contaminate
the gene pool.
• The novel gene could cause the plant to produce a toxin, carcinogen,
teratogen, or allergen.
• Transgenic plants could be inferior nutritionally, less digestible, or have
inferior processing properties.
• A crop-plant resistant to one herbicide may acquire resistance genes for
other herbicides from other crops. Such multiply resistant plants would
become difficult to control in farming rotations.
Whether these hazards will materialize must be considered case by case.
The growth habit and genetics of crop plants are, in most cases, well known,
the gene being introduced and its product are fully characterized, and the
properties of the donor organism also are known. If the host and donor
organism have a long history of safe use, it is highly unlikely that the transgenic
will exhibit injurious or unwanted properties. Nevertheless, pre-commercial
trials offer every opportunity for such possibilities to be detected; such trials
are usually conducted at multiple sites over 5 to 7 years. Problems of gene
introgression can arise from outcrossing either to other crop plants or to weedy
relatives. Canola is such a crop, whereas peas, clover, wheat, barley, etc., are
essentially self-fertile, and present a less serious problem. Plants like cotton
that are polyploid, are restricted by ploidy and type of genome from crossing
with native Gossypium relatives. To manage gene escape in canola trials in
Australia, for example, we require 15-m buffer rows of non-transgenic canola to
be planted, and a 50-m zone to be rogued free of Brassica species and related
weeds. During flowering, a 400-m zone is maintained free of Brassica species.
Post trial, volunteer transgenic and weedy relatives are removed from the trial
site, buffer rows, and the 50-m zone for three seasons. The area may be planted
to pasture or cereals.
This management plan does not guarantee zero risk of pollen escape, but the
likelihood is greatly reduced, and the hazard (a weed or canola plant becoming
herbicide resistant) can be managed using a herbicide with a different mode of
action.
To reduce the possibility that insects may become resistant to Bt, refuge areas
of non-Bt cotton or sacrificial crops like maize are incorporated to allow a ready
source of fully sensitive moths to mate with those that have acquired one copy
of a recessive resistance gene. This strategy slows the emergence of resistant
insects, which must be homozygous recessive diploids. This strategy, combined
with constant observation of the insect population and appropriate timing of
the application of other pesticides will enable the usefulness of Bt crops to be
prolonged.
GOOD AGRICULTURAL PRACTICE
Whereas the pre-commercial stages in the development of transgenic crop
plants are under government surveillance in most countries, the real test comes
when large areas are planted commercially and government surveillance is less
direct, or absent. In an endeavor to meet this situation in Australia, the
agriculture department combined efforts with the genetic surveillance, science,
and farming sectors to produce guidelines for good practice in the use of GM
organisms on the farm. A set of issues was drawn up to be addressed by those
breeding, using, growing, or selling GM organisms, as well as consumer and
environmental groups. It was recognized that diversity of crops/animals,
agricultural region, climate, topography, soil, etc. made uniform rules
impossible. Rather, the plan is to have a workshop of interested parties in the
region at the time of the first field trial to ensure that the right issues are
addressed. When all of the field results are available and commercialization is
imminent, a second workshop will be held with the purpose of developing a
clear set of instructions for growers and consultants as to the best practices to
adopt in managing the GM crop in various rotations, so as to extend the useful
life of the GMO and ensure sustainability of the farm, acceptance by consumers,
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and preservation of environmental values. It will also set out the monitoring
regime required to control any unwanted spread of the introduced gene. It is
recommended that the seed seller make it a condition of sale and license that
the grower adopt the good agricultural practices arising from the results of the
trials and the workshop.
WHAT’S IN IT FOR THE CONSUMER?
The GM plants grown so far are largely those that benefit farmers or large
multinational companies (resistance to insect-predation, herbicides, virus or
fungal diseases). Whereas the technology reduces costs of production, the
consumer does not see a direct benefit, especially as GM foods are not
substantially different from their conventional counterparts, and the price
differential is nonexistent or very small. However, when a 10% price advantage
applied, a well publicized GM tomato paste sold very readily in the United
Kingdom. The other change that will attract consumers is a GM product
that has a clear quality advantage: e.g. a tomato that tastes as they once did.
Consumers will accept what benefits them personally, as is very clear from
the ready acceptance of therapeutics made by gene technology.
I believe that agriculturalists must respond to this reality and direct their
research towards quality attributes that consumers value. This will be more
difficult to achieve than the single-gene changes that have been exploited so
far, but unless the consumer sees the gain, agriculture will bear the pain.
In addition to direct benefits to consumers, GM agriculture results in a
number of important gains for the environment and the sustainability of the
farm, with reduction in wind and water erosion, reduced use of pesticides and
highly persistent herbicides, and an environmentally preferable control of
insect-born viral infections. These benefits appeal to many consumers and
indeed are complementary to the objectives of organic farmers; they need to
be highlighted in discussions with consumers. In response, consumers often
invoke the precautionary principle and seek an absolute guarantee of no risk.
RISKS WE LIVE WITH
I found a chart prepared by an insurance company to be very instructive. It
plotted the age of the population against the probability of death within the
year. The likelihood of death simply by being alive, increases rapidly with age—
the best expectancy is about 1 in 1,000 in our early teens, and from then on it
is all downhill. What disasters will kill us? Being hit by lightning is about 1 in 2
million, death in the air or by drowning is similar at around 1 in 60,000, death
in a car is 1 in 8,000 and from contaminated air 1 in 1,000. We just live with
risks that are beyond our control, but other hazardous activities that could be
avoided, like driving a car, are shrugged off equally nonchalantly. The perceived
benefit far outweighs the risk represented by the toll on the roads each
weekend. So what about the precautionary approach?
PRECAUTIONARY PRINCIPLE
It is critical that the concept is fully understood. It is not a prescription for
achieving zero risk. According to a European Union document, applying the
principle requires:
• objective assessment of hazards and their probability,
• consideration of management options, and
• consistency and transparency in data collection and assessment.
Then the option adopted must:
• relate to the seriousness of risk,
• include a cost-benefit analysis, both economic and social,
• indicate who is responsible for risk assessment, and
• be provisional, so that management can be revised in the light of new
scientific data.
My plea to agriculturalists and the food industry is to develop GM commodi-
ties that will benefit consumers directly, and to ensure that the precautionary
approach is adopted by GM breeders, farmers and food manufacturers, both
during trials and when in large-scale production. It is also essential to label GM
products so that consumers have choice.
Q: You presented information on best practices for release of GM plants and
for their management after release. However, in Australia only one GM crop has
been released. Are regulations there too cumbersome?
A: Only Bt cotton has gained acceptance. Roundup-Ready cotton is coming
along and canola will probably follow. Wheat is a major crop, but it has not had
a lot of GM work done on it, as yet. On the food side, the rules are if a food is
known to have been made from GM material, you must label it as such. If an
ingredient is of GM origin, the ingredient must be so labeled. If it is intended
that the food is conventional, but has a small inadvertent contamination, you
can have up to 1% without requiring a label. In the case of cotton-seed oil,
because it is refined and, therefore, does not contain novel DNA or protein, it
does not require a label. This is true also of sugar and starch.
Q: You suggested that before field trials would be held, that there be a
workshop. It seems to me that, in this country, we get at that in a different way.
We have a virtual workshop through the Federal Register or other public
notices, which provide opportunities for public comment. Do you believe that
the actual workshop interaction is essential, or is the virtual workshop through
the Federal Register and the comment period, etc., an acceptable substitute?
A: We use both. The Government Gazette is the vehicle in which notice is
given of release of a live organism to the environment, and public comment is
permitted. In addition, at the time of the workshop, we are trying to inform
people “on the ground” what sorts of problems might arise.
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Q: I have a comment and a question. You noted the tremendous potential
value of genetic engineering in providing the food that will be needed for a
more populous world. It is worth noting that, if the United States, Europe,
Australia and certain other countries, stopped the production of grain-fed
livestock, we would have a tremendously increased availability of food, which,
for agencies concerned with food production that may be an approach worth
investing in. (Dr. Millis: I couldn’t agree more.) My question is with regard to
labeling in Australia and New Zealand. What are food manufacturers saying
about that? Will they market foods with genetically modified ingredients?
A: This is yet to be fully tested. I have spoken with CEOs of food companies
who have said, “A drop of 5% of sales is critical to me—I won’t touch it. I want
‘GM-Free’ on my label.” Now, this is an interesting statement in that the ‘GM-
Free’ on the label has to be fully documented such that it may be audited.
Therefore, you could find yourself in trouble with that label if someone detects
contamination with PCR.
Q: In this country it seems that companies are afraid of marketing foods with
that label. In Australia, they don’t have to say ‘GM-Free,’ they can just say
nothing. Do you think that is the approach that food companies will take?
A: Yes, I do. And there will be a price differential, I suspect. I cannot imagine
a situation where the company pays but the consumer doesn’t.
Q: But, will the companies actually market that alternative line with the GM
label?
A: I don’t know. But, I have the same feeling as you that they are suspicious of
declaring ‘this is GM.’
The Genetically Modified Crop Debate in the
Context of Agricultural Evolution1
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“Whoever could make two ears of corn, or two blades of grass grow upon a spot
of ground where only one grew before would deserve better of Mankind, and
do more essential service to his country, than the whole race of politicians put
together.”—The King of Brobdingnag, Gulliver’s Travels by Jonathan Swift, 1727
“I believe that we have now reached a moral and ethical watershed beyond
which we venture into realms that belong to God, and to God alone. Apart from
certain medical applications, what actual right do we have to experiment,
Frankensteinlike, with the very stuff of life?”—Prince Charles (Windsor, 1998)
Throughout history, there have been those who have embraced change and
those who have clung to the old ways because they felt that at least the risks
were known. Few Edisons or Einsteins were properly recognized during their
lifetime. And, since feeding ourselves has been the primary occupation of
humankind for most of recorded and prerecorded histories, changes in food
production have been accepted slowly. The first person to try to scratch out a
garden most assuredly heard derisive laughter as the mighty hunters headed
off in pursuit of meat. So, we should not be surprised that eons of history are
being replayed as we enter the era of biotechnology. As the fates of human
society and crops have been inextricably intertwined since the dawn of
civilization, an appreciation of our agricultural past may guide us in addressing
societal concerns and also in ensuring minimal negative consequences from
scientific pursuits.
1Edited from a commentary by the author in Plant Physiology 126 (2001) 8–15, and included here
with the permission of the publisher.
Farmers have embraced biotechnology because it makes them more efficient,
protects or increases yields, and reduces their reliance on chemicals that, other
things being equal, they would prefer not to use. Crops enhanced by bio-
technology are being grown on approximately 110 million acres in thirteen
countries. Ingredients produced from biotech crops are found in thousands
of food products consumed worldwide. However, although no unequivocal
evidence of harm to our health or the environment from these crops is known
or expected, an intense debate is focused on their value and safety.
Societal anxiety over so-called genetically modified (GM) food is understand-
able, and it is fueled by a variety of causes, including consumer unfamiliarity,
lack of reliable information on the current safeguards, negative opinion from
the news media, opposition from activist groups, growing mistrust of industry,
and a general lack of awareness of how our food production system has
evolved. The scientific community has neither adequately addressed public
concerns about GM foods nor effectively communicated the value of this
technology. Clearly, societal acceptance is pivotal to the continued development
and application of biotechnology in agriculture and food.
Two decades ago, many agricultural scientists rightfully saw the emerging
recombinant DNA technology as a potent tool for enhancing crop productivity
and food quality, while promoting sustainable agriculture. The early excitement
and expectation was followed by successive breakthroughs in identification
of valuable genes, development of gene-transfer methods, and the eventual
production of transgenic crops. Breeders saw the technology as a complemen-
tary means of achieving crop improvement, and, for the first time, the products
of their efforts were subjected to rigorous testing, and a regulatory framework
was developed to oversee the commercialization of GM crops on a case-by-case
basis. There has been widespread acceptance of, and support for, biotechnology
within the scientific community. Accumulated experience and knowledge of
decades of crop improvement combined with expert judgment, science-based
reasoning, and empirical research have given scientists confidence that GM
crops may pose no new or heightened risks that could not be identified or
mitigated, and that any unforeseen hazard will be negligible, manageable, or
preventable. Risks from GM crops should be monitored and measured, but
concerns about these risks must be balanced against the enormous potential
benefits from this technology and weighed against alternative options. The
strong trust of the American public in its regulatory agencies (the Food and
Drug Administration, the United Stated Department of Agriculture, and the
Environmental Protection Agency) has fostered higher public acceptance of
GM food in this country than elsewhere.
MUTANT FOOD AND MONARCH BUTTERFLIES
Despite promised benefits, global negative reaction to GM crops ranges from
mild unease to strong opposition. Typical questions include:
• Is it ethical for scientists to modify living organisms?
• Is it morally right to tamper with our food supply?
• Is genetic modification of crops inherently hazardous?
• Despite built-in safeguards, can we unwittingly make our foods unsafe?
• What about the long-term consequences of consuming foods containing
GM ingredients?
• Do GM crops affect the environment or wild ecosystems, reducing crop
biodiversity, beneficial insects, or the revered monarch butterfly?
• Could GM crops lead to the development of noxious “super-weeds”?
• Are we introducing GM crops into our environment without fully
understanding the consequences of such action?
• Should we be concerned about genetic pollution?
• Can these genes be transferred to other organisms, including humans
and animals?
In addition, there are also larger and even more important sociopolitical
issues such as anxiety about the control of food and agricultural systems,
including questions about the pervasive impact of globalization.
How can scientists allay public concerns, given the complexities of these
issues? Creating an awareness of agricultural history may provide a good
beginning. It may also educate scientists about the relevance of the societal
context to our research. Most risk issues related to current GM crops are not
unique when placed in the context of how agriculture was developed through
crop domestication over many millennia and how we have bred modern crop
varieties in the past century. As Frary and Tanksley (2000) put it, “The issue
is not whether we should modify the genetics of crop plants. We embarked on
that road thousands of years ago when plants were first domesticated. Instead
of simply judging the vehicle through which we make genetic changes, we need
to weigh the potential consequences that such modifications hold for the
society and the environment.”
“The issue is not whether we should modify the genetics
of crop plants. We embarked on that road thousands of
years ago when plants were first domesticated. Instead
of simply judging the vehicle through which we
make genetic changes, we need to weigh the potential
consequences that such modifications hold for the society
and the environment.”
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CROP EVOLUTION AND HUMAN CIVILIZATION
Agriculture evolved independently in many places on this earth, but the earliest
evidence of farming dates to 10,000 years ago in present day Iraq (Heiser,
1990). For much of the 200,000 or so years prior to agriculture, humans lived
as nomadic hunters, gatherers, and scavengers surviving solely on wild plants
and animals. Subsequent domestication of these wild plants and animals from
their natural habitats launched agriculture, thus radically transforming human
societies. This occurred initially in the Fertile Crescent in the Middle East, the
Andean region of South America, Mexico, and parts of Asia, and diffused
throughout much of the globe. The change from a nomadic lifestyle to farming
led us to become community dwellers, eventually spawning the development of
languages, literature, and science and technology as people were freed from the
daily task of finding food. These developments were more rapid in some regions
than in others by thousands of years (Diamond, 1999). Plants evolved rapidly,
or, more accurately, they were changed, as a result of human intervention
(Harlan, 1992).
Every crop grown today is related to a wild species occurring naturally in its
center of origin, and progenitors of many of our crops are still found in the
wild. Early humans must have tried eating thousands of feral species from the
pool of a quarter of a million flowering plants before settling on the thousand
or so that were subsequently “tamed” and adapted to farming. A little over a
hundred species are now grown intensively around the world, of which only a
handful supplies us with most of what we eat. Through a process of gradual
selection, our ancestors chose a very tiny section of the wild-plant community
and transformed it into cultivated crops. Some profound alterations in
phenotype occurred during such selection, including determinate growth habit;
elimination of grain shattering; synchronous ripening; earlier maturity;
reduction of bitterness and toxins; reduced seed dispersal, sprouting and
dormancy; greater productivity, including larger seed or fruit size; and even an
elimination of seeds, such as in banana. These changes reduced the survivabil-
ity of crops in the wild, and thus a feature that transcends all of our crops is the
reduction of weedy traits from wild plants. Present crops are totally dependent
upon human care for their survival, and modern varieties would persist in the
wild “no longer than a Chihuahua would last in the company of wolves”
(Trewavas, 2000).
Most of the crops that supply our food were first domesticated at the end of
the Stone Age, often from a relatively narrow pool of wild genetic diversity.
Additional diversity arose within such cultivated crops through new mutations
and natural hybridization, and through judicious selection and perpetuation by
farmers who maintained them as land races. Varied uses and preferences
brought forth further diversification such as with corn (popcorn, sweet corn,
dent corn, broom corn, and flour corn for tortilla and corn bread) and cabbage
(kale, kohlrabi, Brussels sprouts, cabbage, cauliflower, and broccoli).
With the advent of transoceanic navigation and the “discovery” of the New
World, crops were moved rapidly around the globe, and some achieved
acceptance far beyond their natural centers of origin or domestication. For
instance, the United States is the leading producer of corn and soybean in the
world, yet these crops are native to Mexico and China, respectively. The world’s
largest traded commodity, coffee, from its humble origins in Ethiopia now is
grown in Latin America and Asia. Florida oranges have their roots in India,
while sugarcane arose in Papua New Guinea. Food crops that are now so
integral to the culture or diet in the Old World, such as the potato in Europe,
chili pepper in India, cassava in Africa, and sweet potato in Japan, were
introduced from South America. For that matter, every crop in the United States
other than the blueberry, Jerusalem artichoke, sunflower, and squash is
borrowed from elsewhere!
A few sources of our food are recent domesticates. Careful breeding rendered
palatable the Chinese gooseberry, native to China, and it was rechristened “kiwi
fruit” after introduction to New Zealand early in the twentieth century. The
modern strawberry with large fruits is a product of accidental crossing of two
wild species from Virginia (United States) and Chile in France in the mid-
eighteenth century. Rapeseed, grown in India for centuries, was altered recently
through classical breeding to eliminate the toxic erucic acid and malodorous
glucosinolates to result in canola. Triticale, a completely new crop, was
artificially synthesized a century ago by combining the genomes of wheat and
rye (from two genera that do not interbreed in nature). It is now grown on over
three million acres worldwide. Modern bread wheat itself is also a fairly recent
crop in the evolutionary time scale, having arisen only about 4,000 years ago
through hybridization of tetraploid (pasta or durum) wheat with inedible goat
grass.
FROM MESOPOTAMIA TO MENDEL
Farmers have molded the evolution of crop plants for several millennia, leading
to rich diversity especially in traits related to their planting or consumption. At
the same time, global population grew very slowly until the mid-nineteenth
century. It took 1,800 years for the global population to climb from an
estimated 300 million around the time when Christianity began, to reach its
first billion. But it took only 12 years to add the last billion, rising from 5
billion people in 1987 to six billion in 1999. Fortunately, parallel scientific
developments in agriculture ensured that food production kept pace with the
population explosion of the past century (Conway, 1999).
Beginning with Mendel’s study of peas, knowledge of genetics helped usher
in scientific crop development, resulting in high-yielding varieties. Food
production has increased in every part of the world in the past few decades,
including Africa. Per-capita food consumption has also increased steadily
everywhere except in parts of sub-Saharan Africa. In the United States, where
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such scientific developments and their applications have been most intense, the
average farmer now produces enough to feed nearly 150 people. In crops
subject to intensive scientific attention—corn, soybean, wheat, and rice—the
productivity levels have increased several fold. For example, American corn
growers averaged 26 bushels/acre in 1928 and 134 bushels/acre in 1998
(National Corn Growers Association, 2001).
Such a prodigious increase in agricultural production was underpinned by
scientific crop-improvement methods along with other developments, including
irrigation, improved soil-fertility management, mechanization, and control of
diseases and pests (Conway, 1999). To develop better crop varieties, scientists
have used an array of tools. Artificial crossing, or hybridization, helped us
assimilate desirable traits from several varieties into elite cultivars. When
desired characteristics were unavailable in the cultivated plants, genes were
liberally borrowed from wild relatives. When a crop variety refused to mate
with the wild species, various tricks were employed to force intermingling, such
as colchicine or by rescuing the hybrid embryos with tissue-culture methods.
Hybrid vigor was exploited in crops such as corn and cotton to boost
productivity. When existing genetic variation within the cultivated germplasm
was not adequate, breeders created new variants using ionizing irradiation
(gamma ray, X-ray, neutrons), mutagenic chemicals (ethyl methane sulfate,
mustard gas), or through somaclonal variation (cell culture).
Most people who are concerned about modern biotechnology have little or
no knowledge of the processes that have been used to transform crops in the
past. Nor is it likely that they are aware that crops have been continually altered
over time or that, without human care, they would cease to exist. Using a
variety of tools over the past several decades, plant breeders have radically
transformed our crops by altering their architecture (e.g. dwarf wheat and rice),
shortening the time to flowering, developing greater resistance to disease and
pests (all crops), and developing larger seeds and fruits (Figs. 1 and 2). These
Figure 1. Wild Lycopersicon pimpinellifolium (left, diameter 1 cm) and a
commercial tomato. (Kindly provided by Steve Tanksley.)
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Figure 2. Wild teosinte (left), a modern corn hybrid (right), and their hybrid
(center). (Kindly provided by John Doebley.)
crops are also more responsive to management and are better adapted to diverse
ecological conditions. Improved food quality has resulted through fewer toxins
(canola), better digestibility (beans), increased nutrition (high-protein corn),
better taste, longer shelf life (thus withstanding long transportation and
storage), and enhanced freshness in many vegetables and fruits. A one-
thousand-fold increase in the volume of the marble-sized wild Lycopersicon
has resulted in the modern tomato that can now weigh as much as a kilogram
(Frary and Tanksley, 2000). Modern farming has steadily increased the supply
of relatively safe, affordable, and abundant food, not only in the developed
world, but also in most developing countries. The average American family
spends only 11% of its income on food, and yet has access to better choices
with more variety and nutrition than ever before. Without scientific develop-
ments in agriculture, we would be farming every square inch of arable land.
Using gene-transfer techniques to develop GM crops is a logical extension of
the continuum of devices we have used to improve crop plants for millennia.
When compared to the gross genetic alterations associated with wild-species
hybridization or the use of mutagenic irradiation, direct introduction of one or
a few genes into crops results in subtle and less disruptive changes that are
relatively specific and predictable. The process also is clearly more expeditious,
as the development of new cultivars by classical breeding typically takes from
10 to 15 years. The primary attraction of gene-transfer methods to the plant
breeder, however, is the opportunity to tap into a wide gene pool to borrow
traits, obviating the constraints of cross-species compatibility.
When compared to the gross genetic alterations associated
with wild-species hybridization or the use of mutagenic
irradiation, direct introduction of one or a few genes into
crops results in subtle and less disruptive changes that are
relatively specific and predictable.
ADDRESSING PUBLIC CONCERNS
While direct gene transfer is still a relatively new approach, many concerns
arising from its use may be addressed with the “benchmark” of conventionally
bred varieties, as we have more than a century of accumulated experience and
knowledge with the latter. Although it may seem logical to express the concern,
“I don’t know what I am eating with GM foods!” it must be remembered that
we have never had that information with classically bred crops. With GM crops,
at least we know what new genetic material is being introduced, so we can test
for predictable and even many unpredictable effects. Consider, for example,
how conventional plant breeders would develop a disease-resistant tomato.
They would introduce chromosome fragments from its wild relative to add a
gene for disease resistance. In the process, hundreds of unknown and unwanted
genes would also be introduced, with the risk that some encode toxins or
allergens––armaments that wild plants deploy to survive. Yet we never routinely
tested conventionally bred varieties for any food safety or environmental risk
factors, and they were not subject to any regulatory oversight. We have always
lived with food risks, but in the last few decades we have become increasingly
more adept at asking questions.
To address concerns about long-term health consequences of GM foods, it is
instructive to recognize that we never worried about such impacts when
massive amounts of new proteins (and unfamiliar chemicals) were introduced
To address concerns about long-term health consequences
of GM foods, it is instructive to recognize that we never
worried about such impacts when massive amounts of new
proteins (and unfamiliar chemicals) were introduced into
our foods from wild species, or when unknown changes
were created through mutation breeding.
into our foods from wild species, or when unknown changes were created
through mutation breeding. When new foods from exotic crops are introduced,
we often assimilate them readily into our diets. What is more, we rarely, if ever,
asked the same questions that we now pose about GM crops. Lately, many so-
called functional foods, health foods, and nutraceuticals have entered the
mainstream American diet with little or no regulation or testing. We do not
question the long-term health implications of these food supplements, even
though they involve relatively large changes in our food intake.
In contrast, the GM foods currently on the market have been tested
extensively and judged to be substantially equivalent to their conventional
counterparts, with just one or two additional proteins present in miniscule
amounts (introduced into a background of thousands of proteins). And those
proteins are broken down either during processing or digestion, with little long-
term consequence. In food products such as oils, starches, and sugars, such
proteins are not even present. A nagging potential problem with a new protein
in food is that it could be a potential allergen. As most food allergens are now
well studied, we know that they are found in a few defined sources (peanut and
other grain legumes, shellfish, tree nuts, and a handful of other foods) and
share many similar structural features. Moreover, they must be present in large
proportions in our food, and we must be sensitized to them over time if they
are to cause adverse effects. Thus, it is highly unlikely for new allergens to be
introduced into our food supply from GM plants.
HISTORICAL ABSENCE OF ZERO RISK
There is no such thing as safe food, and there never has been. That is not to
suggest that all of our foods are dangerous, only an acknowledgment that trace
levels of toxins and carcinogens are present in everything we eat. But a primary
rule of toxicology, articulated over 400 years ago by Paracelsus, refers to the
importance of dosage: “Every substance is a poison, but it is the dosage that
makes it poisonous” (Poole and Leslie, 1989). Our food naturally contains
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thousands of chemicals, many of which are hazardous in laboratory-animal
studies in huge doses. Our diet includes 5,000 to 10,000 natural toxins, which
plants have evolved as protection against pests, diseases, and herbivores (Ames
et al., 1990a). For instance, roasted coffee has over a thousand chemicals of
which twenty-seven have been tested and nineteen found to be carcinogens in
rodents (Ames and Gold, 1997). The fat-soluble neurotoxins solanine and
chaconine, present in potato, can be detected in the bloodstream of all potato
eaters (Ames et al., 1990b). Naturally then, when crops are bred for resistance
to pests by transferring genes through conventional methods, the resistance is
often accompanied by increases in such toxic compounds.
Thus, it is erroneous to assume that we never had problems with convention-
ally bred varieties. Although any variety found to pose a real health risk was
promptly removed from the market, they were never routinely tested (in
contrast to GM crops). One pest-resistant celery produced rashes in agricultural
workers and subsequently was found to contain 6,200 ppb of carcinogenic
psoralens compared to 800 ppb in the control celery (Ames et al., 1990). This
celery was removed from cultivation as was the potato variety Lenape, which
contained very high levels of solanine. With all innovations we learned by trial
and error. Similarly, crop-improvement practices evolved over time with
continued refinement. It is common, though, for human nature to generate an
exaggerated fear of innovations while perceiving older or “natural” products as
more benign. Huber (1983) discussed this double standard in the larger context
of risk regulation. We have always been lenient toward existing known and
greater hazards, even as we create “gatekeepers” to minimize new risks. Thus,
we fail to recognize and “exorcise” much larger older risks.
While most food hazards arise from pathogens such as Escherichia coli 0:157,
Listeria, and Salmonella, along with mycotoxins produced by fungi (and thus a
function of food storage and handling), certain foods containing toxic
compounds are known to produce adverse health consequences over time.
Cassava, eaten by large numbers in Africa, contains cyanogenic glucosides that
cause limb paralysis if consumed before extensive processing. Solanin in tomato
and potato is known to cause spina bifida. Vetch pea, a common legume known
for its hardiness and thus popular in India among poor farmers, contains highly
dangerous neurotoxins that cause untold misery. Phytohemagglutinin, found in
undercooked kidney beans, is toxic. And peach seeds are extremely rich in
cyanogenic glucosides. None of these were subject to any mandatory testing
before they were introduced into the food chain, nor are they subject to any
regulation now. If the current regulatory standards imposed on GM crops were
to be invoked for traditional crops, many would fail to meet requirements.
Humans have built-in natural defenses for protection against normal
exposure to toxins. But, according to Ames and Gold (1997), we have not
evolved to achieve “toxic harmony” with everything we eat, because natural
selection occurs much too slowly and because much of what is in our diet today
was not eaten at all when we were hunter-gatherers. A balanced mixture of
foods normally provides adequate nutrition. However, none of the crops grown
today were selected with our nutritional requirements in mind. Instead, our
ancestors chose them intuitively from among the edibles that could be found
around them. Thus, the most important food crop in the developing world, rice,
has no provitamin A and little iron in its endosperm. This has led to horrific
problems, such as blindness among millions of children due to vitamin-A
deficiency, and iron-deficiency anemia in nearly a billion women dependent
on a rice diet. Biotechnology research, far from causing any new food-safety
problems, has already demonstrated its potential in enhancing nutritional
quality and is also being employed to reduce harmful toxic compounds that
exist in our food.
ENVIRONMENTAL CONCERNS
All of us have to eat to live, and organized food production is the most
ecologically demanding endeavor we have pursued. Agricultural expansion
over the millennia has destroyed millions of acres of forestland around the
world. Alien plant species have been introduced into nonnative environments
to provide food, feed, fiber, and timber, and as a result have disrupted local
fauna and flora. Certain aspects of modern farming have had a negative impact
on the biodiversity of crop plants and on the quality of air, soil, and water;
nevertheless, it sustains and nurtures most of the world’s six billion people
with adequate nutrition and affordable food.
How can we address the environmental questions concerning GM crops
in the context of our experience with traditional crop-variety deployment?
Through conventional breeding, we have continuously introduced genes for
resistance to diseases and pests into all of our crops. Traits, such as stress
tolerance and herbicide resistance, have also been introduced in many crops,
and the growth habits of every crop have been altered. The risk of crop “gene
flow” to weedy relatives has always existed. Thus, it is comforting to recognize
that no major “superweeds” have developed since the advent of modern plant
breeding, although there have been a few instances of crops becoming weedy
or of weeds becoming more invasive due to gene transfer from crops. Most
noxious weeds, such as kudzu (Pueraria lobata), water hyacinth (Eichhornia
crassipes), and parthenium weed (Parthenium hysterophorus) resulted from
the introduction of whole genomes of exotic semi-domesticated wild species
without the checks and balances of their native pests. Yet, there are probably
no dwarf plants among the wild Oryza and Triticum populations in Asia and
the Middle East, despite the fact that we have been growing diminutive rice
and wheat varieties for decades.
The risk of gene transfer to wild species is exacerbated when crops are
planted in an area with compatible weedy relatives (as often seen at their
centers of origin), when such species are promiscuous out-crossers (canola),
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or, most importantly, when the introduced genes enhance the reproductive
fitness of the recipient weeds (although most genes introduced into crop plants,
conventional or biotech, have little value in the wild). The risk of gene transfer
to weeds is similar with conventional and GM crops and is not contingent upon
how the genes are introduced to the crop. We must be vigilant to ensure that
weeds do not become noxious as a result of any new crop variety. The current
case-by-case testing and monitoring approach with biotech crops is a good
regimen for the future, while experience with conventional crops provides
assurance that such risks will be minimal and manageable.
Crop biodiversity is another issue of concern. The popularity of high-yielding
varieties has already narrowed the genetic variation found in major crops.
Biotechnology, if employed strategically, can reverse this through the recovery
of older varieties that were discarded for lack of certain features (such as
resistance to new disease strains), because modern gene transfer can restore
such traits. Biotechnology research is also enabling the development of better
methods for ex situ preservation of germplasm, such as cryopreservation,
whereby valuable germplasm is being stored and thus saved from extinction.
The introduction of corn with a single transferred Bt gene has led to concern
about its ecological impact. While this concern should not be dismissed, it
should be balanced with hindsight and experience. Corn is an introduced alien
species grown on 75 million acres in the United States, where none existed a
thousand years ago. A crop grown in a new environment entails the wholesale
introduction of thousands of new genes. When cultivated on huge areas of land,
it exerts considerable ecological impact on the native fauna and flora, including
beneficial insects. In contrast, the introduction of one or two genes into this
background of the tens of thousands of genes present in corn will have
relatively less effect on the environment. Whereas the initial fear about the
reported damage to monarch butterflies from Bt corn has not held up in
additional studies, one also needs to consider the negative impact of alternate
practices (such as pesticide spraying) and recognize the potential for positive
impacts on beneficial insects by the GM crop due to its specificity regarding
targeted insects.
For that matter, any concern about “gene pollution” pales in comparison to
the massive “risk” of alien crop introduction, as 95% of the crop area in the
United States now consists of such introduced crops. Concern about horizontal
transfer of genes from GM crops to other organisms, such as bacteria, also has
been expressed. But it appears highly unlikely that any such risk is dependent
upon the method of gene introduction. An inherent feature of biotechnology is
that it lends itself easily to molecular detection of introduced genes, but a true
measure of risk can only come in comparisons with classically bred crops where
little or no such studies have been performed. Concerns over random gene
insertion, gene instability, and genomic disruption due to gene transfer are
unlikely to be unique to GM crops or of any significance considering our
current knowledge of genomic flux in plants. Worries about mixing genes
from unrelated species ignore the history of plant breeding and the existing
overwhelming sequence similarity of genes across kingdoms. Nevertheless,
scientific research aimed at risk analysis, prediction, and prevention, combined
with adequate monitoring and stewardship, must continue so that negative
ecological impact from GM crops will be kept to a minimum.
Most problems raised by science can be solved by additional science itself.
For example, appropriate promoters may ensure that pollen will not express
genes toxic to beneficial insects, while gene expression strategies, such as
sterile pollen, could reduce the risk of gene flow. One must also recognize the
potential positive impact of GM crops on the environment, such as decreasing
agricultural expansion to preserve wild ecosystems; improving air, soil, and
water quality by promoting reduced tillage, and reducing chemical and fuel use;
improving biodiversity through resuscitation of older varieties; promotion of
beneficial insects; and cleaning up contaminated soil and air through
phytoremediation.
As we chart ahead with more exciting developments in biotechnology such
as genomics, and grapple with issues arising from consumer acceptance of
innovations, historical knowledge on societal adoption of technological
innovations may provide some valuable perspectives to scientists. Many
innovations that would be good candidates for generating consumer apprehen-
sion and concern today were introduced in the past without concern because
the public was less informed about innovation. The precautionary principle was
never invoked to ensure the scientific certainty that crop varieties developed
using nuclear irradiation or chemical mutagens were safe. And food labeling
was never demanded for bread wheat improved with the addition of hundreds
of unknown goat-grass genes.
Worries about mixing genes from unrelated species
ignore the history of plant breeding and the existing
overwhelming sequence similarity of genes across
kingdoms. Nevertheless, scientific research aimed at
risk analysis, prediction, and prevention, combined
with adequate monitoring and stewardship, must
continue so that negative ecological impact from
GM crops will be kept to a minimum.
Prakash
Many other innovations that are now commonplace in our lives were met
with skepticism and opposition when first introduced. Such fear of technology
has been especially pronounced in food-related innovations (e.g. pasteurization,
canning, freezing, the microwave oven). However, once consumers recognized
that these innovations enhanced the quality of life and once they understood
that risks are either minimal or manageable, then these technologies enjoyed
public acceptance. This includes even “disruptive” technologies that replaced
older ones (e.g. automobile vs. horse buggy, compact disc vs. cassette tape).
Nevertheless, there are historical instances of useful innovations that have not
been readily accepted due to a variety of reasons, such as recalcitrance to adapt
(e.g. Dvorak vs. QWERTY keyboard), entrenched economic interests opposing
change (e.g. the metric system in the United States; Beta versus VHS videotape),
ideological opposition (e.g. plant breeding by Lysenko during Stalin’s rule of the
Soviet Union), exaggerated notions of risk (e.g. food irradiation), ill-timed
product introductions, and serious conflicts with societal values and beliefs.
The survival of humans and crops will always be mutually dependent, and
the guided evolution of crops will be increasingly knowledge-based. An
appreciation of the history of agricultural development, however, may provide
us with a useful roadmap for devising appropriate strategies to informing and
rationalizing societal responses to crop improvement. Paraphrasing the
American philosopher George Santayana: ignoring history may condemn us
to repeat it. On the other hand, an understanding of the past may well lead us
to an enlightened future.
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I will draw inferences from lessons that are associated not with biotechnology,
but with how consumers deal with risks in other contexts. I will discuss
insights gained from cognitive psychology and research on consumer attitudes.
And I will also touch on economics, drawing principally on my own work with
colleagues. We have addressed issues associated with how one can use
environmental and health risks, both voluntary and involuntary, and the rules
of risk communication, to inform the current discussion of GMOs and
biotechnology.
Will consumer attitudes, in the United States and elsewhere, substantially
retard biotechnological innovations that might ultimately affect the food
supply? If that question is meaningful, then we must ask a subsequent one:
does the accumulated experience and research in risk communication, and
what we know about how to present risk information to consumers, suggest
that there are ways to influence the answer? That is, can we, through policy
measures, undertaken both in the public and in the private sectors, change the
responses that we would otherwise expect if risk information were not
presented? And then, ultimately: do we know enough now to take immediate
action?
Food-production decisions must be taken in the context that food is a world-
wide commodity. Consumers are heterogeneous. They have diverse information
bases, and culture is a very important contextual issue in Europe. Price and
quality attributes, as well as information, are important for decision making.
We have to provide value and change the perceptions of value either directly or
indirectly through price, in order to see a consumer response. It is important to
understand—not just in the area of GM and biotechnology, but in areas such as
the environment—that the production technology used to deliver a food, or any
other product, often becomes a part of the product-attribute set. Consumers
have preferences, and understanding them helps determine how information
associated with that product should be delivered.
In this country, multiple domestic agencies affect food policy and perceived
safety. In the world community we know from sanitary and phytosanitary
standards that trading rules are affected by perceptions of risk and efforts to
maintain or harmonize the information on, and the treatment of, risk. Also, it
is important to understand that the science base of most reporting—not the
New York Times, but the local and regional newspapers—is extremely limited.
Consequently, the ability to explain technical information is also constrained.
In delivering a message, it is necessary to recognize that media are the
consumers’ primary source of information about a whole host of issues.
EXPERIMENTS IN RISK PERCEPTION
I will describe three social-science experiments (not surveys) that provide
evidence that consumers’ subjective perceptions of risk should be taken
seriously. These are matters that are not variable day to day, that do influence
behavior, and that can be influenced. Information and its source clearly do
modify risk perceptions, and I think we understand enough to provide specific
guidance on how to structure that information. Clearly the process is context-
and problem-specific. So one needs to understand how consumers see the
problem in order to adapt what we know about what is important about the
source of risk. The cultural context affects how one delivers a message and
provides information.
You cannot consider risk perception in psychology without coming across the
names of Paul Slovic, Daniel Kahneman, Amos Tversky, and Sarah Lichtenstein.
Their central point is that risk has attributes. You cannot think of probabilities
of events in isolation from whether the source of uncertainty is voluntary or
involuntary, whether the process is perceived to be known or unknown, and
whether the outcomes are dreaded. People do not necessarily behave like the
calculating agents that economists and others imagine, but, where the issues
are personal, the consumer is likely to behave rationally in acquiring and using
information.
In the area of economics, there has been a lot of research on the effects of
labels, for example when the Food and Drug Administration (FDA) changed
advertising rules on fiber and cancer. Economists examined the change—the
Where the issues are personal, the consumer is likely to
behave rationally in acquiring and using information.
demands for cereals with fiber before and after—and attempted to infer the
consequences of the label. Likewise, we can consider organic and non-organic
produce side by side and ask about differences in demand. However, it is hard
to go meaningfully backwards from these observations, which is why I am in
favor of more social-science experiments.
Tom Hoban’s surveys in 1995 and 1997 in the United States, and in 1998 in
Japan (see Table 1), demonstrated that when unprompted American and
Japanese consumers were asked what they feel is the greatest threat to food
safety, biotechnology was at the bottom of the list. When prompted, bio-
technology remained near the bottom of the list.
Hoban adds an important qualifier—and this is the kind of information that
comes from consumer-attitude research—we need to consider the fact that
people answer these questions spontaneously, typically over the telephone.
They have had little time to think about them, yet the responses may form the
basis for policy decisions. Therefore, we should consider alternative sources of
information in framing the policy debate.
Consumer attitudes alone are not enough. How about surveys and experi-
ments? Economists are fond of surveys that offer stated-choice information, and
are fond of trying to mimic natural scientists in conducting controlled
TABLE 1. RESEARCH ON CONSUMER ATTITUDES: “WHAT DO YOU FEEL
IS THE GREATEST THREAT TO THE SAFETY OF THE FOODS YOU EAT?”
(HOBAN, 1999)
United States Japan
1995, 1997 1998
 (%) (%)
Unprompted
Pesticide residues 16 45
Additives or preservatives 2 34
Microbial contamination 69 7
Antibiotics or hormones 1 4
Irradiated foods 0 1
Biotechnology 0 1
Prompted
Pesticide residues 66 80
Additives or preservatives 20 52
Microbial contamination 77 49
Antibiotics or hormones 42 62
Irradiated foods 29 56
Biotechnology 16 8
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experiments in the laboratory that typically involve students who are offered
different choices. And in another category called a simulated market, we sell
real products in a control setting and have consumers actually buy them in this
limited setting; of course, typically the consumer is told that it is an experi-
ment, therefore, it is harder to accurately draw inferences.
I will describe three real-world, long-term, large-scale, social-science
experiments. Two involve radon, which, as a naturally occurring gas associated
with lung cancer, has an important attribute: it is an involuntary source of risk.
In one of the two experiments, individuals were recruited to have their homes
monitored for radon. The objective of our research team— including New York
State Energy Research and Development Authority and the United States
Environmental Protection Agency (EPA)—was to try to communicate
effectively the risk message associated with radon to these homeowners as part
of designing what ultimately became, in the mid-1990s, the EPA’s Citizens Guide
to Radon. It was a panel study involving four interviews of 2,300 households,
and tracking their behavior over a period of four years, 1986 to 1989. We
examined risk-perceptions, and looked for mitigating behavior.
The second study, undertaken by the same team, took place in Maryland,
again in the late 1980s. Three thousand households were involved over a period
of a year and a half to two years. The objective was to inform households that
might not otherwise know anything about the risks of radon and induce them
to take action by having their homes tested for it.
The third experiment was finished recently (with support from the Robert
Wood Johnson Foundation). It involved approximately 12,600 households, in
conjunction with a still-on-going survey—the Health and Retirement Survey—
with a demographically matched sample. We examined a voluntary risk:
cigarette smoking. Surely everyone knows that cigarettes are harmful. Why then
do people of 51 to 61 years of age continue to smoke? What do they believe the
consequences will be? What would be salient messages that would change
smokers’ beliefs?
From each of these experiments I will draw lessons relevant to biotechnology
and GMOs.
INVOLUNTARY ENVIRONMENTAL RISKS — RADON
The experimental design for the New York study involved six brochures in
specifically designed categories. The categories varied the amount of quantita-
tive information and the amount of specific guidance given to each household
about the risk or exposure to radon.
After four interviews and multiple years, we found clearly that an informa-
tional message that presented exceptionally clear guidance, that said, “Do ‘X’
and you will be safe,” was the most effective message in communicating the
risk. Also, we found that people subscribe to the notion that they can undo
damage they have done to themselves by inaction. Reversibility of the process
was extraordinarily important to people’s responses. Each brochure was
randomly assigned to a different group just as for a field experiment. So,
each member of the group during the course of the experiment received only
one type of informational source from us.
About 10% more people took some action as a result of receiving the
quantitative informational brochure in comparison to those who received a
standard government fact sheet. In terms of radon level, an eight-fold increase
would have been needed to have the same level of effectiveness as that
information booklet.
The second study involved three sets of households in three communities
in Maryland: Hagerstown, Frederick, and Randallstown. The experimental
design was carefully constructed. Frederick and Hagerstown received different
information campaigns, and Randallstown, the control, received nothing.
Posters were put up around Frederick, and there was community involvement.
We recruited the mayor and the town council to monitor their own homes; they
were on television and radio, and were very much involved in the process. In
Hagerstown, information was delivered with telephone bills to explain radon,
and posters were displayed around the community, but nothing else was done.
The gray bars in Figure 1 show baseline-survey data: percentages of people
who monitored their homes for radon, which was our outcome measure.
The black bars show the results of the experiment. We saw a 10% increase
in monitoring as a result of the intensive involvement in Frederick, and next
to nothing in the other two communities. These data show that with close
continuous involvement, contributions from community leaders, and a
personalized message, positive results are possible.
Figure 1. Fraction of people in baseline and follow-up surveys
who had tested for radon.
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VOLUNTARY HEALTH RISKS – SMOKING
How do smokers regard the risks from smoking? Advertisements by the
American Lung Association and the American Cancer Association are frequent
on radio and television, as well as in the print media, suggest that we interpret
simple messages in a direct and narrow way. If a smoker quits the habit, then
the adverse health effects will be reversed, eventually. Smokers use that message
to guide their behavior incorrectly: “I will stop smoking when I am 73, get
better in about 18 months, and then play tennis.” Unless they have lost a
spouse or parents, or seen someone else with a smoking-related disease, they
do not accept the message that there is a risk to them.
Personalization is very important. Every two years since 1992 the same
individuals were interviewed for an hour. The question reported here is,
“What are the chances that you will live to 75 or more, on a scale of zero to
100?” Because these individuals were followed every two years and complete
health records were kept, it was possible to observe the effects of health shocks
on their longevity perceptions. We considered all possible health outcomes
between two interviews, and classified shocks as either smoking-related—
lung cancer, other serious lung diseases, and heart disease—or general. In
Table 2 a negative sign implies a revision of the expectation of living to 75 or
more as a result either of a general health shock or of a smoking-related health
shock. Current smokers did not react to anything but a smoking-related health
shock. Those who had never smoked and former smokers reacted to both types
of shock equivalently.
Sometimes you have to hit people over the head with a message. And that
message should address what is at risk, not necessarily probabilities of the
event at risk. In this context, the message should not be the probability of
dying from smoking, it should address the mode of transition to death. You
have to determine from the people specifically what concerns them. You must
communicate with them in that context, and then work from there to develop
a message. The bottom line is that perceptions are informative and they do
affect behavior.
TABLE 2. RISK UPDATING MODEL FOR ‘LIVE TO 75’ (T-TEST) DATA.
Current Former Never
 smoker  smoker  smoked
Smoking-related –0.1237 –0.0692 –0.1095
health shocks (–3.84) (–3.18) (–3.31)
General health 0.0076 –0.0665 –0.0551
shocks (0.27) (–3.69) (–2.74)
As for influencing the demand for cigarettes, we found that people do not
passively accept information from experts. The information must be personal
and tangible. Risk communication requires listening first.
SPECIFIC LESSONS
Consumers generally want complete protection and not complex trade-offs.
It is fruitless to tell them that they can do X, Y, and Z and reduce their marginal
risk by a defined amount, although, as an economist, I wish it were otherwise.
Unfortunately, they do not want to hear it. Honest, full disclosure is central
to building trust. Trust can be very difficult to earn, and very quickly lost.
Perceived irreversible choices—and the key issue is irreversibility—are central
when concerns are serious.
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Q: On one of the overheads you had a Japan/United States comparison
on perceived risks associated with food. There was a tremendous difference.
Microbial contamination was high in the US, and pesticides and other additives
were important in Japan. What do you think the basis for those differences
might be?
A: A considerable amount of research has been done by economists,
psychologists, and sociologists on the role of culture in perception of what’s
safe. Sheila Jasanoff, a lawyer with a background in political science and
sociology at the Kennedy School, suggests that it is important to understand
the context associated with how risky activities are regulated in different
countries, and how information is delivered as a starting point for understand-
ing differences in perceptions. So it is not simply a question that Japanese
and Europeans are different from Americans, it is the policy infrastructure
that builds trust—that which delivers information, that which delivers
process and product safety to consumers, that which monitors the sources
of involuntary risk. That context builds up a set of prior expectations as to
what comes from outside the market and inside the market. And that context
is central to how they respond to different sources of risk.
Trust can be very difficult to earn, and very quickly lost.
Perceived irreversible choices—and the key issue is
irreversibility—are central when concerns are serious.
Q: How do you go about defining a risk-communications strategy for
perceived risk in the case of GMOs as opposed to real risk, for example, radon?
A: At the time we were doing this in the 1980s, there was very little public
information on radon. The individuals involved in those studies, both in
Maryland and New York, did not realize that they faced this risk. So there is
a parallel. I don’t mean that to be defensive. I am simply saying that in many
situations, when risks are real, people will not know about them. The beginning
point is listening and trying to understand from individuals what is important
about the choices they made with respect to voluntary risks. This can be
achieved via a series of activities: focus groups, cognitive interviews, and
a whole series of other one-on-one interactions with consumers to identify
a template of attributes that are important to the typical person. Then match
that template with the attributes that are associated with the product or process
that might be the source of a perceived risk. An economist will also tell you
that you have to identify a set of choices that are consequential from a financial
perspective to consumers and identify how they respond in those consequential
choices to different information sets. That gives you the beginnings of a
template for a risk-communication program. You have seen people take an
action that means something to them with consequences in response to
different kinds of information sets: you have an “if check,” if you will, on the
importance of the information process. It is hard to give you a blueprint for
every single problem, because each one has a different attribute set to start
with. What I have described is the process of developing a communication
program.
Q: You mentioned that consumers prefer complete protection over trade-offs.
Are you saying that they want to be assured of absolute safety?
A: I am not saying that they want to be assured of absolute safety. But they
want a very clear message that says, if they do something there will be a
response. Let’s take a tangible example. In the case of radon, at the time we
were presenting the information associated with mitigation, there was really no
experience with the production technologies that were associated with
removing radon from basements. So, we were, in effect, stating: if you ventilate
your basement it will probably work, if you seal up the floor on the underside of
the first floor, it might reduce radon. If you install a $3,000 ventilator in your
basement, we know it will work but we don’t know by how much. Those sorts
of messages are not very effective. If, on the other hand, you can say that if you
reduce your consumption of cigarettes by X packs in the course of a typical
month, you’ll reduce your chances of walking around with an oxygen tank
from five out of ten to two out of ten—that’s a salient, direct message. And they
prefer the latter to the former. It’s not complete protection. They don’t want
uncertainty over the mechanism that is going to protect them. They want to
know what will work.
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Over the past two years, agricultural biotechnology has captured public
attention in the United States, notably with news stories on the monarch
butterfly studies and StarLink™ corn. In addition, interest groups have been
engaged in an intensive struggle for consumers’ hearts and minds. Opponents
of biotechnology, such as Greenpeace and the organic-farming industry, have
used a variety of tactics to frighten consumers about potential risks. On the
other side, the biotechnology industry, through the Council for Biotechnology
Information, has launched an intensive public-information campaign stressing
potential benefits. Therefore, it is helpful at this stage to evaluate available
survey research concerning American consumers’ awareness and acceptance
of agricultural biotechnology and foods with genetically modified (GM)
ingredients.
Before beginning this assessment, it will be useful to put agricultural
biotechnology into the larger context of innovation diffusion, which has been
the subject of over 50 years of research (Rogers, 1995). The basic conclusion
from that work was that anything new takes time to garner awareness and gain
acceptance and adoption. Early studies of hybrid corn conducted in central
Iowa during the 1930s found that over a decade passed before farmers in
general were using the higher-yielding varieties. Some farmers objected to
the fact that they could no longer save their seed for planting—similar to
technology fees and crop-protection technology (i.e. the “terminator” gene)
associated with modern plant biotechnology.
Consumer adoption of new food technologies also takes time. The microwave
oven is an interesting example. When introduced, there were concerns over
risks of radiation leakage into the kitchen. Over time, as consumers recognized
the benefits and when concerns over risks were addressed, most people
accepted microwave ovens in their homes. It is interesting that adoption of a
new technology varies between cultures. French consumers are much less
accepting of foods prepared by microwave than are Americans. Also, the French
are appalled by another American innovation: the drive-through restaurant.
Another example of societal resistance to new technology is pasteurization, as
described by Joseph Hotchkiss in this volume.
Given the fact that no new technology will ever be 100% accepted by the
public, it is important to examine some unique characteristics of the biotech-
nology controversy that make associated innovations more likely to meet with
consumer resistance. First, agricultural biotechnology is a relatively complex
subject. Full understanding of the technical issues associated with benefits and
risks requires at least some knowledge of agriculture, food processing, and of
the biological sciences. Not many consumers in the United States or elsewhere
have direct connection with agriculture and food processing. Most take it for
granted that food will be readily available and do not think, or care, much
about how it gets to the store or restaurant. In addition, most people are
unfamiliar with the advances in the biological sciences that have occurred over
the past two decades. This lack of literacy makes some consumers apprehensive
about developments in food biotechnology.
It is also important to consider how consumers receive information about
food biotechnology, and the messages that they are hearing. Most of what
consumers learn about any innovation comes through the filter of the mass
media, which have a tendency to feature sensational news stories. Also, the
media oversimplify issues to fit within their sound-bite framework. Stories
about agricultural biotechnology tend to have a tone of conflict and controversy
that makes people concerned. Once something is in the media it becomes part
of the public agenda. Up to that point, most people have little awareness of, or
interest in, a particular subject. Clearly, media coverage of biotechnology in the
United States has increased over the past few years.
Another major factor that is slowing consumer acceptance of biotechnology
involves the aggressive campaigns of a variety of special interest groups (Hoban,
1995). Groups such as Greenpeace and the Earth Liberation Front are trying to
shake public confidence in science and the federal regulatory process. They do
not find it necessary to prove their assertions, but are satisfied to raise doubts
and fear. They also capture media attention with extreme tactics, such as
destroying research plots, harassing food companies, and engaging in street
theater. These groups have a variety of motives for their campaigns, including
anti-corporate and anti-globalization ideologies. They have a vested interest in
building the controversy since it increases their donations and membership. In
addition, the organic food industry supports the anti-biotechnology movement
because some consumers are motivated to spend more money on organic foods.
Another problem for agricultural biotechnology is that benefits to consumers
from the early products were not obvious. Many observers note that agricul-
tural biotechnology tends to be less acceptable to consumers than is medical
biotechnology. This makes sense given the fact that sick people are likely to
accept risk from a medical treatment in order to regain health. Patients are
likely to trust their doctors and follow their advice without question. The
situation is quite different with food. People feel qualified to make their own
decisions and are more risk-adverse, especially when they see few direct
benefits from a new food-production technology.
For the most part, new medicines developed through biotechnology have
been well accepted by consumers. However, developments in human genetics
and genomics may prove to be even more controversial than food biotechnol-
ogy. For example, media coverage of human cloning and stem-cell research has
captured public attention recently, tending to push agricultural biotechnology
into the background. Society has some important and real concerns to deal
with. Policy makers and scientists are only now beginning to grapple with
questions about genetic privacy, genetic discrimination, and eugenics. Given
that the public and the media have a limited attention span, it is possible that
agricultural biotechnology may well be viewed as more acceptable by
comparison.
With this background in mind, I now turn to an assessment of recent
research on consumer awareness and attitudes about agricultural biotechnology.
In general, the studies that I will review involved telephone surveys of the
Americans. Most involved approximately 1,000 interviews, representing a
confidence level of just over 3%. Where possible, I will highlight trends in the
results over time.
CONSUMER AWARENESS OF BIOTECHNOLOGY
The process of innovation adoption starts with awareness. For almost a decade,
consumers have been asked in various surveys, “How much have you heard or
read about biotechnology—a lot, some, a little, or nothing?” (Hoban, 1996,
2001; IFIC, 2001.) It is reasonable to equate awareness with having heard
something or a lot (Figure 1). There are several notable trends in consumer
awareness of biotechnology in the United States. For the first half of the 1990s,
it remained rather low at about one-third. It hit a peak in 1997 when a survey
was conducted soon after the news about Dolly, the cloned sheep. Then
awareness dropped until May 2000, but has grown gradually since, to 53% in
June 2001.
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Most Americans are not aware of the extent to which biotechnology
has become part of their food supply. According to a January 2001 survey
conducted by the Pew Foundation for Agricultural Biotechnology, few
consumers believed that GM foods are in wide use in the food supply, and
even fewer believed that they have eaten them (Pew, 2001). Most consumers,
60%, believed that less than half of the food in grocery stores contains GM
ingredients, while 38% thought that less than a quarter of food contains such
ingredients. Only 14% of consumers believed that more than half of our food
contains GM ingredients, which was the correct answer. Additionally, few
Americans recognized that they had already eaten GM foods. Only 19% said
they had eaten GM foods, 62% said they had not, and 19% said they did not
know.
At the same time, consumers were uncertain about how safe GM foods are.
When asked initially, with little background information, whether GM foods
are safe, almost half said that they did not know, 29% said they are basically
safe, and 25% said they are basically unsafe. However, after being informed that
more than half of the products at the grocery store contain GM ingredients,
almost half said that GM foods are safe, only 21% said that they are unsafe, and
31% said they were unsure (Figure 2). In fact, one in five of those who initially
said GM foods were unsafe, changed their minds. Thus, when some consumers
learn how widespread are GM foods, they are more likely to believe they are
safe. However, it is also true that some consumers become angry when they
realize that they have not been told about the widespread presence of GM
ingredients.
Figure 1. American consumers’ awareness of biotechnology, 1992–2001
(Hoban, 1996, 2001; IFIC, 2001).
. . . few Americans recognized that they had
already eaten GM foods.
CONSUMER ACCEPTANCE OF BIOTECHNOLOGY
Consumer acceptance has been measured in a variety of ways in different
surveys. I have had the opportunity to repeat the same set of questions with
three surveys through my own research (Hoban and Kendall, 1994), as well as
in a survey conducted by Angus Reid, Inc. in 2000 (personal communication).
The objective was to assess the level of consumer acceptance of three
applications of biotechnology (Figure 3). In the case of insect-protected crops,
acceptance was higher in 1992 (63%) and 1994 (67%) than in 2000 (51%).
The same overall trend was noted for disease resistance in farm animals and for
larger, faster-growing fish; but these applications were relatively less acceptable
than plants at all points in time. This is of particular concern, because disease-
resistant animals and faster-growing fish are either on the market or close to
commercialization.
Figure 2. American consumers’ views on the safety of genetically
modified foods (Pew, 2001).
Figure 3. American consumers’ acceptance of three applications of
biotechnology (Hoban and Kendal, 1994; Angus Reid, Inc., pers. comm.).
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Surveys conducted by Hoban and Miller (1998) and by Priest (2000)
evaluated more-recent trends in American consumers’ support for four
applications of biotechnology (Figure 4). Compared to 1998, a greater
percentage of consumers in 2000 believed that applications of biotechnology
to crops and foods should be encouraged. It is interesting to note that
consumers tended to view insect-protected crops as more acceptable than
improved foods. Support for development of new human genetic screening
techniques rose significantly between 1998 and 2000 (Figure 4). At the same
time, concerns have been raised in the media about loss of genetic privacy
and the potential for discrimination that could result from increased access
to such genetic information.
It is instructive to compare these results from the United States with
trends for the same questions asked on the Eurobarometer2 in 1996 and 1999
(Figure 5). In Europe, public support for all four applications of biotechnology
dropped significantly during this period, which corresponds to the growth
of the public controversy. It is understandable that agricultural and food
applications would become less acceptable given the fact that they were the
focus of opponents’ campaigns. However, it is noteworthy that support for the
two medical applications of biotechnology also dropped significantly. Such a
pattern could mean some difficult challenges for the European economy and
diminished prospects for new advances in health care.
Figure 4. American consumers’ support for four applications of
biotechnology (Hoban and Miller, 1998; Priest, 2000).
2European Commission public-opinion surveys, http://europa.eu.int/comm/dg10/epo/.
IMPACTS OF THE STARLINK™ CORN CONTROVERSY
One incident that captured the attention of the media in the United States
involved the discovery in food of a protein from a corn variety that had not
been approved for human consumption, i.e., StarLink™. To evaluate consumer
response to the story, I conducted a survey for the Grocery Manufacturers
of America in October 2000, immediately after the taco-shell recall was
announced. Most of the questions were asked again in January 2001 by the
International Food Information Council (IFIC, 2001). These results indicate
no significant impact from the StarLink™ controversy on consumers’ attitudes
or behavior.
Early in the interview, before any mention of StarLink™ or biotechnology,
respondents were asked the open-ended question, “Over the past few months,
what, if anything, have you been avoiding or eating less of?” (Figure 6). The
largest percentage indicated that they had not changed their eating habits in
any way. This was particularly true in January, which may reflect holiday eating
patterns. Of those who had limited their consumption of a particular food,
responses were almost evenly divided among fats, carbohydrates, or meat and
dairy products. No one in either survey said they had stopped eating taco shells
or corn, nor was there any other reference to biotechnology. The next open-
ended question was, “What if anything are you most concerned about when
it comes to food safety?” The most common responses involved microbial
contamination or pesticides. Only 2 to 3% mentioned anything related to
biotechnology or genetic modification.
Figure 5. European consumers’ support for four applications of
biotechnology, 1996 and 1999 (Eurobarometer).
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The interview later posed specific questions about biotechnology and the
StarLink™ issue. One question that I developed in 1995 has been repeated
in other surveys (FMI, 1997; IFIC, 2001) to indicate the extent to which
consumers are willing to buy tomatoes or potatoes developed through
biotechnology for enhanced protection against insects (Figure 7). Overall,
there was a modest drop in willingness to buy such products from the highest
levels found between 1995 and early 1999. However, the results for October
2000 and January 2001 showed that consumers were just as willing to consume
insect-protected plants after the StarLink™ incident as before.
As a final question, respondents were asked, “During the past few months
have you done anything or taken any action because of any concerns you may
have about genetically modified foods?” Despite this clear opportunity to
answer “yes,” only 5% of the respondents in the October 2000 and January
2001 surveys said they had done anything. In my October survey, we followed
up and asked that small pool of respondents what they had done. Mainly, they
had sought out more information or had talked to someone. No one reported
boycotting any food company or changing their food-consumption behavior.
Figure 6. Foodstuff avoidance over the previous few months
(Hoban, 2000; IFIC, 2001).
The most common responses involved microbial contami-
nation or pesticides. Only 2 to 3% mentioned anything
related to biotechnology or genetic modification.
CONSUMER VIEWS ON FOOD LABELING
A complex and contentious issue in the United States is whether foods
developed through biotechnology should accordingly carry some type of label.
On this particular subject, how questions are asked clearly has a major impact
on how consumers respond. One neutral way is to simply ask, in an open-
ended question, if they can think of any information not currently included
that they would like to see on food labels. Surveys conducted in October 2000
(Hoban, 2000) and January 2001 (IFIC, 2001) found that only 2% of the people
surveyed responded “genetically modified.” In both cases, three-quarters of
the respondents said they could not think of any additional information they
would like to see on food labels. This is noteworthy in that the interviews took
place after the StarLink™ controversy became a public issue.
Many consumers claim to want information on food labels about how
foods and their ingredients are produced. The Center for Science in the Public
Interest (CSPI) found in May of 2001 that about two-thirds of consumers
wanted foods containing genetically engineered ingredients to be labeled
(see pages 31, 32; CSPI, 2001). However, even more consumers (76%) wanted
labeling for crops grown using pesticides, 65% for crops grown using plant
hormones, and 56% for crops that are imported. In fact, 40% of respondents
said that they would like products containing hybrid corn to be labeled, which
would apply to any food containing oil, high-fructose syrup, or any other
ingredients derived from corn.
Figure 7. American consumers’ willingness to buy potatoes or tomatoes
genetically modified for enhanced resistance to insects
(Hoban, 1996; FMI, 1997; IFIC, 2001).
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One way to measure consumers’ desire for labeling is to determine
willingness to pay for that information. The CSPI survey found that 44% of
consumers would pay “nothing” and another 17% would pay $10 per year on
top of their family’s current annual food bill for such labeling. Only 28% were
willing to pay $50 or more. In fact, of the 17% of consumers who said that
their highest labeling priority was genetic engineering, 50% would pay nothing
or $10 per year for that labeling. Similarly, of the people who believed that
labeling genetically engineered foods should be required, 56% would pay
nothing or $10 per year for it. Although as many as two-thirds of consumers
may desire labeling of GM foods, few appear willing to pay the real costs for
that information, which would result from the need for identity preservation,
testing, certification, etc.
One concern about labeling is that consumers may perceive the information
to be a warning. In fact, when respondents to the CSPI survey were asked
whether foods labeled as containing GM ingredients were just as safe as, not
as safe as, or safer than, similar products without such a label, about 30%
said that the labeled product was less safe. Only 7% said that the GM-labeled
product was safer, and about 33% said that the labeled product was equally safe.
CONCLUSIONS AND IMPLICATIONS
Review of recent research makes it possible to anticipate future consumer
acceptance of agricultural biotechnology in the United States. Given that public
perception of plant biotechnology has not changed much over the past few
years, it is unlikely that acceptance will change much in the future, provided
that no real health problems are encountered with GM foods. Research into
food-shopping preferences and behavior shows that consumers in the United
States tend to be pragmatic in their choices. They select food based upon taste,
value (price), convenience, and nutrition. No one spontaneously reports that
seed genetics influenced their purchasing.
However, animal biotechnology will raise a host of complex issues that will
make it less acceptable than plant biotechnology. Some people view animals as
having feelings and due more respect than plants. Also, animal-rights activists
will step up their protests as new products arrive on the market. Consumer
reaction to transgenic animals, such as those used to produce human organs,
will likely be extreme, particularly if the meat enters the food supply. Faster-
growing fish may meet with poor acceptance, especially if they are labeled
accordingly and/or the opposition groups have a significant impact on media
coverage. Clearly, animal and veterinary scientists should learn from the
experience of plant scientists about the importance of ongoing communication
and social science research. Unfortunately, this may not be the case as
evidenced by their lack of communication on these issues.
Media coverage of agricultural biotechnology over the past few years has
generally been balanced in the United States, at least compared to Europe. It
seems that the media’s focus is shifting to the range of complex issues related to
human genomics, including the controversies of stem-cell research and human
cloning. These issues may generate public concern as the products of medical
biotechnology and genomics come to the market place. In particular, diagnostic
tests and other screening tools will make it possible to identify genetic traits
that predispose humans to disease. This will be controversial if people do not
want to know, particularly where there is no cure for the disease that could be
diagnosed. Also, concerns are already being raised about genetic privacy and
the possibility for genetic discrimination by employers and health-insurance
providers.
Relatively little social-science research has been done to assess public
perceptions of either animal biotechnology or human genomics. Clearly, we
need to start addressing these issues to understand public concerns and hopes,
as well as information needs. In addition, no organizations have stepped
forward to begin the challenging, but vital, job of informing the public about
the future of animal biotechnology and human genetics, as the Council for
Biotechnology Information, NABC, and others have done for plant biotech-
nology. We may look back and realize that the issues associated with plant
biotechnology were easier to address than those with animal or human
applications.
There are many reasons why opinion has remained more positive in America
than in Europe, despite the best attempts of activist groups to promote fear and
uncertainty. American consumers tend to have a greater level of confidence in
scientists and government regulatory agencies, whereas in Europe confidence
has been seriously eroded by mad cow disease and other problems. Scientists
and others have been actively committed to providing the American public
with information for over a decade, whereas EU leaders and scientists have
generally been silent or ineffective. The activists who oppose biotechnology
have relatively little credibility in the United States, partly as a result of terrorist
tactics. In Europe these groups have filled the information vacuum and
established credibility with the public.
America’s relatively young culture tends to focus on the future, whereas
Europeans generally look to the past. Our cultural values include a much
greater appreciation for the role of science and technology in progress and
economic growth. Americans also have feelings about agriculture and food
that differ from those of Europeans. Many Europeans live to eat whereas most
Americans eat to live. European consumers are more concerned with how food
Many Europeans live to eat whereas most
Americans eat to live.
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is produced and by whom, and they have closer connection to farming, due in
part to the fact that they have few public wilderness areas. Their concept of
natural is tied to small-scale farming. This ideology is also present in the United
States among the relatively elite consumers of organic food.
Research and experience have provided some guidelines for providing
relevant information to interested consumers about agricultural biotechnology.
The first thing that people generally want to know is why scientists are using
biotechnology. In other words, what are the benefits? In fact, many American
consumers appreciate the potential of biotechnology for helping people in
developing countries to feed themselves, which is a less persuasive message
for Europeans. American consumers also have a greater appreciation of the
fact that food produced with biotechnology is as safe as, or safer than, food
produced through traditional breeding methods and grown with more chemical
inputs. It is also important to make the point that no technology is without risk
and that those associated with biotechnology are being managed and regulated.
Finally it is worth considering the implications of consumer attitudes toward
biotechnology for land grant university research and extension programs. For
the past year I have been chairing a national task force looking at ways in
which universities can play a more meaningful and credible role in the
discussions and deliberations about biotechnology. In some respects the future
of biotechnology is closely linked to the future of our colleges of agriculture.
Most universities have made major investments in biotechnology research
and now have obligations to openly explain what they are doing and to ensure
they are providing benefits to society in an ethical manner. We also will have
a major role in developing and implementing education programs and fostering
two-way communication. This is appropriate because American consumers
and leaders still trust our universities. We must make sure we maintain that
level of confidence.
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What You See Depends On How You Grind
the Lens
CAROL TUCKER FOREMAN1
Consumer Federation of America
Washington, DC
“The promise of agricultural biotechnology is immense. Advances in
this technology will result in crops with a wide range of desirable
traits that will directly benefit farmers, consumers, and the
environment and increase global food production and quality.”––
Seeds of Opportunity: an Assessment Of The Benefits, Safety, and
Oversight of Plant Genomics and Agricultural Biotechnology, United
States House of Representatives, 1999
“Food biotech is dead.”––Henry I. Miller, Hoover Institute, Stanford
University (Eichenwald et al., 2001)
1Ms. Foreman was scheduled to deliver this presentation at the meeting, but was unable to do so.
I believe agricultural biotechnology does indeed offer the promise of substantial
benefits to farmers, consumers, and the environment. However, after almost
twenty years of industry advocacy and government promotion, the American
people have not embraced this new technology. Spurred by such events as the
StarLink™ corn contamination and European rejection of genetically modified
foods, there is an increasingly visible and contentious debate in this country
about the potential risks and benefits of agricultural biotechnology and its
appropriate role in our lives. Radical environmentalists trash biotech fields.
Obdurate biotech advocates trash the intelligence and integrity of anyone who
disagrees with them.
If we want to realize the potential benefits of agricultural biotechnology, we
must achieve agreement and compromise. Beginning that process requires
taking a realistic view of the public’s willingness to accept agricultural
biotechnology, appreciating some of the factors that contribute to continuing
public concern, and considering changes in government regulation that might
increase the public trust that is so vital to greater acceptance and full realization
of agricultural biotechnology’s promise.
PUBLIC ACCEPTANCE OF AGRICULTURAL BIOTECHNOLOGY AND
GENETICALLY MODIFIED FOODS
Dozens of polls have examined the level of public acceptance of agricultural
biotechnology and genetically modified foods in United States. Each poll is
structured differently, asking slightly different questions, and getting somewhat
different answers. If you support biotechnology, you can find a poll that agrees
with your point of view. If you oppose the technology, you can find a poll that
condemns it. Not surprisingly, poll questions are often structured in a manner
to assure a response consistent with the views of the poll’s sponsor.
But it is possible to get a snapshot of the general level of public acceptance.
I reviewed five polls, taken between 1999 and 2001, and totaled the positive
and negative responses (see below). There is good news and bad in the results
of these surveys. The good news is that only one poll showed more people with
negative than positive opinions. The bad news is that none of the polls showed
strong public support for genetic engineering. Only one question came close to
eliciting a positive response from two-thirds of those polled.
Survey/Questions Total Total
positive negative
International Food Information Council Foundation
(January 19–21, 2001)
Would you purchase foods modified by biotechnology
in ways that provided direct and obvious consumer
benefits such as: fresher, tastier produce?  58% 38%
reduced saturated fat? 46% 17%
Do you expect benefits to your family from biotech
within 5 years? 64% 22%
Pew Foundation Initiative on Food and Biotechnology
(January 22–28, 2001)
Are genetically modified foods: basically safe / unsafe  48%  21%
(unsafe)
Harris Poll (June 8–12, 2000)
Do benefits of developing / growing GE plants
outweigh risks? 38% 48%
(risks greater)
Gallup Poll (March 30–April 2, 2000)
Do you support use of biotechnology in food / agriculture? 48% 41%
National Science Foundation / Texas A&M
Public Policy Research Institute (April–May 2000) (Priest, 2000)
Do you believe GE will improve our way of life
in next 20 years? 53% 30%
Perhaps more troubling, Susan Horning Priest (2000), writing in Nature
Biotechnology, reported that Americans are less enthusiastic about genetic
engineering than about other recently introduced technologies.
FAVORABLE ATTITUDES TOWARD NEW TECHNOLOGIES
The NSF/Texas A&M survey asked respondents their views of whether
particular technologies would improve their lives:
Technology Positive response
Computers/information technology 88%
Solar energy 88%
Telecommunications 82%
The Internet 72%
Space exploration 62%
Genetic engineering 53%
UNFAVORABLE ATTITUDES: GENETIC ENGINEERING VERSUS
NUCLEAR ENERGY
The NSF/Texas A&M survey found that Americans are equally as negative
about genetic engineering as they are about nuclear energy, a technology that
has had limited application in the United States because of a lack of public
acceptance:
Technology Positive response
Genetic engineering 30%
Nuclear energy 32%
Now many biotech advocates take comfort in the fact that polls show many
Americans are still not aware of genetic engineering. They assume that, as
people become more familiar with the technology, they will feel more
comfortable with it. Unfortunately, research indicates that familiarity with
agricultural biotechnology does not breed affection. Priest (2000) compared
responses to genetic engineering over seventeen years. The number of people
who had negative attitudes toward agricultural biotechnology almost doubled,
rising from 16 to 30%:
Genetic Engineering Will Make
the Quality of Life Worse Positive response
1982 16%
1986 22%
1999 30%
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Last year we accepted the election of the President of the United States by
something less than a convincing majority. We are much more demanding when
it comes to new products. They do not survive unless they gain popularity and
do it quickly. A new technology that affects the safety and quality of our food
supply will almost surely have to secure an overwhelming level of public
acceptance if it is to survive.
WHY AMERICANS ARE UNENTHUSIASTIC ABOUT GENETICALLY
MODIFIED FOODS
I can identify three reasons why Americans have embraced computers and cell
phones and medical biotechnology, but are less accepting of genetically
modified foods.
First, food is special. The manufacturers of genetically modified products
think they are purveying commodities. Consumers believe they are tinkering
with something more basic to the human psyche: a “cultural metaphor for life.”
We eat to live, but we also live to eat. Food provides energy and essential
nutrients, but food is more than fuel for the body. It is sustenance for the soul.
From the Apple in the Garden of Eden to the golden arches on the highway,
food is a key component of human civilization. Food is a cultural and religious
icon. Throughout history, people have been defined by what they are obligated
or forbidden to eat. Even in twenty-first century America what you eat reveals
who you are and where you are from. If you want to experience true cultural
isolation, walk into a New York deli and order corned beef on white with mayo.
Food is intensely personal. In 1996, the Agriculture Council of America
commissioned an intensive study of our emotional attachments to food. They
found that food is integrally tied to nurturance, bonding and love. Participants
in the study viewed unsafe food as a hostile invader of their homes and an
assault on themselves and their families.
Second, agricultural biotechnology presents an unbalanced distribution of risks
and benefits. When it comes to food, most of us are risk-averse. This is
especially true if the risk is imposed on us by someone else, is invisible, and
lacks a countervailing direct and specific personal benefit.
It is easy to see why genetically modified foods light up all the risk-aversion
receptors. The products on the market today have no direct consumer benefit.
They were developed to enhance the economic fortunes of farmers and
When it comes to food, most of us are risk-averse. This is
especially true if the risk is imposed on us by someone
else, is invisible, and lacks a countervailing direct and
specific personal benefit.
chemical companies. Lowering farmers’ input costs is important to farmers, but
not to American consumers. Lowering the cost of producing corn, does not
translate to cheaper meat at the supermarket.
There are promises of nutritionally superior products, but we cannot eat
promises. And, the adamant refusal to label genetically modified products
cannot help but increase consumer suspicion that these foods carry some risk.
Most consumers believe that if you have to hide it, there must be something
wrong with it. In short, there is no reason for consumers to willingly accept any
risk from genetically engineered food.
Third, acceptance of agricultural biotechnology is affected by the social and
political context into which it has been introduced, including instantaneous
communication and globalization. No product or technology comes to market in
a vacuum. Unfortunately, the advent of genetically modified crops has
coincided with a rash of food-safety disasters. Because we live in an era of
instantaneous communication, the details of those disasters are flashed into our
homes. Because we eat from a global plate, we can never be sure that a food
safety disaster half-way around the world will not end up on our dining-room
table.
Finally, the very fact of globalization creates discomfort for many people.
Agricultural biotechnology is associated with increasing global corporate
power. This, coupled with a diminishing level of trust in both private and
public institutions compounds the problem for those seeking to gain accep-
tance of agricultural biotechnology.
THE ROLE OF GOVERNMENT IN ASSURING SAFETY AND ACCEPTANCE
Given all these impediments to public acceptance of genetically modified food
products, it would seem reasonable that supporters of agricultural biotechnol-
ogy would benefit from, even insist upon, a food safety regulatory system in the
United States so rigorous and credible and above reproach that it cannot fail to
dispel doubt and instill public trust.
The United States government and agricultural biotechnology industry chose
another course. Our government, especially the Food and Drug Administration
(FDA):
• opted for a system that favored a rush to market over assurance of safety
and acceptance. The White House, in an election year, became actively
involved in writing FDA’s 1992 Policy Statement on Foods Derived from
New Plant Varieties. Vice President Quayle described the Statement as
“regulatory reform,” designed to help American agricultural biotechnology
companies gain advantage in a new field. This effort to speed genetically
modified foods to market has served instead to deny genetically modified
products the most valuable assets they could acquire: a rigorous and
transparent pre-market safety approval by FDA, and resulting public
comfort level.
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• contorted existing statutes to regulate a technology that was never
contemplated when the relevant laws were written in 1906 and 1958.
Contrast this to the course chosen in the European Union, which enacted
new law specifically designed to deal with “novel foods.”
• established what amounts to a system of “nonregulation” (based on
McGarity and Hansen, 2001). Foods altered by agricultural biotechnology
are not subject to rigorous premarket safety testing and FDA approval.
Today FDA does not require notice that a firm intends to market a
genetically modified food organism so long as the firm concludes that its
product is “generally recognized as safe” (GRAS). Changes under
consideration by the agency will not require FDA to approve products
before they are marketed.
HOW FDA AVOIDS REGULATION OF, AND RESPONSIBILITY FOR,
GENETICALLY MODIFIED FOODS
The FDA has determined that adding a new gene to a conventional food falls
under the 1958 Food Additive provisions of the Food Drug and Cosmetic Act,
unless the resulting genetically modified food is “substantially equivalent” to a
conventional food that is GRAS.
Substantial equivalence—limiting the factors that would cause a product to be
considered different. The new genetically modified food is considered “substan-
tially equivalent” to its conventional counterpart unless the transfer involved
genes coding for fats, proteins, or carbohydrates that might cause allergic
reactions, are known to be toxic, or change the nutritional value of the food.
Some FDA scientists urged that at least basic toxicological testing be done on
all genetically modified foods. The FDA has established no protocols to detect
unanticipated effects, no chemical analyses of the molecular characteristics of
the altered food, no tests for stability of the transferred gene or of the key
nutrients and toxicants.
Accepting the manufacturer’s assertion that a product is GRAS. For all practical
purposes a company that produces a genetically modified food is the judge of
whether the product falls within the “GRAS” category. The GRAS determination
relies almost exclusively on a manufacturer’s finding that the food meets this
requirement.
When the FDA approves a petition for a new food additive, it publishes a
regulation stating that FDA finds that the additive is safe, making public the
data that support its decision, establishing requirements for the use and
labeling of the additive.
If a company claims that its product is GRAS, FDA must either accept the
data presented to it by the company or take on the burden of disproving the
safety of the product. If the FDA accepts the company’s data, it takes no
responsibility for the safety of the product. There is no Federal Register notice
and no explanation of reasoning. Virtually all of the FDA-regulated genetically
modified products now on the market got there because the producing
company claimed the product is GRAS. The company receives a letter from
FDA, the operative language of which is that the company has determined that
the product is the same as a safe product.
For example, on January 27, 1995, FDA wrote to Monsanto regarding the
Roundup Ready® soybean, stating, “…it is our understanding that, based on the
safety and nutritional assessment you have conducted, you have concluded that
the new soybean variety is not materially different in composition, safety, or any
other relevant parameter from soybean varieties now on the market… as you
are aware, it is Monsanto’s continued responsibility to ensure that foods the
firm markets are safe, wholesome and in compliance with all applicable legal
and regulatory requirements.”
FDA and the biotechnology industry express surprise that anyone objects to
the current system of bringing modified foods to market. The argue that all the
new products are tested are rigorously reviewed. However, the products are
tested by the company that makes them, and, although FDA reviews summaries
of the tests, the agency does not provide a formal pre-market safety approval of
genetically modified foods. The FDA never states that it finds a new genetically
modified product is safe. It is hard to account for the inability of the FDA and
industry to see that allowing a company that produces a GM food to determine
that it is safe—based on data collected by the company and opinions of experts
that the company may have hired—creates the potential for serious problems.
The GRAS process assumes that a company with a large investment in a new
product will never be unduly influenced by its self-interest in the product’s
development and success. It assumes that a company and its experts will never
make a mistake in their assessments. A regulatory system that does not require
the regulatory agency to take public responsibility for allowing a new and
If a company claims that its product is GRAS, FDA must
either accept the data presented to it by the company or
take on the burden of disproving the safety of the product.
If the FDA accepts the company’s data, it takes no respon-
sibility for the safety of the product. There is no Federal
Register notice and no explanation of reasoning.
Foreman
untried product on the market, and explaining its reasons why, assumes that
a company that must meet its profit goal will never put its own interest above
that of the public and excludes the possibility of human error, is a regulatory
system that is likely to fail both the regulated industry and the public.
The FDA’s decision, in its 1992 Policy Statement, to examine genetically
modified foods on the basis of GRAS has been determined by at least one court
to fall within FDA’s regulatory discretion. The GRAS process has been around
for a long time. It was devised in part to shorten the period of time needed to
move new, but uncontroversial, food additives to market. The question is why
FDA decided to apply this doctrine to move the products of a new and
controversial technology to market.
Again, the record indicates that the Bush administration was eager to give
American companies an advantage in getting a new technology on the market
quickly. In addition, the FDA apparently was driven to pursue this policy of
“nonregulation” in order to avoid asking Congress either to write new law
needed to address the new technology appropriately or to provide the
additional staff and resources required to perform more intensive safety reviews.
The decision was shortsighted and unwise. The policy has failed the test of
public trust. Under the pressure of increasing public criticism, FDA asked for
comments on the existing system. It received 35,000 responses, most
unfavorable. The agency is now trying to buy a little more credibility by
making small changes to its review process, but it adamantly refuses to make
the changes necessary to assure the kind of scrutiny that builds public trust.
Instead it has given those who oppose the technology a powerful weapon to
use against the new products.
If the products of agricultural biotechnology are as benign as both industry
and government insist, why not subject them to the most searching scrutiny?
The FDA never states that it finds a new genetically
modified product is safe. It is hard to account for the
inability of the FDA and industry to see that allowing
a company that produces a GM food to determine that it
is safe—based on data collected by the company and
opinions of experts that the company may have hired—
creates the potential for serious problems.
IS IT POSSIBLE TO REGRIND THE LENS AND SECURE CONSUMER
ACCEPTANCE OF BIOTECHNOLOGY?
Scientists and public officials have advocated a regulatory system that inspires
public trust. Perry Adkisson, chair of the National Academy of Sciences
Committee on Genetically Modified Pest-Protected Plants, has stated, “Public
acceptance of these foods ultimately depends on the credibility of the testing
and regulatory process” (Bettleheim, 1999).
And in 1999, Secretary of Agriculture Dan Glickman urged, “With all that
biotechnology has to offer, it is nothing if it’s not accepted. That boils down to
a matter of trust—trust in the science behind the process . . . trust in the
regulatory process that ensures a thorough review. . . .”
Proponents of agricultural biotechnology have tended to dismiss critics as
either ignorant, intellectually dishonest, or extremist. It is a serious mistake.
In the end, the biotechnology industry and its supporters will succeed neither
in insulting people into buying these products nor concealing their presence.
We would all benefit if we could find some way to improve the regulatory
regime, increasing public confidence in the safety of genetically modified foods
without imposing such expense and delay that the industry fails. There is at
least one example where representatives of the stakeholder groups demon-
strated that it is possible to reach some agreement on key issues related to
agricultural biotechnology, as follows.
Cognizant of the increasing disagreement between the trans-Atlantic partners
on this subject, President Prodi of the European Union and President Clinton
appointed a Consultative Forum comprising twenty private individuals, ten
from each side of the Atlantic, to meet and try to reach some consensus. It was
an extremely diverse and impressive group—including a former Prime Minister
of the Netherlands, Nobel Laureate Norman Borlaug, officials of DuPont and
Unilever; a farmer from Portugal and one from Missouri, a consumer advocate
from the United Kingdom and one from the United States, and three scientists
actively engaged in agricultural biotechnology. It also included a scientist from
Environmental Defense, a representative from European Friends of the Earth,
and a bioethicist from Georgetown University. I was privileged to be part of the
American delegation.
We reached agreement and produced a report. None of us loved every line.
Each of us disliked some part of it. But we were able to agree on the following
about agricultural biotechnology:
• It has promise that must not be squandered.
• It can be a major contributor to fighting hunger in the developing world.
• It presents the threat of unforeseen, unintended, negative consequences
that must be addressed.
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• Its successful use requires public trust and that trust will be generated
by a rigorous, comprehensive and open regulatory process, including
mandatory pre-market safety review of each product and a determination
by the appropriate government agency that the product is safe.
• Final products containing novel genetic material should be labeled.
In December 2000 we presented our recommendations (US-EU, 2000),
which—at the urging of industry and government agencies—have been
ignored by Presidents Clinton and Bush. The EU has begun to respond to
the recommendations, positively in most cases.
I disagree with Henry Miller that agricultural biotechnology is doomed.
The recommendations of the US-EU Consultative Forum offer a way to have
the technology and some assurance of safety. The report is evidence that a wide
range of people would like to see agricultural bioechnology move forward and
can agree on changes that would facilitate progress.
Without actions similar to those recommended by the US-EU Biotechnology
Consultative Forum, it is unlikely that agricultural biotechnology will gain the
public trust essential to the fulfillment of its promise.
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Genetic Engineering and the Concept
of the Natural
MARK SAGOFF
University of Maryland
College Park, MD
Why do many consumers view genetically engineered foods with suspicion? I
want to suggest that it is largely because the food industry has taught them to
do so. Consumers learn from advertisements and labels that the foods they buy
are all natural—even more natural than a baby’s smile. “The emphasis in recent
years,” Food Processing magazine concludes, “has been on natural or nature-
identical ingredients” (Food Processing, 1988). According to Food Product
Design, “The desire for an all natural label extends even to pet food” (Saunders,
1995).
The food industry, I shall argue, wishes to embrace the efficiencies offered by
advances in genetic engineering. This technology, both in name and in concept,
however, belies the image of nature or of the natural to which the food industry
constantly and conspicuously appeals. It should be no surprise that consumers
who believe genetically modified foods are not “natural” should regard them for
that reason as risky and as undesirable. Consumers might be as suspicious of
many other foods, however, if they were less misled about the extent to which
technology—not nature—is responsible for producing them and especially for
endowing them with color and flavor.
ALL-NATURAL TECHNOLOGY
Recently, I skimmed through issues of trade magazines, such as Food
Technology and Food Processing, that serve the food industry. In full-page
advertisements, manufacturers insist that the ingredients they market come
direct from primordial Creation or, at least, that their products are identical to
nature’s own. For example, Roche Food Colors runs in these trade magazines
a full-page ad that displays a bright pink banana over the statement: “When
nature changes her colors, so will we.” The ad continues:
Today more and more people are rejecting the idea of artificial colors being used
in food and drink. . . .
Our own food colors are, and always have been, strictly identical to those
produced by nature.
We make pure carotenoids which either singly or in combination achieve a whole
host of different shades in a range of yellow though orange to red.
And time and time again they produce appetizing natural colors, reliably,
economically, and safely.
Just like nature herself.
Advertisement after advertisement presents the same message: food comes
directly from nature or, at least, can be sold as if it did. Consider, for example,
a full-page ad that McCormick and Wild, a flavor manufacturer, runs regularly
in Food Processing. The words “BACK TO NATURE” appear under a kiwi fruit
dripping with juice. “Today’s consumer wants it all,” the advertisement purrs,
“great taste, natural ingredients, and new ideas... Let us show you how we can
put the world’s most advanced technology in natural flavors at your disposal...”
This advertisement clearly states the mantra of the food industry: “Today’s
consumer wants it all.” Great taste. Natural ingredients. New ideas. The world’s
most advanced technology. One can prepare a flavor artificially with just a little
chemistry know-how, for example, that of almond by mixing oil of clove and
amyl acetate to produce benzaldehyde. To get exactly the same compound as a
“natural” flavor, one must employ far more sophisticated technology to extract
and isolate benzaldehyde from peach and apricot pits. The “natural” flavor, an
extract, contains traces of hydrogen cyanide, a deadly poison evolved by plants
to protect their seeds from insects. Even so, consumers strongly prefer all-
natural to artificial flavors, which sell, therefore, at far lower prices.
In its advertisements, the Haarman and Reimer Corporation (“H&R”)
describes its flavor enhancers as “HypR Clean Naturally.” With “H&R as your
partner, you’ll discover the latest advances in food technology” that assure
“the cleanest label possible.” A “clean” label is one that includes only natural
ingredients and no reference to technology. In a competing advertisement, Chr.
Hansen’s laboratory announces itself as the pioneer in “culture and enzyme
technologies. And because our flavors are completely natural, you can enjoy
the benefits of ‘all-natural’ labeling.” Flavor manufacturers tout their stealth
technology—i.e. technology so advanced it disappears from the consumer’s
radar screen. The consumer can be told he or she is directly in touch with
nature itself.
The world’s largest flavor company, International Flavors & Fragrances
(IFF), operates manufacturing facilities in places like Dayton, NJ, an industrial
corridor of refineries and chemical plants. Under a picture of plowed, fertile
soil, the IFF Laboratory, in a full-page display states, “Where Nature is at Work,
IFF is at work.” The text describes “IFF’s natural flavor systems.” The slogan
follows: “IFF technology. In Partnership with Nature.” Likewise, Meer
Corporation of Bergen, NJ, pictures a rainforest under the caption, “It’s A Jungle
Out There.” The ad states that “true-to-nature” flavorings “do not just happen.
It takes... manufacturing and technical expertise and a national distribution
network... for the creation of natural, clean label flavors.”
Food colors are similarly sold both as all-natural and as high tech. “Vegetone‘
colors your foods naturally for a healthy bottom line,” declares Kalsec Corp.
of Kalamazoo, MI. Its ad shows a technician standing before a computer and
measuring chemicals into a test tube. The ad extols the company’s “patented
natural color systems.” The terms “natural” and “patented” fit seamlessly
together in a conceptual scheme in which there are no trade-offs and no
compromises. Only the most sophisticated technology will assure your product
a clean, all-natural label. The natural is patentable.
If you think any of this is contradictory, you will not get far in the food
industry.
ORGANIC TV DINNERS
As a typical American suburbanite, I can buy not just groceries but “Whole
Foods” at Fresh Fields and other upscale supermarkets. I am particularly
impressed by the number of convenience foods that are advertised as “organic.”
Of course, one might think that any food may be whole and that all foods are
organic. Terms like ”whole” and “organic,” however, appeal to and support
my belief that the products that carry these labels are less processed and
more natural—closer to the family farm—than are those that might be sold
by multinational megacorporations, such as Pillsbury or General Foods.
My perusal of advertisements in trade magazines helped disabuse me of
my belief that all-natural, organic, and whole foods are closer to nature in a
substantive sense than are other manufactured products. If I had any residual
sentiments, they were removed by an excellent cover story, “The Organic-
Industrial Complex,” that appeared in the May 13, 2001, issue of the New York
Times Magazine. The author, Michael Pollan, was shocked to find that the
prepackaged microwavable all-natural organic TV dinners at his local Whole
Foods outlet are not gathered from the wild by red-cheeked peasants in native
garb. They are highly processed products manufactured by multinational
corporations. Contrary to the impression created by advertisements, organic
and other all-natural foods are often fabricated by the same companies—using
comparable technologies—as those that produce Velveeta and Miracle Whip.
And the ingredients come from as far away as megafarms in Chile, not from
local farmers’ markets.
Reformers who led the organic food movement in the 1960s wished to
provide an alternative to agribusiness and to industrial food production. But
some of these same reformers bent to the inevitable. As Pollan pointed out,
they became multimillionaire executives of Pillsbury and General Mills in
charge of organic-food production systems. This makes sense. A lot of advanced
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technology is needed to produce and market an all-natural or an organic ready-
to-eat meal. Consumers inspect food labels to ward off artificial ingredients; yet
they also want the convenience of a low-priced, pre-prepared, all-natural
dinner.
General Mills Senior Vice President, Danny Strickland, told Pollan, “Our
corporate philosophy is to give consumers what they want with no trade-offs.”
Pollan interpreted the meaning of this statement as follows. “At General Mills,
the whole notion of objective truth has been replaced by a value-neutral
consumer constructivism, in which each sovereign shopper constructs his own
reality.”
Mass-marketed organic TV dinners do not compromise; they combine
convenience with a commitment to the all-natural, ecofriendly, organic
ideology. The most popular of these dinners are sold by General Mills through
its subsidiary, Cascadian Farms, whose advertising slogan, “Taste You Can
Believe In,” as Pollan observed, makes no factual claims of any sort. It “allows
the consumer to bring his or her personal beliefs into it,” as Vice President for
Marketing, R. Brooks Gekler, told Pollan. The absence of any factual claim is
essential to selling a product, since each consumer buys an object that reflects
his or her particular belief-system.
What is true of marketing food is true of virtually every product. A product
will sell if it is all-natural and ecofriendly and, at the same time, offers the
consumer the utmost in style and convenience. A recent New York Times article,
under the title “Fashionistas, Ecofriendly and All-Natural,” points out that the
sales of organic food in the United States topped $6.4 billion in 1999 with a
projected annual increase of 20%. Manufacturers of clothes and fashion
accessories, such as solar-powered watches, are cashing in on the trend. Maria
Rodale, who helps direct a publishing empire covering “natural” products,
founded the women’s lifestyle magazine Organic Style. Rodale told the Times
that women want to do the right thing for “the environment but not at the cost
of living well.” Advances in technology give personal items and household
wares an all-natural ecofriendly look and feel that is also the last word in
fashion. Consumers “don’t want to sacrifice anything,” Ms. Rodale told a
reporter. Why should there be trade-offs between a commitment to the natural
and a commitment to the good life? “Increasingly there are options that don’t
compromise on either front” (La Ferla, 2001).
The food industry does not sell food any more than the fashion industry sells
clothes or the automobile industry sells automobiles. They sell imagery. The
slogan, “Everything the consumer wants with no tradeoffs,” covers all aspects
of our dream-world. Sex without zippers, children without zits, lawns without
weeds, wars without casualties, and food without technology. Reality involves
trade-offs and rather substantial ones. For this reason, if you tried to sell reality,
your competitor would drive you out of business by avoiding factual claims and
selling fantasy—whatever consumers believe in—instead. Consumers should
not be confused or disillusioned by facts. They are encouraged to assume that
they buy the products of Nature or Creation not industry. In view of this
fantasy, how could consumers view genetic engineering with anything but
suspicion?
NATURE’S OWN METHODS
Genetic engineering, with its stupendous capacity for increasing the efficiencies
of food production in all departments, including flavors and colorings, raises a
problem. How can genetic recombination be presented to the consumer as
completely natural—as part of nature’s spontaneous course—as have other
aspects of food technology? A clean label is needed to tell consumers that there
is nothing unnatural or inauthentic about genetic engineering. Industry has
responded in two complementary ways to this problem.
First, the food industry has resisted calls to label bioengineered products.
Gene Grabowski of The Grocery Manufacturers Association, for example,
worries that labeling “would imply that there’s something wrong with food, and
there isn’t” (Lambrecht, 1999). Michael J. Phillips, an economist with the
Biotechnology Industry Organization (BIO), adds that labeling “would only
confuse consumers by suggesting that the process of biotechnology might, in
and of itself, have an impact on the safety of food. This is not the case”
(Wilson, 2000).
Second, many manufacturers point out that today’s genetic technologies do
not differ, except in being more precise, from industrial processes that result in
the emulsifiers, stabilizers, enzymes, proteins, cultures, and other ingredients
that do enjoy the benefits of a clean label. Virtually every plant consumed by
human beings, canola, for example, is the product of so much breeding,
hybridization, and genetic modification that it hardly resembles its wild
ancestors. This is a good thing, too, since these wild ancestors were barely
edible if not downright poisonous. Manufacturers argue that genetic engineer-
ing differs from conventional breeding only in that it is more accurate and,
therefore, changes nature less.
For example, Monsanto Corporation, in a recent full-page ad, pictures a
bucolic landscape reminiscent of a painting by Constable. The headline reads,
“FARMING: A picture of the Future.” The ad then represents genetic
engineering as all-natural, or at least as natural as are conventional biotechnolo-
gies that have enabled humanity to engage successfully in agriculture. “The
products of biotechnology will be based on nature’s own methods,” the ad
assures the industry. “Monsanto scientists are working with nature to develop
innovative products for farmers of today, and of the future.”
In this advertisement, Monsanto applies the tried-and-true formula to which
the food industry has long been committed by presenting their technology as
revolutionary, innovative, highly advanced, and as “based on nature’s own
methods.” Everything is natural. Why not? As long as there are no distinctions,
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there are no trade-offs. Consumers can buy what they believe in. A thing is
natural if the public believes it is. “There is something in this more than
natural,” as Hamlet once said, “if philosophy could find it out.”
FOUR CONCEPTS OF THE NATURAL
If consumers reject bioengineered food as “unnatural,” what does this mean? In
what way are foods that result from conventional methods of genetic mutation
and selection, which have vastly altered crops and livestock, more “natural”
than those that depend on gene splicing? Indeed, is anything in an organic TV
dinner “natural” other than, say, the rodent droppings that may be found in it?
Since I am a philosopher, not a scientist, I am particularly interested in the
moral, aesthetic, and cultural—as distinct from the chemical, biological, or
physical—aspects of the natural world. I recognize that many of us depend in
our moral, aesthetic, and spiritual lives on distinguishing those things for
which humans are responsible from those that occur as part of nature’s
spontaneous course.
Philosophers have long pondered the question whether the concept of the
natural can be used in a normative sense, that is, whether to say a practice or a
product is “natural” is to imply that it is better than one that is not. Why
should anyone assume that a product that is “natural” is safer, more healthful,
or more aesthetically or ethically attractive than one that is not? And why is
technology thought to be intrinsically risky when few of us would survive
without quite a lot of it?
Among the philosophers who have questioned the “naturalistic fallacy”—the
assumption that what is natural is, for that reason, good—John Stuart Mill
(1969) has been particularly influential. In his “Essay on Nature,” he argued
that the term “nature” can refer either to the totality of things (“the sum of all
phenomena, together with the causes which produce them”) or to those
phenomena that take place “without the agency... of man.” Plainly, everything
in the world, including every technology, is natural and belongs equally to
nature in the first sense of the term. Mill commented:
To bid people to conform to the laws of nature when they have no
power but what the laws of nature give them—when it is a physical
impossibility for them to do the smallest thing otherwise than through
some law of nature—is an absurdity. The thing they need to be told is,
what particular law of nature they should make use of in a particular
case.
Of nature in the second sense, i.e. that which takes place without the agency
of man, Mill had a dour view: “Nearly all the things which men are hanged or
imprisoned for doing to one another, are nature’s every day performances.”
Nature may have cared for us in the days of the Garden of Eden. In more recent
years, however, humanity has had to alter Creation to survive. Mill concluded,
“For while human action cannot help conforming to nature in one meaning of
the term, the very aim and object of action is to alter and improve nature in the
other meaning.”
Following Mill, it is possible to distinguish four different conceptions of
nature to understand the extent to which bioengineered food may or may not
be natural. These four senses of the term include:
• Everything in the universe. The significant opposite of the “natural” in this
sense is the “supernatural.” Everything technology produces has to be
completely natural because it conforms to all of nature’s laws and
principles.
• Creation in the sense of what God has made. The distinction here lies
between what is sacred because of its pedigree (God’s handiwork) and
what is profane (what humans produce for pleasure or profit).
• That which is independent of human influence or contrivance. The
concept of “nature” or the “natural” in this sense, e.g., the “pristine” is
understood as a privative notion defined in terms of the absence of the
effects of human activity. The opposite of the “natural” in this sense is the
“artificial.”
• That which is authentic or true to itself. The opposite of the “natural” in
this sense is the specious, illusory, or superficial. The “natural” is
trustworthy and honest, while the sophisticated, worldly, or contrived is
deceptive and risky.
These four conceptions of nature are logically independent. To say that an
item or a process—genetic engineering, for example—is consistent with the
laws of nature, for example, is by no means to imply it is “natural” in any other
sense. That genetically manipulated foods can be found within the totality of
phenomena does not show that they are “natural” in the sense that they are part
of primordial Creation, free of human contrivance, or authentic and expressive
of the virtues of rustic or peasant life.
The problem of consumer acceptance of biotechnology arises in part because
the food industry advertises its products as natural in the last three senses. The
industry wishes to be regulated, however, only in the context of the first
conception of nature, which does not distinguish among phenomena on the
basis of history, source, or provenance. The industry argues that only the
biochemical properties of its products should matter to regulation; the process
(including genetic engineering) is irrelevant to food safety and should not be
considered.
The food industry downplays the biochemical properties of its products,
however, when it advertises them to consumers. The industry—at least if the
approach taken by General Mills is typical—tries to give the consumer
whatever (s)he believes in. If the consumer believes in a process by which
rugged farmers on the slopes of the Cascades raise organic TV dinners from the
soil by sheer force of personality, so be it. You will see the farm pictured on the
package to suggest the product is close to Creation, free of contrivance, and
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authentic or expressive of rural virtues. What you will not see on any label, if
the industry has its way, is a reference to genetic engineering. The industry
believes regulators should concern themselves only with the first concept of
nature—the scientific concept—and thus with the properties of the product.
Concepts related to the process are used to evoke images that “give consumers
what they want with no trade-offs.”
SHAKESPEARE ON BIOTECHNOLOGY
I confess that, as a consumer, I find organic foods appealing and I insist on
“all-natural” ingredients. Am I just foolish? You might think that I would see
through labels like “all natural” and “organic,” not to mention “whole” foods,
and that I would reject them as marketing ploys of a cynical industry. Yet like
many consumers, I want to believe that the “natural” is somewhat better than
the artificial. Is this just a fallacy?
Although I am a professional philosopher (or perhaps because of it), I would
not look first to the literature of philosophy to understand what may be an
irrational, or at least an unscientific, commitment to buying “all natural”
products. My instinct would be to look in Shakespeare, who has been correctly
called the world’s most underrated poet, to understand what may be contradic-
tory attitudes or inexplicable sentiments.
Shakespeare provides his most extensive discussion of biotechnology in The
Winter’s Tale, one of his comedies. In Act IV, Polixenes, King of Bohemia,
disguises himself to spy upon his son, Florizel, who has fallen in love with
Perdita, whom all believe to be a shepherd’s daughter. In fact, though raised as a
shepherdess, Perdita is the castaway daughter of the King of Sicily, a close, but
now estranged, friend of Polixenes. Perdita welcomes the disguised Polixenes
and an attendant lord to a sheep-shearing feast in late autumn, offering them
dried flowers “that keep / Seeming and savour all winter long.” Polixenes
merrily chides her: “well you fit our ages / With flowers of winter.” She replies
that only man-made hybrids flourish so late in the fall:
…carnations, and streak’d gillyvors,
Which some call nature’s bastards. Of that kind
Our rustic garden’s barren; and I care not
To get slips of them.
Polixenes asks why she rejects cold-hardy flowers such as gillyvores, a
dianthus. She answers that they come from human contrivance, not from “great
creating nature.” She complains there is “art” in their “piedness” or variegation.
Polixenes replies:
Say there be;
Yet nature is made better by no mean
But nature makes that mean; so over that art
Which you say adds to nature, is an art
That nature makes... This is an art
Which does mend nature—change it rather; but
The art itself is nature.
The statement, “The art itself is nature” anticipates the claim made by
Monsanto that “the products of biotechnology will be based on nature’s own
methods.” Polixenes, Mill, and Monsanto remind us that everything in the
universe conforms to nature’s own principles, and relies wholly on nature’s
powers. From a scientific perspective, in other words, all nature is one. The
mechanism of a lever, for example, may occur in the physiology of a wild
animal or in the structure of a machine. Either way, it is natural. One might be
forced to agree, then, that genetic engineering applies nature’s own methods
and principles; in other words, “the art itself is nature.”
The exchange between Perdita and Polixenes weaves together the four
conceptions of nature I identified earlier in relation to John Stuart Mill. When
Polixenes states, “The art itself is nature,” he uses the term “nature” to
comprise everything in the universe, that is, everything that conforms to
physical law. Second, Perdita refers to “great creating nature,” that is, to
Creation, i.e., the primordial origin and condition of life before the advent of
human society. Third, she contrasts nature to art or artifice by complaining that
hybrids do not arise spontaneously, but show “art” in their “piedness.” Finally,
Perdita refers to her “rustic garden,” which, albeit cultivated, is “natural” in the
sense of simple or unadorned, in contrast to the ornate horticulture that would
grace a royal garden. The comparison between the court and the country
correlates, of course, with the division that exists in Perdita herself: royal in
carriage and character by her birth, yet possessed of rural virtues by her
upbringing.
Shakespeare elaborates this last conception of “nature” as the banter
continues between Perdita and the disguised Polixenes. To his assertion, “The
art itself is nature,” Perdita concedes, “So it is.” Polixenes then drives home his
point: “Then make your garden rich in gillyvors, / And do not call them
bastards.”
To which Perdita responds:
I’ll not put
The dibble in earth to set one slip of them;
No more than were I painted I would wish
This youth should say ‘twere well, and only therefore
Desire to breed by me.
Besides comparing herself to breeding stock—amusing in the context, since
she speaks to her future father-in-law in the presence of his son—Perdita
reiterates a fourth and crucial sense of the “natural.” In this sense, what is
“natural” is true to itself; it is honest, authentic, and genuine. This conception
reflects Aristotle’s theory of the “nature” of things, which refers to qualities that
are spontaneous because they are inherent or innate.
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Perdita stands by her insistence on natural products—from flowers she raises
to cosmetics she uses—in spite of Polixenes’ cynical but scientific reproofs.
Does this suggest Perdita is merely a good candidate for Ms. Rodale’s organic
chic? Should she receive a free introductory copy of Organic Style? Certainly
not. There is something about Perdita’s rejection of biotechnology that
withstands this sort of criticism. Why have Perdita’s actions a moral authority
or authenticity that the choices consumers make today may lack?
HAVING IT BOTH WAYS
Perdita possesses moral authority because she is willing to live with the
consequences of her convictions and of the distinctions on which they are
based. By refusing to paint herself to appear more attractive, for example, she
contrasts her qualities, which are innate, with those of the “streak’d gillyvor,”
which result from technological meddling. This comparison effectively gives
her the last word because she suits the action to it: she does not and would not
paint herself to attract a lover. Similarly, Perdita does not raise hybrids, though
she admits, “I would I had some flow’rs” that might become the “time of day”
of the youthful guests at the feast, such as Florizel.
She does not try to have it both ways, to reject hybrids but expect to grow
cold-hardy flowers. She ridicules those who match lofty ideals with ordinary
actions, whose practice belies their professed principles. For example, Camillo,
the Sicilian lord who attends Polixenes, compliments Perdita on her beauty. He
says, “I should leave grazing, were I of your flock, / And only live by gazing.”
She laughs at him and smartly replies, “You’d be so lean that blasts of January /
Would blow you through and through.”
Many people today share Perdita’s affection for nature and her distaste for
technology. Indeed, it is commonplace to celebrate Nature’s spontaneous course
and to condemn the fabrications of biotechnology. Jeremy Rifkin speaks of
“Playing Ecological Roulette with Mother Nature’s Designs,” and Ralph Nader
has written the foreword to a book titled, “Genetically Engineered Food:
Changing the Nature of Nature.” Prince Charles, in a tirade against biotechnol-
ogy, said, “I have always believed that agriculture should proceed in harmony
with nature, recognizing that there are natural limits to our ambitions. We need
to rediscover a reverence for the natural world to become more aware of the
relationship between God, man, and creation.”
Insofar as consumers reject genetically engineered food, this need not be
understood as an animadversion to recombinant DNA as such. In fact,
consumers are equally likely to reject “mutated” foods even if the mutation
occurs (as it does in nearly every food product) through cross-breeding,
hybridization, and other conventional methods. In a typical survey of consumer
attitudes, “only 28% (of respondents in New Jersey) thought they had ever
eaten a hybrid fruit or vegetable that was the product of traditional cross-
breeding. Moreover, 40% did not approve of making hybrid plants.” The
consensus view held it was best “not to meddle with nature” (Hamstra, 1998).
While consumers today share Perdita’s preference for the natural in the sense
of the authentic and unadorned and spurn technological meddling, they do not
share her willingness to live with the consequences of their commitment. Even
in winter, they expect to enjoy fruits and vegetables of unblemished appearance
and consistent taste and nutritional quality. Gardeners wish to plant lawns and
yards with species that are native and indigenous, and they support commis-
sions and fund campaigns to throw back the “invasions” of exotic and alien
species. Yet they also want lawns that resist drought, blight, and weeds, and—to
quote Perdita again—to enjoy flowers that “come before the swallow dares, and
take / The winds of March with beauty.” In other words, the consumer wants it
both ways. As Ms. Rodale knows, they “don’t want to sacrifice anything.”
Today’s consumers insist, as did Perdita, on the local, the native, the spontane-
ous. Yet, they lack her moral authority because they are unwilling to live with
the consequences of their principles or preferences. Consumers today refuse to
compromise; they expect fruits and flowers that survive “the birth / Of
trembling winter” and are plentiful and perfect all year round.
NAKED LUNCH
Those who defend genetic engineering in agriculture are likely to regard as
irrational consumer concerns about the safety of genetically manipulated crops.
The oil and other products of Roundup Ready® soybeans, according to this
position, pose no more risks to the consumer than do products from conven-
tional soybeans. Indeed, soybean oil, qua oil, contains neither DNA nor protein
and so will be the same whether or not the plant is herbicide resistant. Even
when protein or DNA differs, no clear argument can be given to suppose that
this difference—e.g., the order of a few nucleotides—involves any danger.
Crops and livestock are the outcome of centuries or millennia of genetic
crossing, selection, mutation, breeding, and so on. Genetic engineering adds
but a wrinkle to the vast mountains of technology that separate the foods we
eat from wild plants and animals.
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Genetic engineering adds but a wrinkle to the vast
mountains of technology that separate the foods we eat
from wild plants and animals.
The same kind of argument may undermine consumer beliefs that “natural”
colors and flavors are safer or more edible than artificial ones. In fact, chemical
compounds that provide “natural” and “artificial” flavors can be identical and
may be manufactured at the same factories. The difference may lie only in the
processes by which they are produced or derived. An almond flavor that is
produced artificially, as I have mentioned, may be purer and, therefore, safer
than one extracted from peach or apricot pits. Distinctions between the natural
and the artificial, then, need not correspond with differences in safety, quality,
or taste, at least from the perspective of science.
An almond flavor that is produced artificially may
be purer and, therefore, safer than one extracted from
peach or apricot pits. Distinctions between the natural
and the artificial, then, need not correspond with
differences in safety, quality, or taste, at least from
the perspective of science.
Distinctions consumers draw between the natural and the artificial, and
preferences for the organic over the engineered, reflect differences that remain
important nonetheless to our cultural, social, and aesthetic lives. We owe
nature a respect that we do not owe technology. The rise of objective, neutral,
physical and chemical science invites us, however, to disregard all such moral,
aesthetic, and cultural distinctions and act only on facts that can be scientifi-
cally analyzed and proven. Indeed, the food industry, when it is speaking to
regulators rather than advertising to consumers, insists on this rational,
objective approach.
In an essay titled, “Environments at Risk,” Mary Douglas (1975) character-
ized the allure of this objective, rational, value-neutral science:
This is the invitation to full self-consciousness that is offered in our
time. We must accept it. But we should do so knowing that the price is
William Burroughs’ Naked Lunch. The day when everyone can see
exactly what it is on the end of everyone’s fork, on that day there is no
pollution and no purity and nothing edible or inedible, credible or
incredible, because the classifications of social life are gone. There is no
more meaning.
Advances in genetic engineering invite us to the full self-consciousness that
Douglas described and aptly analogizes to the prison life depicted in Naked
Lunch. It is the classifications of social life—not those of biological science—
that clothe food and everything else with meaning. Genetic engineering poses
a problem principally because it crosses moral, aesthetic, or cultural—not
biological—boundaries. The fact that the technology exists and is successful
shows, indeed, that the relevant biological boundaries (i.e. between species)
that might have held in the past now no longer exist.
Given advances in science and technology, how can we maintain the
classifications of social life, for example, distinctions between natural and
artificial flavors and between organic and engineered ingredients? How may
we, like Perdita, respect the difference between the products of “great creating
nature” and those of human contrivance? She honors this distinction by living
with its consequences. Her severest test comes when Polixenes removes his
disguise and threatens to condemn her to death if she ever sees Florizel again.
Florizel asks her to elope, but she resigns herself to the accident of their
origins—his high, hers (she believes) low—that separates them forever. Dressed
up as a queen for the festivities, Perdita tells Florizel: “I will queen it no further.
Leave me, sir; I will go milk my ewes and weep.”
Perdita, of course, both renounced her cake and ate it, too. In Act IV, she
gives up Florizel and his kingdom, but in Act V she gets them. Her true identity
as a princess is eventually discovered, and so the marriage happily takes place.
If you or I tried to live as fully by our beliefs and convictions—if we insisted on
eating only those foods that come from great creating nature rather than from
industry—we would not be so fortunate. “You’d be so lean that blasts of January
/ Would blow you through and through.”
Perdita is protected by a playwright who places her in a comedy. Shakespeare
allows her to live up to her convictions without compromising her lifestyle.
This is exactly what the food industry promises to do: “to give consumers what
they want with no trade-offs.” It is exactly what Ms. Rodale offers: to protect
the environment, “but not at the cost of living well.” The food, fashion, and
other industries work off-stage to arrange matters so that consumers can
renounce genetic engineering, artificial flavors, industrial agriculture, and
multinational corporations. At the same time, consumers can enjoy an
inexpensive, all-natural, organic, TV dinner from Creation via Cascadian Farms
Perdita lives in the moral order of a comedy. In that moral order, no
compromises and no trade-offs are necessary. You and I are not so fortunately
situated. Indeed, we must acknowledge the tragic aspect of life, the truth that
good things are often not compatible and that we have to trade off one for the
sake of obtaining the other. The food industry, by suggesting that we can have
everything we believe in, keeps us from recognizing that tragic truth. The
industry makes all the compromises and hides them from the consumer.
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Q: In a debate that has become confrontational through and through, how
do you introduce trade-offs without weakening your position immediately?
A: It would help to have a greater availability of literature on the history of
crops, such as corn, that people accept as being safe, and show the vast
differences that have resulted from technology—breeding and selection. Then
people would begin to understand that technology is a normal part of food
production and there would be less embarrassment about admitting it with
respect to biotechnology.
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I had to come up with a title for the abstract, and this one might seem
rather dramatic. But, considering the experiences of farmers, including their
connection with biotechnology—its origins and where it may lead us—this
title may be more fact than fiction. Many times in the past, producers were left
holding the bag, so to speak, as new technologies ran into unforeseen problems.
I will start with a brief overview of our farming operations to provide
background on how my thinking has developed and how we use technologies
that are being discussed at this conference. We farm in a family corporation.
That is a nasty word to some people, but our corporation involves my wife,
Nancy, and myself. The board of directors of our corporation has two members,
and all decisions are unanimous. “LAND” in LANDcorp stands for Leland,
Ann, Nancy, and David, i.e. it originally included Nancy’s parents, who are now
retired. We also manage farmland on a crop-share basis for absentee landowners
in Illinois and, to a small extent, in flooded river valleys in Missouri.
OUR CURRENT FARMING PRACTICES
For a corn-soybean farmer, nothing looks better than a weed-free field of beans
as far as the eye can see. All of our soy is no-till planted; we drill directly into
the standing corn stalks from the previous year. And the majority of our corn
is grown with minimum till. For those unfamiliar with no-till, you can see the
residue from the previous corn crop under the canopy of the soybean. Where
the lie of the land allows it, some of our fields are in continuous no-till with a
corn/soybean rotation. Although this practice definitely has benefits, we do not
adopt it in every case.
We use a combination of different types of products. Corn and soybeans
sound pretty straightforward, but there are variations. For example, different
varieties mature at different times in close proximity in the same field. We
tailor-fit the management system for each field. We have some ground that is
highly erodable, which means that it falls under a required conservation plan
for government programs. But even on ground that is not highly erodable, we
maintain grassed waterways to help improve the environment, not only on our
farm but also downstream from it. Over the past several years, we have been
adopting new types of seed. High-oil corn––quite prevalent in our area
although not as much as in some others––is used mainly for livestock feed
because of its higher energy content. And we grow Bt corn, but not strictly for
prevention of corn-borer damage. Some varieties with the BT gene are healthier
and produce more grain than the non-Bt counterpart. Although I cannot prove
this to you scientifically, I know from personal experiences that it is the case.
We use Roundup Ready® soybeans and Bt corn as part of a management
program, but not across all of our acres. This year we are about 10% Bt corn
and about 55% Roundup Ready® soybean. I have neighbors who are 100% Bt
corn and Roundup Ready® soybean and I have neighbors who have never used
either technology. Farmers should not be defined on the basis of national,
regional, or even local averages.
All of our grain is stored on-farm. We have a drying system at our corn
facility. All of our grain, corn and soybean, goes to either terminal markets or
processor markets. The vast majority of our corn goes to Peoria or Pekin on
the Illinois River, most of which is made into ethanol. The corn-gluten feed is
shipped out of Peoria, e.g. for export, depending on market dictates.
Some in the industry think that smaller storage units are needed to identity-
preserve grain for niche markets. I agree, but only if it is economically viable.
We have three smaller grain bins for soybean as well as a large bin. Last year,
we raised high-pro soybean, soybean for seed, and we raised clear-hilum
soybeans for tofu. But, in the end, the economics were unfavorable, and the
smaller grain bins have sat empty. You have to be willing to make some
adjustments in farming, and that is a good example.
Since 1993, we have employed a grid-based soil-sampling system on all of the
farms that we own and manage. We sample the soil at least every 4 years, using
a 21/2-acre grid. One farm was soil-tested in 1993 and again in 1995. In 1993
We grow Bt corn, but not strictly for prevention
of corn-borer damage. Some varieties with the
BT gene are healthier and produce more grain than
the non-Bt counterpart.
we did not have complete global positioning satellite capability, so we tested
again in 1995. Our goal for potassium is a reading of about 400 lb/acre, and the
variability range was 316 to 1,037. We apply the fertilizer on the basis of the
soil-test figures, therefore, many areas receive no potassium at all, otherwise
it is applied in response to the measured shortfall. We realize that, in the long
term, we have to be responsible and accountable for the fertilizer that we use,
not only from a cost-savings standpoint, but also for environmental reasons. Of
course we carry the soil-test and fertilizer-application information on to yield
mapping: we collect second-by-second yield data that, hopefully, is correlative.
In fact, our yields are pretty stable, including those zero-input areas.
BIOTECHNOLOGY: SILVER BULLET? . . .
Nancy and I began farming in 1985, just ahead of the passage of the 1985
farm bill. With the 1990 farm bill, it was probably the most environmentally
sensitive—or most restrictive, depending on your point of view—farm bills ever
passed. We have been told by consumers to reduce pesticide use and to reduce
soil run-off. And, as producers, we must be more efficient: use less, produce
more, while spending less money. As the products of biotechnology came to
the market place in the late 1980s and early 1990s, I thought that we had found
the silver bullet. It was exciting.
When you look at biotechnology as a whole—how it has affected our lives—
it makes a lot of sense. In some cases, it has helped improve crop productivity.
It probably has reduced pesticide usage; if you think of it in terms of active
ingredient, it certainly has. And possibly most importantly, it has affected us in
terms of health-care. Our 14-year-old son was stricken with juvenile diabetes
when he was 9 months old. The new type of insulin is so close to what his body
would produce, if it were able to produce it, that it may add 10 to 15 years to
his life. It’s a “no-brainer!” It works and he is healthy. In a room with other 14-
year olds, you cannot tell the difference. And I have a brother with a congenital
heart condition. I am convinced that research in human genetics has helped
improve the care that he has received. New treatments have resulted from
knowledge created from gene mapping. For me, the results of biotechnology
have been incredible, from the medical standpoint as well as from the
production-agriculture standpoint.
When I joined the American Soybean Association, I had the opportunity to
travel to abroad, and spoke with consumers, officials in government, and
farmers in Mexico, Canada, Germany, Austria, France, Belgium, Japan, and
China. Many times, when they talked about the United States food supply, their
first two questions had nothing to do with technology. In an importing country,
they asked, “Do you have food that we can buy?” And their second question
was, “Is it a stable supply?” They are interested in those two aspects first, and
then come other questions. My experience tells me that, while we do need to
educate consumers and give them information on a world-side basis of what
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we are doing, we also have to be aware that their interests, at least initially, are
basic. There is trust—regardless of what you might see in the media—in the
American system of developing and testing new technologies, and removing
them or their products from the marketplace when they fail to perform as
expected. We have proven it time and again: hamburger recalled from the
marketplace, pesticides removed from sale after further review, for example.
I do not believe that there is a system better than ours. For one thing, it is not
political, and that is important. You may not like the systems that are in place,
but, at least they are not political.
If farmers knew 5 years ago what they know today about biotechnology,
would they still be using it? I would say, one hundred percent. Growers will
use a technology when it makes sense from the business standpoint. They
believe in a system that requires testing and approval up-front, from the
companies that bring them to the marketplace plus from third parties—
university testing in many cases.
. . . OR MANAGEMENT TOOL?
Ask farmers what percentage of the corn crop planted last year was genetically
modified, and they would probably have to think about it. They can tell you
exactly, maybe to a tenth of an acre, what area of corn or soybean they planted,
or wheat or alfalfa, or the number of cattle or hogs they have on feed. But if
you ask them what percentage of their corn crop is genetically modified, they
would not necessarily know because to them it is still corn. They view genetic
modification as a management tool in the vast majority of cases, and not
different from the norm. It as a tool to help make them more efficient as
producers, and if it fits, it fits, and if it does not, then so be it. They do not
make decisions based on that issue alone.
If farmers knew 5 years ago what they know today about
biotechnology, would they still be using it? I would say, one
hundred percent. Growers will use a technology when it
makes sense from the business standpoint. They believe in
a system that requires testing and approval up-front, from
the companies that bring them to the marketplace plus
from third parties—university testing in many cases.
GAINING GLOBAL ACCEPTANCE
Is there a solution to the controversy? One thing that I learned a long time ago,
through organizational work, is that the process is every bit as important as the
end product. If the biotech companies have been guilty of anything, it is that
the process was not all that it should have been. They failed to make the system
transparent, and failed to get all of the “stakeholders” involved. From the
farmer’s point of view, the key ingredient is predictability in the products that
he buys. Predictability in being able to buy and in being able to sell. In my
opinion, global acceptance of the processes that review and regulate the
products of biotechnology is necessary. I do not know how that will be
achieved, but I believe it is possible if those involved are of the mindset to do
so. With that process in place, then let it work. If they keep changing the rules,
no one knows if they are still on the “A” set or if the “B” set now applies.
So, with the process in place and allowed to work, the third aspect—possibly
a bitter pill for some—is to make stakeholders accountable. Farmers should
sign agreements knowing that the harvested crops cannot be put into the
normal marketing channels. If they do, they ought to be held accountable,
because they are hurting my credibility. The same applies to companies that
develop such varieties, if they do not fully disclose to farmers that the crop
probably cannot be sold in the market-stream, that it does not have all of the
approvals. I have heard and seen commercials on radio and television about
how you can channel these through normal marketing processes if you just
look for them. But, in my area, they cannot be sold within thirty miles.
Therefore, people must be held accountable. After the agreement is made, there
should be no turning back unless there is new evidence that supports a change
in the process for developing approvals. In my mind, it is not so very difficult;
with the system in place, you have to get people to believe that it can work, you
have to let it work, and then you hold people accountable. If we do not, we run
the risk of being what the “nay” sayers say that we are: interested solely in our
own well-being and not in the well-being of the consumer.
Q: Thank you for the farmer perspective. For me it was the first. I have three
questions.
• You mentioned that you had neighboring farms that were GM or non-GM
crops. What is your opinion about the lawsuit in Canada? Are you
concerned over the possibility of similar lawsuits on pollen drifting into
neighboring fields?
• You mentioned that you are using GM crops for pest or weed control, but
as management tools. If genetic engineering were to stall, are there
alternative technologies, techniques, or ways of accomplishing the
environmentally sensitive goals of the 1985 and 1990 farm bills? Do you
think that you could have accomplished those things without too much
imposition?
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• Assuming that we have the second and third generations of genetic
modifications, and you have a variety of output traits—say vaccines and
altered starch and protein traits—if I tell you here are ten seeds and there is
a market for them somewhere, what kind of costs or flexibility would you
have as a farmer to manage that kind of variety of crop; handling them in
your silos and moving them to the elevator, etc. Do you think that it is
practical?
A: I’ll respond in reverse order.
• On your last point, farmers can handle new technologies when given the
proper information, such as on handling and storage. There’s a big
difference between asking someone to store and keep a crop identity-
preserved for a dollar per bushel more than for ten cents more. The
problem in production agriculture right now is the people who are paying
a dollar—their guidelines are not a whole lot more stringent than those
who are paying five or ten cents. There are huge inequities, and farmers are
the ones paying the difference.
• When looking at environmental concerns, yes, there would be products
without biotechnology. The marketplace in general has its set of needs,
which would be met even without biotechnology. Without making guesses
as to whether it would have happened as quickly or as easily or as
effectively, by the nature of private enterprise I think that alternative
products would be available.
• I am not a plant breeder, but as a farmer I do understand that corn self-
pollinates at about 90%. Yes, pollen will drift, as seen in seed fields or
seed-corn production. But I do not believe that it will drift far enough to
infect a neighbor’s field beyond a tolerable level.
Q: I read in your bio that you farm about 3,000 acres, but you are also an
administrator in the American Soybean Association. So you must deal with
some smaller farmers as well. Do you think that they hold the same beliefs as
you in terms of this technology?
A: Agriculture is having a hard time defining what is a small farm, a medium
farm, and a large farm. Our operation may be a little above average in terms
of the number of participants. We have one full-time employee besides
ourselves, and some part-time workers. And we are in transition, going from
one generation to the next, and not yet involving the next generation. My
experience through the American Soybean Association was as an unpaid
volunteer. Sure, there are differences of opinion among producers. That old
adage, once you’ve met one farmer you’ve met one farmer, is very true. They
have a broad range of opinions. Being forward in your thinking is not limited
by farm size. I refuse to believe that you cannot be an active, progressive farmer
with fewer acres than some others. You may do things differently. You may do
things with neighbors and you may hire out more services, but I think that
farmers who are looking toward the growth and the future of the industry have
to look at new technologies. I do not think that they have to use a new
technology, but if they do not examine it they will never know if they are right
or wrong in the decision-making process.
Q: Can you give us some sense of the economics of biotechnology vs. non-
biotechnology? How much extra do you have to pay for GM soybean and corn
seed, and how does that work out? And secondly, how much is the premium for
non-biotech soybean or corn in your area?
A: From a cost stand-point, I think you have to look at the complete system
of how a farmer would farm under Plan A and how she or he would farm under
Plan B or C, to make a comparison. In our situation we have conventional
soybeans, STS soybeans, and Roundup Ready® soybeans. Across the board,
there is little difference in cost. But you need to include all of the costs, such
as the seed, and whether or not that includes a technology fee. You need to look
at additional trips across the field with one system over another. So, across the
board, there isn’t much price difference. That is why it comes down to a
management decision as to what fits best for each field.
There isn’t a lot of market premium for non-GM corn, because of where we
are located, and the markets we have. You might get two or five cents for non-
GM corn, but it might have to be delivered in a very short period of time, and it
might have to be at 13% moisture instead of 15%. You’re giving up maybe three
cents per bushel in moisture that you are allowed under grain standards in
order to get the premium. For soybeans, at Decatur Illinois, they may have the
best thing going. They are probably in the range of fifteen to twenty cents,
maybe eighteen cents for non-GM soybean. In that area it works well, because
not a lot of Roundup Ready® soybean is grown there. The effort involved in
keeping the crop separate is worth that eighteen or twenty cents.
Q: If you take off your grower hat for a minute and put on your farm-
manager hat, what kind of discussions about biotechnology do you have with
your absentee landlords?
A: As much as we can, we keep our absentee landowners apprised of current
issues in the industry, such as biotechnology and the present farm bill debate.
The only advice we have ever given absentee landowners and tenants about
what to plant is that they should plant varieties that are approved for export to
major markets for the United States. We will not take a crop that might not be
marketable; we have told tenants that we won’t accept the risk of them selecting
such crops. Other than that, I tell them pretty much what I’ve said today. We try
to keep them informed of the issues and give them a clear picture of where we
think we are and where we’re going.
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A Scientist’s Perspective:
the International Arena
ANATOLE F. KRATTIGER
bioDevelopments LLC (International Consultants) and Cornell University
Ithaca, NY
While preparing this paper, I pondered what a scientist’s perspective should be.
Although I no longer work at the bench, I am closely involved in the
continuum of scientific research through technology to its application, and
especially in its transfer to developing countries. I will briefly consider six
aspects of science and end with a challenge: to come up with new proposals for
action. How can people in the over-stocked grocery stores be made to change
their attitudes to the new science and technology so that its benefits will accrue
to those who are most deserving—the disadvantaged millions in the developing
world?
SCIENCE AND PUBLIC POLICY
The modern world-view includes science as a central element. Indeed, almost
everyone demands scientific certainty, e.g. with regard to global warming, ozone
depletion, and biotechnology’s safety. Yet, many people do not hold scientific
views as to the origins of life and other areas that affect our daily lives. On one
hand, we “demand” scientific certainty, yet on the other hand we reject
scientific information, data, and conclusions. How does that paradox continue
to exist? Evidently, it persists because we all seem to have a high degree of
tolerance for contradictions, and because we select the areas in which we
demand scientific certainty to suit our impulses. Consequently, it seems
impossible for policy makers to formulate science-based policies.
Paradoxically, although Europeans reject biotechnology that affects their
food, they accept it in the pharmaceutical area. But in developing countries
the most pressing health hazard is malnutrition. Diseases related to under-
nourishment kill approximately 40,000 children per day. So what is a luxury
for Europeans—safer food with fewer pesticide residues, more plentiful and
less expensive—is a matter of survival for the majority of the inhabitants of
this Earth.
A sufficiency of high-quality food is the most basic element of good health.
By denying the transfer of this technology to developing countries through
restrictive policies so prevalent in Europe and elsewhere, we deny it also to
most of the people on this planet. But how does one cope with the environmen-
tal luddites and anti-industry activists who claim to be cleaning things up as
they misquote, misrepresent, misunderstand, or knowingly fail to read the
scientific literature? How should we respond to their propagation of error-
riddled rhetoric?
Even those who see biotechnology as a potential “problem” at least
acknowledge current population/resource problems. Yet many fail to recognize
that agricultural biotechnology is an imperative for the 2.4 billion people—40%
of the world’s population—who survive on less than $2 per day. They somehow
fail to see the potential for biotechnology to increase the productivity of
existing farmland and thereby reduce the impact of agriculture on the
environment, particularly in marginal and fragile ecosystems.
The critics of biotechnology, with their often-mindless comments, are doing
little to meet the developing world’s growing food needs, and, in a paradoxical
twist, this will result in even more environmental destruction. We need to make
it clear to people, such as Prince Charles, that the latest environmental
catastrophe in Mozambique will seem like a royal garden party compared to the
consequences of the social shifts and environmental degradation to come.
Denying the poor access to the benefits of biotechnology will deny them the
means of lifting themselves out of poverty. Denying technological advances is
surely one way of sustaining subsistence farming, which farmers do not want
and which does not help the environment.
I conclude from these few considerations and thoughts about science and
policy that the power of politics has trumped the truth of science. Therefore,
we must better communicate the science of biotechnology to the public and to
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politicians, and supplant current views with more-convincing arguments. In
view of the paradox outlined in the first paragraph of the section, if biotechnol-
ogy is to flourish, it will not be science-based arguments that will win the day.
SCIENCE AND COMMUNICATION
Scientists are notoriously inept at communicating their progress. This is partly
because science is often far removed from technology. Debating positive effects
of technology on society and on the consumer is a very different matter from
debating scientific advancements.
The general public’s views of science and technology are strongly influenced
by overall education level, science education, and cultural and social back-
ground, to name but a few criteria. Yet, divergent social groups are united by
common cultural values. Hence, for each group, communication strategies have
to be adapted to reflect the target audience’s cultural values. Communicating
values is vital for public acceptance of new technologies, and requires widening
of scientists’ perspectives. An attempt to widen perspectives of the impacts of
biotechnology is long past due. The goal, however, should not be to take the
issue away from environmentalists, but to ensure that more voices from more
constituencies are included in the discussion. Similarly, the “negative” debate
that industry has initiated in the context of organic agriculture—by pointing
out its limitations and dangers—is also a shortsighted approach that may
backfire.
We could attempt to characterize what different constituencies want, ranging
from farmers, commodity traders, food processors, consumers, environmental-
ists, and parents, to ministers of agriculture and heads of state (Table 1). It is
immediately apparent that the primary concerns of the various constituencies
are varied; hence, the messages to them must be different. Unfortunately, the
benefits of biotechnology have been conveyed to the public mainly by
scientists, whose talents, generally, do not include ability to communicate
effectively with lay people. Scientists must step outside the province of science
itself and abandon the belief that the truth is their bailiwick. The truth is,
nobody holds the truth.
Denying the poor access to the benefits of biotechnology
will deny them the means of lifting themselves out of
poverty. Denying technological advances is surely one way
of sustaining subsistence farming, which farmers do not
want and which does not help the environment.
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Indeed, according to Roger Highfield, Science Editor of the Daily Telegraph,
“Many journalists would like you to think that they are seekers of the truth, but
I suspect that most are like me: curious gossips who like to show off by sharing
hot news with a big audience. That audience distrusts hacks as much as boffins.
But scientists could still learn from journalists. Journalists think carefully about
their audience and communicate accordingly.”
Farmers
TABLE 1.
Constituency Objectives/Goals Environmental/Development impact
High-yielding crops.
Less use of pesticides.
More-efficient use of inputs
(e.g. water, less transport).
High-quality products.
Decreased environmental impact.
Decreased secondary environmental
impact.
Productivity increases, value added,
healthier crops.
Plant
breeders
Better tools to make their work
more efficient.
Produce varieties that farmers
want and need.
Provide consumers with more
nutritious and all-round better
varieties.
Scientists in developed and developing
countries are now able to breed disease-
resistant, delayed-ripening, and hardier
varieties of crops.
Scientists To advance the frontiers of
science.
Discover and invent exciting
new technologies.
Benefit humankind.
Progress has been made, especially in
medicine, where disease diagnostics and
the production of substances that were
too expensive, such as insulin, are now
allowing people everywhere to lead
healthier lives.
Consumers Plenty of food with good and
increasingly better nutritional
value at relatively affordable
prices.
Biotechnology is making progress in that
direction possible—these are the most
exciting applications in the research and
development pipeline.
Company
(large and
small) CEOs
To sell what the consumer
needs in a way that ensures
that the company is sustainable
and profitable.
The economic potential of biotechnol-
ogy is enormous, for industrialized and
developing countries. It can be a win/
win proposition if we work together and
resist fear and distrust.
Government
officials
To ensure that the people of
their country equitably enjoy
the benefits of science and
technology.
To cast out the specter of
national poverty.
Biotechnology could help worldwide,
but only if the politicians are true
friends of the earth!
Parents To ensure that their children
can enjoy a better life on this
planet.
Biotechnology is helping already, in
agriculture, health, and the environ-
ment, to make the world a better place.
Scientists have failed to recognize that, for the lay public, biotechnology is
neither a technical nor a scientific matter. It is now part of the intricate
question of life itself. Hence, we must communicate this science and technology
in all-encompassing ways, invoking both traditional concepts of human culture
and economic development, and that of stewardship. Also, we must give
credence where it is due, including to organic agriculture. Contrary to what
activists and industry try to make the public believe, these are not two opposing
principles, but complementary ideals that should guide the creation of our
vision of the future and the steps we take to reach it.
Finally, communication has to begin at the school level. I believe it will take a
generation before biotechnology will be fully accepted.
SCIENCE AND INTELLECTUAL PROPERTY
It is evident that resolving the intellectual property (IP) aspects of this science
and technology is a rather multifaceted matter that daily increases in complex-
ity. The typical plant biotechnology company has a budget of millions of
dollars, sometimes into the hundreds of millions of dollars, for legal costs. But
scientists fail to see this as their concern—and indeed it is not—they would
rather avoid it and use the funds for research.
One of the fundamental problems is that the knowledge revolution enabled
by biotechnology has not been followed by a revolution in IP law. Once a sacred
right of the inventor, IP was stimulated both by metaphysical arguments over
ownership and by a desire to take practical measures to make inventions
quickly available. But times have changed. Consider Linux, the open-source
software to which everyone can contribute. It has seen the fastest software
evolution ever. At first Linux was developed as a response to Microsoft
Corporation’s domination of the operating-system world. Although driven by
this ideology, it makes good business sense too. The collaborative efforts of
programmers from around the world have created an impressive operating
system that is rapidly gaining market share. This “open-source,” group effort
has turned a fundamental business assumption on its head: people now see that
the value in software is not the software per se, but the productivity gains it
affords.
The same may apply to DNA and genes. One might well argue that we need
an open platform where everyone can contribute, where everyone benefits.
What a difference it would make if everyone could contribute to, and benefit
from, the productivity gains enabled through a better understanding and
knowledge of DNA and genes!
What proposals for action make sense? To make such an “open platform”
happen, a new definition of patents is needed to foster continued investment in
the science and technology and products. Perhaps a working group is needed to
try to come up with something new to save companies hundreds of millions of
dollars in legal fees. Yet, today we are bogged down in discussions about the
morality of ownership. We need less dogma and more common sense.
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BRINGING TECHNOLOGY TO THE CONSUMER
Food labeling is a typical aspect that may help or hinder the transfer of tech-
nology to the consumer. It can be a barrier, including a trade barrier. In the
context of the title of this paper, who will make the decisions for the world?
Wealthy, middle-aged, white, well fed, well clothed, well educated activists
in Seattle? Bureaucrats in Brussels? Let us remember that at least 60% of the
world’s consumers do not care about labeling—they simply want food on the
table. And of these, nearly 40% cannot read anyway. In any case, the majority
of foods sold to local consumers comes without packaging. Who is representing
the hungry and poor in such debates?
This gives us another criterion for our proposals for action: they must be
based on the world as it is rather than based on a romantic image of how
the world should be. We need to stop holding more than half the world’s
population hostage to poverty under the guise of debates about “safe” foods or
“safe trade.” In any case, safe food is not on offer; only safer food is on offer.
The “debates” are more about lifestyle choices in the industrialized, western
countries than they are about science-based analyses of new agricultural
technologies or of socio-economic realities affecting the 2.4 billion poorest of
our world. Further, the biotechnology debate is about technological acceptance
and not about science. This is something scientists find extremely difficult to
understand and even more so to accept. They prefer to indulge in the well
entrenched celebratory discourse because of the technological power that
biotechnology bestows.
SCIENCE AND BUSINESS
Whereas large companies spend huge amounts on legal fees, research per se is
being conducted more and more by smaller companies, often start-ups. Large
companies increasingly depend on small companies as sources of new products
and enabling technologies. Hence science—and research—is far from
moribund. There are many ways by which companies acquire research results.
They range from purchasing other companies to contract research to various
intermediate forms. The strategic alliance, one such intermediate form, is a
most critical part of technology-based industries. For example, 60% of Merck’s
products in the pipeline stem from alliances and partnering. This is nothing
We need to stop holding more than half the world’s
population hostage to poverty under the guise of debates
about “safe” foods or “safe trade.” In any case, safe food
is not on offer; only safer food is on offer.
new. Similar shifts took place in other industries such as computers and
automobiles, and are still taking place in different forms in the chemical
industry.
Hence, in agricultural biotechnology, major shifts are likely, such as mergers
for consolidation. Some of these shifts have already been brought about by
those who oppose multinational companies. Other changes will be forced by
governments due to public opinion, which will significantly shape the decade
to come.
Some of these changes are due to the fact that agricultural biotechnology is
being deployed so incredibly quickly. Monsanto today earns perhaps as much as
$650 million from its biotechnology-based products. This has never been seen
in agriculture with any other product only five years after the first large-scale
commercial launch. In an area where change has been notoriously slow, how
come we are so surprised that the consumer has been unable to keep pace?
Naturally, scientists are as baffled as consumers are confused and as those in
developing countries are mystified, about the many corporate changes. And
more are to come.
SCIENCE AND INTERNATIONAL DEVELOPMENT
When considering international development, one invariably thinks of the
“Third” World, of small-scale farmers, of poverty, of hunger, of neo-colonialism,
of exploitation, of the Brazilian rain forest, of over-consumption, and of the
WTO, to name but a few. Biotechnology rarely enters the debate.
Changed attitudes are needed to introduce biotechnology in an appropriate
way in this area. And changing attitudes may result from two related ap-
proaches. First, for northern countries, biotechnology needs to be understood
better in terms of its significance for the lives of individuals in industrialized
countries and their children. One means of accomplishing this is to present the
issues in tangible terms, emphasizing actions that can be taken in industrialized
countries. Biotechnology needs to be understood as a global issue. Examples
abound primarily in the biodiversity area. The mold for penicillin, for example,
was discovered in North America, and a major Swiss pharmaceutical company
has found useful soil organisms in Scandinavia. Yellowstone Park, a center of
hot-spring activity, is a major source of heat-resistant microbes.
Care must be taken to present biotechnology as a concept. This message can
be enhanced by the second approach: the advancement of environmental
stewardship. Individuals, even those with limited contact with natural
environments on a daily basis, seem to understand the need to conserve natural
systems as the basis for life. And biotechnology must be presented more
predominantly in the debates as an integrated form of production that reduces
the farmer’s imprint on the environment. This can be explained in terms of a
legacy for future generations. Biotechnology can be presented as a component
of good stewardship.
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The challenge is to bridge the gap between economic realities in the North
and the aspirations of the billions of people living in developing countries,
largely in the South. Clearly, the first problem to overcome is the communica-
tion gap due to differences in social and political heritage. Organizations that
speak (or claim to speak) for local or indigenous communities, however, are
often merely of the reactionary type with little or no support in those
communities. Such are also the most vocal in international political forums
with the effect of further delaying rapprochement among the systems, i.e. the
establishment, corporations, and local/indigenous communities.
No matter how worthwhile the claimed aspirations of such activist entities
may be, they contribute little in today’s world but polarize the debates. True
change in attitudes does not, and will not, come from the actions of environ-
mental pressure groups nor from multinational conglomerates, but from a
systematic sensitization of the public. This, in turn, will influence policy
makers and corporations alike, and will yield results in the longer term.
The first conclusion from this discussion should be that the issues are
complex, not so much in themselves but because they all meet at one place:
the new technology of biotechnology.
SCIENCE AND HISTORY
Oscar Wilde said, “The one duty we owe to history is to rewrite it.” I say it is
better to make history rather than to rewrite it!
How might we make history in the area of biotechnology and international
development? What institutional arrangements could ensure that benefits are
“equitably” shared among companies and countries and individuals and the
environment? How can we even define “equitable sharing” when equitable
is so much a concept that depends more on the eye of the beholder than
on measurable characteristics? Clearly, we need to bring about shifts in the
perception of values, including prejudices about modern biotechnology.
Perhaps a new type of biotech enterprise, one publicly owned and managed
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like a private enterprise, would allow us to sway public opinion. We certainly
need something big and bold if we are to bring about needed change.
The solution, perhaps, lies in the creation of an entirely new type of
enterprise. We all recognize the exceptional achievements of the CGIAR in the
latter part of the twentieth century, yet I challenge the CGIAR system that it is
no longer appropriate for the twenty-first century. The CGIAR system’s success
was based on the transfer of public technologies, but it has not been able to
“recover” from its successes and adapt to the changing environment in which it
operates. After years of internal debate on the impact of IP and biotechnology,
the CGIAR still does hot have a consistent policy towards either, yet alone a
comprehensive strategy on how to deal with the proprietary nature of the
science on which it relies. The CGIAR operates in a global context, but so far
it has failed to “use” globalization to its own advantage and thus it has failed to
serve the poor most effectively with its dwindling financial and technological
resources.
Yet, with the advent of the life sciences, the potential to improve the human
situation was unprecedented in history. Globalization is enabling the mobiliza-
tion of worldwide science and technology for the betterment of humankind. Yet
the promise is ours only if we manage to deploy improved products to the poor
and wealthy alike. A new vision and initiative is warranted for biotechnology to
produce and deliver its capabilities not only for the most vulnerable billion
people but also the wealthy. The developing world is superbly and uniquely
positioned to translate this vision into reality.
At a seminar at Cornell University in September 1999, I proposed the
creation of a novel, highly efficient and sustainable organization as a model
for the next century, with the potential to exceed many-fold the impact of the
CGIAR and the green revolution of the twentieth century. In short, the vision is
to “sustain globalization in the life sciences” by creating a new form of private/
public partnership with the life science capabilities of a large biotechnology
company as the keystone. Development, both economic and scientific, would
be accelerated through the synergy of private/public energies.
At the centerpiece of the “privic” strategy would be, for example, a large
biotechnology company’s agricultural life sciences division. The science and
technology would be poised to deliver the long-promised benefits of biotech,
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gradually, to the entire world. Meanwhile, the value embedded in other
divisions of the biotech company, including chemicals and seeds, would be
returned to shareholders as these business units of the current enterprise are
spun off.
Financing for the “privic” would come from public (government, multi-
lateral), foundations, and private sources, and from future licensing of its
technologies (to corporations and at a discount to developing countries).
All would benefit from this strategy as the most effective means of sustaining
agricultural and economic advancement, and human well-being.
Market growth would come by expanding biotech into developing-world
markets where the technology is needed most. Current revenue streams would
be maintained and expanded through licensing arrangements with corporations
(current competitors), the CGIAR, universities, and national programs around
the world.
Public opposition to plant biotech would be curbed rapidly as a result of
the display of its startling value for the world’s poorer people, thus realizing
biotech’s promise in the near term.
Research and development would be efficiently expanded by focusing on a
mix of commercial (for licensing) and developing-country needs and priorities.
Human capital would be enhanced by ensuring that researchers in developing
countries would participate in the R&D and would have ready access to
biotech’s tools to solve their national and regional agricultural and nutritional
problems.
The staff, talent, strategies, R&D priorities, and finances of the “privic”
would be managed according to corporate principles by a CEO supported by
an executive and management board. A small non-executive oversight board of
senior people serving in their individual capacities would represent national
and topical interests.
CONCLUSIONS
Only two questions remain. First, is there a better idea on the table to bring
about the change needed to make biotechnology flourish and deliver its
promise to the world’s citizens at large? And if there is no better idea, then
the question is: what is to be done next to make the “privic” work? Seven
simple steps would be needed:
• Seek limited funding for a feasibility study.
• Prepare issues and options briefs (financing the deal, governance,
management, R&D strategy, cash-flow projections, etc.).
• Commission an investment bank’s preliminary assessment of valuation
and financial options.
• Approach the Chairpersons and CEOs of the other major agricultural
biotechnology companies.
• Organize a “retreat”-type meeting with senior people and advisers to:
— determine feasibility, refine concept, and set policy and implementation
strategy,
— elaborate specific areas for further investigation/determination and
allocate follow-up tasks, and
— identify members for a formal steering committee.
• Convene the formal steering committee meeting to implement strategy.
• Launch the “privic.”
It could all be done in 9 months, or perhaps even less. Because biotechnology
is at the heart of the long-term sustainability of our environment, because
biotechnology is at the heart of our survival in the long term, it represents an
opportunity today to forge new partnerships for tomorrow.
Q: As you mentioned, the green revolution resulted from research at CGIAR
institutes in the Philippines and Mexico. I happen to know that biotechnology
research is in progress at the International Institute of Tropical Agriculture in
Nigeria and at the International Rice Research Institute in the Philippines, and,
I assume that significant effort is being expended in biotechnology at the other
international institutes. Please elaborate on that, and address the question: to
what extent is it possible for the international institutes to make a significant
contribution to increasing food production in developing countries, using the
tool of biotechnology, without any involvement of industry?
A: Intellectual property rights are often blamed as a stumbling block, but I
think that reveals a lack of understanding of IP and patents. The annual budget
for the CGIAR centers, CIMMYT in Mexico, IITA in Nigeria, IRRI in the
Philippines, CIAT in Colombia, etc. is about $310 million, of which $28 million
are spent on biotechnology. A few years ago, the R&D budget of a typical
company like Novartis may have been three to four times that amount for
agricultural biotechnology alone. Based on published data, private investment
in biotechnology in agriculture is approximately $1.1 billion, whereas the entire
developing world spends just over $100 million, of which most goes into
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capacity building and not into product development. So, the CGIAR system
is not in a position to develop major biotechnology applications for the
developing world. It can best do so by forging stronger alliances with the
private sector. But progress in this has been very slow because, for the past
seven or eight years, the CGIAR has been debating what their policy should be
on biotechnology, so far without resolution. The reason is that, around the table
are funding donors, bilateral agencies, representatives of developing countries,
environmental pressure groups, and companies, all with conflicting agendas.
It seems impossible for such an institution to elucidate a clear vision, which is
very regrettable. The green revolution was successful because relatively few
individuals were involved, Norman Borlaug among others. I think it is possible
for the CGIAR to contribute a great deal, but not within the strictures of its
current governance. That is why new institutions are needed, possibly as
brokers or go-betweens, with dramatic new approaches, such as the develop-
ment of the “privic” concept.
What the European Union Wants the
United States To Understand About
European Biotech Imports
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1European Commission public-opinion surveys, http://europa.eu.int/comm/dg10/epo/.
Globalization, while offering the advantages of increasing trade, prosperity,
and choice, has created problems and new uncertainties. Genetically modified
organisms (GMOs) in agriculture have been available for about ten years.
Their commercial use has been expanding rapidly in the United States, creeping
quietly and stealthily into the consumer’s food. According to recent figures,
75% of food on the shelves contains at least one genetically engineered
ingredient. Since 1998, difficulties in placing GM products on the market in the
European Union (EU) have given rise to trade tensions with the United States.
THE EU CONSUMER, FOOD SAFETY, AND LABELING
Safety, the most important food issue for European consumers, is currently
the number-one political issue in Europe—a large majority is worried about
transgenic food. More than 60% of the 1997 Eurobarometer1 respondents were
concerned about risks associated with GM food, compared with 40% in the
case of the medical applications of biotechnology. This result is consistent with
those of private polling institutes. The 2000 Eurobarometer helped in assessing
reasons for consumer concerns over GM food. Items gaining the highest degree
of support were: “even if GM food has advantages, it is against nature”; “if
something went wrong, it would be a global disaster”; “GM food is simply
not necessary.”
Seventy-four percent of EU consumers favored clear labeling of GM
food (Eurobarometer, 1997). Fifty-three percent of respondents said
that they would pay more for non-GM food whereas 36% would not
(Eurobarometer, 2000).
THE PSYCHOLOGY OF THE EU CONSUMER
One can argue at length about the rationality or irrationality of the EU
consumer’s attitude towards GMOs. Some even call it “neurotic.” This attitude
is due largely to a series of factors that are fundamental to understanding the
European situation:
• There is a food surplus, thus consumers have choice.
• Food involves far more than mere sustenance. Generally speaking, the
European has a relationship with food that is emotional and even a
fundamental part of the local culture. Every town has its regional products,
and sitting together for hours eating good food is part of the pleasures of
life.
• Americans are more prone to adopt modern technology, whereas
Europeans are more conservative.
• The blood scandal (blood tainted with the AIDS virus), which occurred
in the EU at the end of the 1980s, as well as later food scares related to
bovine spongiform encephalopathy (BSE or mad cow disease, since 1995,
which is still a terminal disease), dioxin (1999), and currently hoof and
mouth disease (HMD). Beef is no longer on the menu of most schools in
Europe. Politicians said there was no danger. British Minister of Agricul-
ture, Mr. John Gummer, gave a hamburger to his 5-year-old daughter in
front of television cameras—but he and others were wrong. Of course,
their risk assessments were based on information provided by scientists
(e.g. BSE could not jump the species barrier, sheep to cattle to humans).
In the case of BSE (approximately ninety already dead), uncertainty
about the incubation period makes extrapolation by British scientists
distressing: they project between 150,000 and 200,000 deaths. Every year
50,000 Europeans are killed on the roads and 500,000 die from smoking-
related diseases. The difference in attitude seems to lie in the risk factor.
People are not averse to taking risks, but do not want them to be forced
on them.
The BSE and dioxin crises have cost the jobs of two Belgian and two
German government ministers, and has seen the arrival of a Green minister
at the head of the new Ministry for Agriculture and Consumer Affairs in
Germany, which in some ways is a revolution.
• These scares have been greatly amplified by environmental activists and
by the tabloid press, which demonize plant biotechnology, particularly in
the United Kingdom and in Austria, where resistance to GMOs is greatest.
The tabloid press has invented the destructive expression “Frankenstein
food, no trust,” i.e. no trust in scientists and no trust in politicians. No
longer is “science-based” necessarily a quality label in Europe. Apart from
the blood scandal and BSE, some consumers remember the precedents of
DDT and thalidomide.
• Faced with growing popular pressure to phase out GMOs, many retailers
have adopted a restrictive stance on GM food. The first to respond in
the United Kingdom were supermarkets, and the movement spread to
continental Europe in 1999.
The retailing industry is the linchpin in the food market due to its
proximity to the consumer. Retailers are in a key market position that
allows them to amplify consumer preferences and relay them to the food
industry. Retailers are not anti-GM in principle—they are responding to
consumer demands. Already, McDonald’s in Europe, and British supermar-
kets such as ASDA and Tesco (42% market share), have decided that their
lines of meat or poultry will come from animals raised on GM-free feed.
Furthermore, companies such as Kraft Foods, Nestlé, Kellogg, and PepsiCo
have promised not to use GM grain or corn in their production plants.
This restrictive approach to GM food has had cascading effects on the
upstream side of the food chain, in domestic as well as in foreign markets.
Food processors and grain companies have been hard-pressed to segregate
GM from non-GM products.
• The disastrous and, for some, arrogant PR campaign of biotech companies
(supply-driven, totally ignoring the final consumer, considered by some
as forcing down their throats food they do not want to eat) was definitely
counter-productive.
The heart of the matter: to the EU consumer, GM food is neither cheaper
nor does it taste or ripen better, nor are their quasi-pharmaceutical benefits
(prevention of decaying teeth, weight reduction, etc.). With no added value and
plenty of other choice, why take the risk? “Do we really know the potential
long-term risks and health hazards?” asks the EU consumer, although no one
has died from eating GM foods.
The retailing industry is the linchpin in the food market
due to its proximity to the consumer. Retailers are in a key
market position that allows them to amplify consumer
preferences and relay them to the food industry. Retailers
are not anti-GM in principle—they are responding to
consumer demands.
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WORLD TRADE ORGANIZATION
The risk is real that the American GMO industry, or at least some of its
representatives, will ask the United States administration to take the case
of the de facto moratorium on approving GMOs in Europe to the WTO.
It would be a bad idea for the United States to go to the WTO and create a
new EU-US dispute. First of all, I am not sure that the United States would win
[technical barriers to trade (TBT) and sanitary and phytosanitary (SPS) texts
are not clear on this], which would undermine further the confidence that
American citizens and Congress have in the WTO. The same would, however,
be true were the United States to win; since food is the number-one political
issue in Europe, I do not see how policy-makers there could comply with such
a WTO ruling.
RESUMING THE APPROVAL PROCEDURE
Under pressure from public opinion, five EU Member States blocked the GMO
approval procedure in October 1998. At that time, eighteen GMOs had been
approved and fourteen were pending. In July 2000, however, the Commission
decided to break the deadlock and proposed to Member States a strategy to
regain public trust in the procedure for approval of GMOs. The objective was
and is to resume the authorization process.
The idea was to put in place a series of new regulatory building blocks
replacing the GM legislation of 1990, in order to address public concerns and
to give clear responses to political and legal concerns, which favor consumer
safety and choice. The first of these new blocks is the revised directive 90/220
on deliberate release of GMOs into the environment, approved in February
2001 by the European Parliament and the Council of Ministers, and now called
Directive 2001/18. Once the new Directive was adopted, the European
Commission believed that the GMO approval procedure could be resumed.
The new Directive covers food and feed, and confirms premarketing-
authorization and risk-assessment procedures for all GMOs. It strengthens
previous Directives and foresees an exception for pharmaceutical products.
The new Directive not only applies to the fifteen member countries of the EU,
but also to the twelve candidate countries, which have to adopt EU legislation
and are already in the process of doing so––in total, twenty-seven countries
with the same GM legislation, introducing:
• mandatory traceability and labeling at all stages of movement to market,
• mandatory monitoring requirements after placing on the market,
• mandatory consultation with the public (as with the United States
Federal Register)
• mandatory consultation of the EU Scientific Committee,
• application of the precautionary principle when implementing the
Directive, and
• a time-limited consent of a maximum ten years.
The country of origin of the food and whether it has been imported into the
EU has no bearing on the enforcement of the legislation, in particular as far as
traceability and labeling requirements are concerned. These measures apply
equally to American and EU biotech products.
While adopting Directive 2001/18, six Member States (France, Italy, Austria,
Greece, Denmark, and Luxembourg) declared that they would accept the
relaunch of the GMO approval procedure only on condition that the Commis-
sion would come forward with more specific proposals regarding traceability
and labeling. The Commission is now in the process of preparing regulations on
traceability and on labeling of food and feed. The new proposals are expected to
extend the existing labeling requirements to nearly all foods derived from
biotechnology and to extend labeling requirements to animal feed. These two
draft regulations are expected to be adopted by the European Commission
(Executive) on June 6, 2001, and then be sent to the Council of Ministers and
the European Parliament for adoption in order to become effective EU law.
Traceability concerns the whole food and feed chain. The idea is to have a
unique identification through a code for the life of the GMO and to be able to
recall the products in case of problems (cf. StarLink™).
Labeling is process-based (in the United States it is content-based). In other
words, even if no trace of DNA or protein can be found in a GMO-derived
product, it must still be labeled, the basic concept being consumer choice. It
should be noted that, in Europe, labeling is not meant to be, and has never
been, a warning.
Regarding traceability and labeling, Commissioner David Byrne wanted a
system that is workable also for the United States, which is why the draft
regulation on food and feed foresees a 1% threshold for the adventitious
presence of American-approved GMs that are not yet EU-approved.
Furthermore, in order to speed up the approval process, the Commission
intends to follow a special procedure, according to which the main provisions
of the two draft regulations could become the conditions for approval of
individual approval requests, in order to allow the approval process to be
resumed as soon as possible.
Some say that labeling will stigmatize GM foods. But to restore confidence,
we need transparency even if there are no traces of GM DNA or proteins. We do
not want any activist organization scaring consumers again by announcing that
a food is of GM origin and that the EU tried to conceal it.
Some say that labeling will stigmatize GM foods. But to
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no traces of GM DNA or proteins.
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We are conscious that people, both pro and con, may not find our solution
fully acceptable. But both sides should recognize that it is an honest exercise
balance between the interests of the consumer and of industry. If companies
want to sell their products, then they must comply. If consumer trust is to be
gained, they must be assured that there is strong regulation to meet their
concerns.
A CHANGING WORLD AND PERHAPS EVEN A COPERNICAN
REVOLUTION
A Green minister heads Agriculture in Germany and Greens are members of the
governmental coalitions in Germany, France, Belgium and, until the spring of
2000, in Italy. Agriculture is no longer regarded in a positive light by many
European governments. The days when European food policy was determined
by the need to increase output and efficiency in order to achieve food security
are probably over. The new motto is Food Safety and Food Quality.
Farmers have become less important than consumers. But will these
consumers pay more for higher quality products? How much more? Do modern
production methods militate against tasty and wholesome food produce? These
questions are simple and straightforward, but I expect that the answers will be
complex, particularly given the complexity of the modern food chain and the
higher expectations of the modern consumer. All this may, in time, have policy
implications for the European Common Agricultural Policy.
Many things can happen if consumer confidence is not restored in Europe, or
if a food scare (e.g. BSE or HMD) were to erupt in the United States. In the field
of food safety, trust in regulators can be lost overnight.
Where the EU was isolated with its GM legislation a year ago, today eighteen
of the main trading partners of the United States have adopted GM legislation
or are in the process of doing so.
SEGREGATION
If the American farmers want to maintain their export shares to Europe and
other parts of the world, they should look carefully for lessons from the
StarLink™ problem. In the long run, consumers around the world will decide
what premiums they will pay for non-biotech products. On the other hand,
some exporting countries are likely to produce and export both types of crops
(GM and non-GM) and to develop marketing systems that offer consumers
products that are differentiated according to their biotech status. But the
problem will always be the risk of commingling GM-free with GM crops, or
GM-approved crops with GM-non-approved crops (especially if there is no, or a
very low, threshold). That will mean that efficient segregation will have to be in
place, with concomitant investment and costs.
“GIVE TIME TO TIME”
As for the irrational attitude of the EU consumers, I think one should apply the
French saying, il faut donner du temps au temps, “one should give time to time,”
and try to educate the consumer in this field in order to gradually restore
confidence.
The biotech industry should also become much more proactive. It should
repudiate misinformation. It should educate the consumer––without television
campaigns with nice music, but with facts––stressing the tremendous
environmental advantages of GM crops. And the consumer should no longer
be scared to death by activist organizations.
SECOND, THIRD GENERATION BIOTECHS
There will be no real incentive for consumers to buy bio-engineered food
unless (a) it is cheaper: until now, the benefit of a better yield from GM crops
has not been passed on to the retailer or consumer (perhaps the premium for
GM-free commodities will be such that consumers will start buying cheaper
GM food); or (b) unless a second or third generation of GMOs brings real
added value to the consumer such as medical and nutritional benefits. If this
happens, I am convinced that genetically engineered food will break through
during the next decade. At that point, I believe that these companies will want
their GM products to be labeled.
Q: Europeans want perfect traceability of genetically engineered products. Is
there any interest in having traceability or labeling regarding pesticide use,
particularly in view of concerns over dioxin and DDT?
A: No. We are thinking of traceability in a lot of fields, we are thinking of
labeling GM-free products according to the White Paper published in January
of last year. We will also have labeling of other products—in principle all
products will be labeled. But, for the moment, we are dealing mainly with GM
foods.
I am convinced that genetically engineered food will
break through during the next decade. At that point,
I believe that these companies will want their GM
products to be labeled.
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Q: Has anybody, either in the European Government or at a university, made
a cost/benefit analysis of the current or future laws on GM foods, looking at
externalities and so on?
A: Not to my knowledge. I wonder if such has been done in the United
States—that would be interesting.
Q: A two-part question: you mentioned the European consumer’s desire for
choice in relation to products from GM crops. Does the same apply to meat
products? Can the European consumer try American pork or beef—even if they
are labeled as such—bearing in mind that growth promotants are not used for
pork in this country. Also: you mentioned Europeans’ disbelief in scientists. Yet,
I traveled recently in Europe and found pervasive belief in the science of global
warming. Would you comment on these inconsistencies?
A: You are right. It is amazing that there is no belief in science as far as food
is concerned, but there is trust in the science that indicates climate change—
although President Bush doesn’t believe it. The contradiction may result from
the fact that food is an emotional issue. As far as meat is concerned, we are not
against importation of American beef provided it is hormone-free. A greater
beef quota has been proposed, as compensation to the United States, but at this
time there is a glut of beef in Europe. There is overproduction of pork in
Europe also; and it is coming in by the ton from Poland.
Q: What about some of the other manipulations that are used in crop
genetics? Recently in the press, attention has been paid to irradiation, for
example.
A: We intend to label it. We intend to label everything. Perhaps we are
overdoing it, but the lesson from BSE is such that we see no other political
solution.
Q: What are your thoughts on the future of non-food products that are
genetically modified?
A: There is a promising future for such non-food products. Cotton is now the
most successful of the GM crops in the United States, at 66% on an area basis.
In attending several biotech conferences in the United States recently, I have
been amazed to learn what is in store in the field of non-food GM products.
This information would serve to demonstrate to Europeans that biotech has far-
reaching advantages, yet it has had very little coverage in the media even here
in the United States.
Q: What is your prognosis on European attitude to the development and use
of GMOs in countries in which food is not in excess?
A: First of all, Europeans are much more cynical. There is no such thing as
“compassionate conservatism” there, for example. When biotech companies
claim that they will feed the world, Europeans don’t buy it and see it as a
strategy for expanding business opportunities. This issue is much more
complicated than it looks at first sight. I don’t see subsistence farmers in Africa
or Asia being able to buy seeds every year. Will biotech companies sell seeds at
prices that are affordable to developing countries? I don’t think so. As an aside,
which has nothing to do with your question: sometimes it seems that biotech
companies want it both ways. In the United States when a GM product is
considered similar, it doesn’t have to be labeled, in which case, why is the
difference patentable?
Q: You brought up what I see as one of the great disconnects in this. You did
a wonderful job in covering the sensitivities of the Europeans, their high level
of awareness of the issues, and aspects that we might all agree on regarding
mishandling by the biotechnology industry. The disconnect lies in the fact that
most of these biotech companies are owned by Europeans.
A: Many European biotech companies are moving operations to the United
States. In the Research Triangle of North Carolina, for example, most of the
biotech companies are European because they fear for their future in Europe. I
am in the process of discussing with companies here in the United States what
thresholds, etc., they would like to see, and my counterparts in Europe are
having similar discussions with the same companies. They don’t provide the
same answers, which makes our job more difficult.
Q: Is there any European vehicle that provides an open forum where
interested stakeholders can come together in a non-threatening environment for
dialogue? They may disagree on issues, but they may build trust—it sounds like
trust is lacking.
A: Some months ago, a conference was organized by the European Parlia-
ment, and all of the stakeholders were in attendance, including Green Peace
and other advocates. Everybody explained their positions, but there was no real
dialogue.
Q: I’ve always thought that you need to have a vehicle to begin to have
dialogue. Regulation helps build trust, but without dialogue and the ability to
relate to real people, it is difficult to solve differences.
A: Yes, our regulation is only part of the solution. I feel strongly that biotech
companies should make a concerted effort. I participated in a brain-storming
session at a large company here in the United States, and it was striking that the
biotech division was in dispute with the chemical division because the latter
was still producing pesticides. This underlines how the environmental benefits
of biotech are not being explained to consumers.
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Q: I’ve been wondering why it wouldn’t be consistent to extend the same
traceability requirements to crops produced by conventional breeding in
which—particularly if you use exotic germplasm—you actually introduce many
more new proteins, most of them unknown, that might be allergens for
example. Alternatively radiation or chemical mutagenesis might have been
used. If these manipulations result in resistance to pests, for example, that
phenotype can be translated to wild relatives. Therefore, I am having trouble
seeing why you would place extreme traceability and other requirements on
genetically modified plants with which you have a good understanding of the
characteristics of the limited numbers of new proteins that are produced.
A: In Brussels, a lot of thought is being devoted to the legislative bricks that I
mentioned. One of the ideas is to require traceability for all new products.
Q: Did you say that traceability will be required also for animal feed?
A: Yes. That has been decided.
Q: So, will you start testing corn gluten meal?
A: As of next year we’ll have a European Food Authority, but it won’t have the
powers of the FDA to do testing for instance. Testing will remain with the
member states. The legislation being drafted will have the advantage of
applying to the whole of the European Union, otherwise we’d probably have
fifteen different legislations.
Q: Corn gluten meal from the United States will be GM. What will happen to
it? Will people buy it?
A: I’m not a buyer. I don’t know. It will be labeled, but we really don’t know
what is going to happen. Some extremists in my administrations want us, for
instance, to label eggs from chickens given GM feed.
The European Situation
DIRK-ARIE TOET
Nestec Ltd.
Vevey, Switzerland
Not developing biotechnology would be a greater risk
than developing it
My opinions on biotech and of what is happening in Europe are from a general
industrial perspective rather than from Nestlé’s perspective in particular. To
avoid any misunderstanding, the Nestlé corporate position on biotechnology is
very clear: we believe that we need to develop and use it, and we will support it
wherever and whenever we can. Only a few days ago, our CEO in Switzerland
said that not developing biotechnology would be a greater risk than developing
it. That is an unmistakable position, but we have to realize that we operate in
the real world, and sometimes there are things that you want to do but cannot.
I gave a presentation on this subject here in the United States about a year
and a half ago, and, in response, people saw me as a doomsayer, out of touch
with reality. It is rather unfortunate, but the situation today is no more rosy
than I pictured it then; if anything, it is probably worse than I predicted it
would be. Take, for example, the shift in European soybean imports from
the United States to Brazil. We believe that a major motive was that Brazil
positioned itself as a “non-GM” country. Four million tons that previously came
from United States now come from Brazil. Apparently, no one was hurt by that
move, because global trade increased enormously with China. What could not
be sold to Europe is being sold to China. Ironically, the Chinese use that
genetically modified soy to grow chickens that are exported to Europe.
LABELING
About twenty countries in the world now either have labeling regulations or are
considering them. They are all different. The following is a short, perhaps
imprecise, summary. One country has enacted a complete ban: Sri Lanka
banned all GM ingredients as of May 1, 2001. We have been in discussion with
Saudi Arabia for some time, because they are considering a ban. Their very
restrictive labeling legislation will come into effect in November, 2001.
Obviously, this is a significant barrier to trade. If you have centralized
production and want to export to those countries, you face problems similar to
those of about 20 or 25 years ago with additives and other ingredients.
PERSPECTIVE
I will spend a little time on how we got to this point, just a few remarks. We
have seen food scares and mounting public distrust. Opinion polls on
biotechnology in Europe, showed an across-the-board decrease of 10% in public
acceptance between 1996 and 2000. This was not limited to agriculture and
food, it included pharmaceuticals. More striking was that it focused on moral or
ethical aspects of acceptability. Opinions being formed at the moment are not
very positive. Uncertainty was at the root of the problem. When GM products
came to the market in Europe, we were faced with contradictory statements or
even silence both from regulators and from industry. This contributed
substantially to the lack of confidence now prevalent.
European culture, food culture, and agriculture have been mentioned at this
meeting. It would not be so bad if we Europeans were more modest. European
food culture is extremely important, but, on the other side of coin, are the food
scandals and scares of the past ten years, such as BSE and foot and mouth
disease.
A little modesty would also help with European agriculture. I have the
impression, when talking to Europeans –– it does not matter which member
state you are in –– that farming is seen as part of the fabric of daily life. I
commute seven minutes from my home to work and pass many farms, with
sheep, horses, cows, grapes, corn, wheat, and potatoes. There is a feeling that
European agriculture is purer and much closer to nature compared to industrial
agriculture in the United States. Yet, if you look at data that are available on
various web-sites, you will find that use of chemicals in Europe is much higher
than it is in America. When I use this argument in Europe, they are not pleased
to hear it. But, it is a fact. Therefore, more modesty would be beneficial.
POSITIVE DEVELOPMENTS
So far, it has been all gloom and doom. Let us consider positive developments,
because there definitely have been some. It looks as if the ban on thinking and
speaking about biotech has been broken! For years politicians did not dare
speak out on this subject, or they were very secretive. People who were
supportive dared to say so only in closed meetings far away from publicity. That
has changed. The European Parliament recently published a report on the
future of biotechnology in Europe. There is a strong emphasis on pharmaceuti-
cal biotechnology and applications in the medical sector, but attention is given
also to applications in the agri-food sector with a strong encouragement to look
at it, to work on it, and to take what is applicable in a European situation. The
same is true of an opinion drafted by Mikko Pesälä, a Finnish member of the
European Parliament, which focuses on agriculture applications and is positive
regarding environmental benefits in the short term and food-quality advantages
in the longer term.
In the European Commission there is great deal of activity. Several commis-
sioners are involved in getting biotechnology going again; one group is headed
by the Commission President, Romano Prodi himself. Sound regulation that
will authorize the possibility to grow genetically modified crops has finally been
adopted. Currently under discussion is the framework for research, which is
focusing on genomics and genetics.
The European Council, which consists of representatives of the European
member states, convened in Stockholm and made very clear statements on the
advantages of biotechnology, focusing mainly on pharmaceuticals, but
including agricultural and food applications.
These are all positive elements; however, quite a few “buts” remain. The
moratorium continues. Six member states have indicated that they will stop the
moratorium only when traceability labeling and liability are regulated. The new
proposals from the commission may or may not satisfy demands from those six
member states, from activist organizations, from consumers, and from the
biotech industry. There is fear that this collection of new proposals may
overshoot the target because it is focusing completely on GMOs and includes
fundamental change in certain policies.
SEED TO FATE
What are the major changes? The framework goes further than “seed to plate”;
it covers release into the environment including seed thresholds, traceability,
labeling of food and feed, and monitoring and post-marketing of the final
product. This is “seed to fate” rather than “seed to plate.” The food industry is
concerned that the focus is on GMOs, as if they have become the scapegoat for
everything wrong in our legislation, and in our European food culture and
agriculture: thus, in bearing responsibility for all of these sins, biotechnology
will be sacrificed. Singling out biotech will have a negative effect on the public.
We do not have to look far to see that other problems are related to our agri-
food chain.
What will change? First of all there is traceability, which is often confused
with identity preservation. Traceability depends on the informatics, the
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infrastructure of a country, and it already exists. Normally when you buy an
ingredient, you know from whom you are buying and you know what you are
buying. The producer of the ingredient knows from whom he is buying, and so
on and so forth. There is a requirement in hygiene legislation and there will be
a requirement in the new European food law for all of the players to preserve
that information and to make it available. However, at this time, a gap exists
and the gap is feed, and we think that that gap should be filled because many of
our problems have originated from that sector.
So, traceability should be extended to the full chain for reasons of safety and
quality. It is not information that is usually communicated—it is not informa-
tion that is transported along the chain. There is no master dossier that goes
with each ingredient to the end-producer. Some of the systems now in place are
such that we can trace back to a certain time, say between 12:43 and 12:57, for
a specific problem (of course not all parts of the chain are so precise).
Identity preservation is entirely different. To give you one example: yogurt
made with apples or pears from Anjou is marketed in France. For a certain
period of time, the yogurt is made using only those fruits. There you have a
system with identity preservation, meaning that you go to the supplier, tell
them what you want and get the information, which travels along the chain and
is communicated to the consumer, and, eventually, that yogurt will be 10, 15, or
20% more expensive. In the discussions on-going in Brussels, this identity-
preservation idea, where you limit your purchasing flexibility, where you
increase costs, where you increase the amount of data and information to be
managed, is seen as traceability and is explained as traceability. But I see it as
being at odds with the concept of traceability.
The next aspect, labeling, has seen an important change. In the EU, as of
mid-1999, we had to label all ingredients that were derived from raw materials
with a GMO content of more than 1% based on DNA. Proteins also were
mentioned, but no analytical methods are available. If you are below that 1%
and have documentation to prove efforts to separate or segregate, labeling is not
needed. If the ingredient is negative by PCR, you do not have to label. These are
the three criteria for current European legislation. Along with other food
producers, we at Nestlé introduced labeled products to the market that came
heavily under fire and were removed from the shelves by the supermarkets.
Genetically modified ingredients were slowly phased out, and, by and large, the
European market no longer uses GM ingredients.
We saw a rapid decrease in consumer calls. In 1999, Nestlé France received
more than 15,000 phone calls on GM: Are you using GMOs? What is it? Are
they safe? Can you guarantee that it’s not in there? etc. Labeling regulations
brought clarity about what was happening, and we stopped receiving consumer
calls on GM. In 2000, we had about 1,500 calls referring to GM, but they were
all triggered by concern over BSE. From our perspective, calm had returned and
consumers were reasonably happy with the situation.
However, Europe is not GM free. In Switzerland checks are made regularly
by local inspectors who usually find that 10 to 20% of samples are positive,
but well below the threshold of 1%. So, although Europe is non-GM, it is not
GM-free.
THE FUTURE
If I understand the proposals correctly––I saw the first draft only a week and
half ago––then detectability, as a criterion, has disappeared. There is a move to
process labeling, meaning that even if an ingredient is negative by PCR and you
do not have documentation, you must label. It includes food ingredients,
additives, and flavorings. As I see it, we are moving from practical labeling,
based on facts, to ethical labeling. Practical labeling indicates when GM
ingredients are present. If GM ingredients are not detectable, then the product
is not labeled; however, realizing that the world is not an ideal place, a GM
ingredient may be present—below a certain threshold—that you wish to avoid.
With ethical labeling, the use of biotechnology anywhere in the process must be
indicated on the label. This different proposition exists already, but only for
some niche markets. Many people offer “organic” as an example of it, which is
not entirely true since organic has a 5% tolerance. Ethical, or process, labeling
is an entirely different approach from practical labeling, in my view.
We are concerned about the enforceability of this legislation. If there no
longer is detectibility then reliance on a paper trail is necessary and we are
afraid that, in practice, for highly processed products containing large numbers
of ingredients, enforcement will be difficult.
It looks as if products that have already been authorized will have to be
reauthorized within a period of four years after the law is enacted. I do not
understand why. It may be that concerns remain about safety or that we want to
adopt a ten-year limit also on those products.
The other new element is post-market monitoring or surveillance. I have had
a number of very confusing discussions on post-market surveillance. A few
weeks ago, a group of eminent European scientists, food-safety experts, and
molecular biologists, gathered in an EC research center in Italy. I was there
as a representative of the food industry. Consumers were represented also.
Discussion ensued on the safety of “one-gene” products currently on the
market and those expected in the next five to ten years. Within a few hours
Checks are made regularly by local inspectors who
usually find that 10 to 20% of samples are positive,
but well below the threshold of 1%. So, although Europe
is non-GM, it is not GM-free.
Toet
there was agreement that these do not constitute a serious safety issue. We have
the tools, we have the people, and we have the equipment to come to consistent
conclusions about safety. But when discussing more complicated products, the
group felt that reviews of equipment and available tools would be needed, to
verify safety. Some people said that there is a need to look for unknown long-
term effects of ingredients and components that come from the consumption of
GM raw materials in the long term. This confuses me. I can imagine that you
would have post-market monitoring if you have a product that is said to have a
certain effects, such as decreasing blood pressure or reducing cholesterol. If you
want to monitor those effects, you can devise tools accordingly. A product
might have a negative side effect that you would want to monitor in a certain
sensitive group, although I have difficulty envisaging a company marketing
such an item. If the idea behind post-market surveillance is that the product
might not be safe, then, in my opinion, it should not be on the market. If you
have post-market surveillance for safety reasons, you might also ask, why do we
have food-safety authorities? I do not believe that any responsible company
would bring a food product to market if it was to be monitored for general
safety reasons. Certainly it would not be done in the United States, where
liability is commonly an issue. I would be happy to discover that I misunder-
stand the intent here, because this development seems dangerous.
What will be the effect of this package? If all goes well, if questions are
resolved about traceability, about labeling, and about liability, we may see
approvals of GM crops. But if labeling will be extended to virtually every
product, given the current situation, it will result in increased demands for non-
GM foods. I believe the European market will follow the clean-label policy in
the current climate. We will also see increased pressure on GM animal feed and
derived animal products. The moment you have an ethical basis for labeling, it
is very difficult to keep it contained to the original intent because there seldom
exists a good argument not to extend it to other areas.
The situation regarding processing and use of components such as enzymes
is also unclear. Currently they are not within the scope of the legislation, but
we do not know how this will evolve. We see world-trade implications as major
issues for the future that may involve the WTO. Importation of a composite
product is going to be extremely difficult to monitor and control. Enforcement
is going to be extremely difficult also. Availability of ingredients may become an
issue. And finally, formulating legislation on the premise that GM is fundamen-
tally dangerous engenders public concern. Therefore, I am afraid that safety will
re-enter the general discussion.
Q: Having looked a lot at nutrition surveys, the thing I don’t understand is
how do people imagine you can do a post-market surveillance? How would you
recognize a cause-and-effect relationship in the complexity of the human diet,
considering the small amount of any one particular product that people eat?
A: Frankly, I haven’t a clue. There is a system that involves physicians. It
differs with each member states, but if there is a persistent pattern of problems,
then at a certain point, after having passed a number of hurdles, it goes into the
health system and, based on epidemiological studies, a link may be found.
Certain cases are known over the past twenty years even, where this has
happened. Based on clusters of symptoms, the system reacts. But it is largely
passive, and I fail to see how it could be made active when the symptoms are
unknown at the outset.
Q: About labeling: if it does go into effect as you suggest, wouldn’t almost
everything get the “GM” label and then the stigma would be lost?
A: It is true that if you do have massive labeling, it’s over. If everybody would
label there would no longer be a problem. First of all you could question the
value of having massive labeling. Secondly, we saw with the labeling exercise we
went through in the late 1990s, that despite all of the agreements, all sorts of
people wiggled out. You get a very disturbed market and a situation that is very
difficult to handle.
Q: Along those lines, what kind of label were people responding to? Was it a
big label on the front of the package? Was there any law on how you had to
display the fact that there was a GMO in there?
A: The labeling in Europe is quite clear. If you have a soy protein, then
immediately following the soy protein name on the label it must be stated that
it comes from genetically modified soya, or you can do it with an asterisk if
there are other ingredients. The asterisk indicates that it contains GM soya. We
should not forget one thing, however that the initial introduction provoked no
reaction whatsoever from the public. Only after activists discovered long-term
food safety in the supermarket as their battlefield, did problems arise.
Q: Will any food processor in Europe ever market a product containing
GMOs, given these conditions?
A: That depends on the product. There are practical considerations why you
would not use GM ingredients. You do not offer the consumer a choice of two
similar products if the GM ingredient is not characteristic or critical; you look
for the simple solution. Where you have an ingredient that is characteristic for
the product, an ingredient to which the consumer attaches value, then you offer
the choice. I am not saying that you will never see any GM product in Europe.
We will go through a prolonged difficult period during which we will see
avoidance efforts. But, the moment something appears that is attractive or the
moment somebody comes to the conclusion that it will be better for the
environment to use GM crops in Europe, and that idea is sold, there will be a
turn-around.
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Q: It seems rather amazing to many of us in the United States that a process
label could be put in place––an ethical label could be put in place. How can you
limit then what goes on to a label if people are concerned about pesticide use, if
people are concerned about what ethnic group produced their food, etc.?
A: That’s a question mark.
Ethics and Genetically Modified Foods
GARY COMSTOCK
Iowa State University
Ames, IA
Much of the food consumed in the United States is genetically modified (GM),
i.e. derived from microorganisms, plants, or animals that have been manipu-
lated at the molecular level to provide them with traits that farmers or
consumers desire. These foods often are produced using techniques in which
“foreign” genes are inserted into the microorganisms, plants, or animals.
Foreign genes are those taken from sources other than the organism’s natural
parents. In other words, GM plants contain genes they would not have
contained if researchers had only used traditional plant breeding methods.
Some consumer advocates object to GM foods on ethical grounds, and in
such cases they typically have reasons for their opposition. In scrutinizing their
reasons, we are practicing applied ethics. Applied ethics involves identifying
peoples’ arguments for various conclusions, and then analyzing those
arguments to determine whether they support the conclusions. A critical goal
here is to decide whether an argument is sound. A sound argument is one
in which all of the premises are true and no mistakes have been made in
reasoning.
Ethically justifiable conclusions inevitably rest on two kinds of claims: (a)
empirical claims, or factual assertions about how the world is—claims ideally
based on the best available scientific observations, principles, and theories,
and (b) normative claims, or value-laden assertions about how the world ought
to be—claims ideally based on the best available moral judgments, principles,
and theories.
Is it ethically justifiable to produce genetically modified crops and foods? There
is an objective answer to this question, and we will try here to figure out what
it is. But we must begin with a proper, heavy, dose of epistemic humility,
acknowledging that few ethicists at the moment seem to think that they know
the final answer.
Should the law allow GM foods to be grown and marketed? The answer to this,
and every, public-policy question rests ultimately with us, citizens who will, in
the voting booth and shopping market, decide the answer. To make up our
minds, we will use feelings, intuitions, conscience, and reason. However, as we
citizens are, by and large, not scientists, we must, to one degree or other, rest
our factual understanding of the matter on the opinions of scientific experts.
Therefore, ethical responsibility in the decision devolves heavily upon scientists
engaged in the new GM technology.
ETHICAL RESPONSIBILITIES OF SCIENTISTS
Science is a communal process devoted to the discovery of knowledge, and to
open and honest communication of knowledge. Its success, therefore, rests on
two different kinds of values.
Epistemological values are those by which scientists determine which
knowledge-claims are better than others. The values include clarity, objectivity,
capacity to explain a range of observations, and ability to generate accurate
predictions. Claims that are internally inconsistent are jettisoned in favor of
claims that are consistent and in accord with established theories. (At times,
anomalous claims turn out to be justifiable, and an established theory is
overthrown, but these occasions are rare in the history of science.) Epistemo-
logical values in science also include: fecundity, the ability to generate useful
new hypotheses; simplicity, the ability to explain observations with the fewest
additional assumptions or qualifications; and elegance.
Personal values, including honesty and responsibility, are a second class of
values that allows scientists to trust their peers’ knowledge-claims. If scientists
are dishonest, untruthful, fraudulent, or excessively self-interested, the free
flow of accurate information so essential to science will be thwarted. If a
scientist plagiarizes the work of others or uses fabricated data, that scientist’s
work will become shrouded in suspicion and otherwise reliable data will not be
trusted. If scientists exploit those who work under them, or discriminate on the
basis of gender, race, class, or age, then the mechanisms of trust and collegiality
under-girding science will be eroded.
The very institution of scientific discovery is supported—indeed, perme-
ated—with values. Scientists have a variety of goals and functions in society, so
it should be no surprise that they face different challenges.
University and government scientists must be scrupulous in giving credit for
their research to all who deserve it, careful not to divulge proprietary
information, and painstaking in maintaining objectivity, especially when funded
by industry. Industry scientists must also maintain the highest standards of
scientific objectivity—a particular challenge since their work may not be
subject to peer-review procedures as strict as those faced by university
scientists. Industry scientists must also be willing to defend results of their
research that are not favorable to their employer’s interests. Scientists employed
by nongovernmental activist organizations face challenges, as well. Their
objectivity must be maintained in the face of an organization’s explicit advocacy
agenda, and in spite of the fact that their research might provide results that
seriously undermine the organization’s fund-raising attempts. All scientists face
the challenges of communicating complex issues to a public that receives them
through media channels that often are not equipped to communicate the
qualifications and uncertainties attached to much scientific information.
At its core, science is an expression of some of our most cherished values.
The public largely trusts scientists, and scientists must in turn act as good
stewards of this trust.
A METHOD FOR ADDRESSING ETHICAL ISSUES
Ethical objections to GM typically center on the possibility of harm to persons
or other living things. Harm may or may not be justified by outweighing
benefits. Whether harms are justified is a question that ethicists try to answer
by working methodically through a series of questions1:
1. What harm is envisaged? To provide an adequate answer to this
question, we must pay attention to how significant the harm or potential
harm may be (severe or trivial?); who the “stakeholders” are (who are
the persons, animals, even ecosystems, that may be harmed?); the extent
to which various stakeholders might be harmed; and the distribution of
harms. The last question directs attention to a critical issue, the issue of
justice and fairness: are those who are at risk of being harmed by the
action in question different from those who may benefit from it?
2. What information do we have? Sound ethical judgments go hand-in-
hand with thorough understanding of the scientific facts. In a given case,
we may need to ask two questions. Is the scientific information about
harm being presented reliably? Is it fact, hearsay, or opinion? And, what
missing information should we have before making the decision?
3. What are the options? In assessing the various courses of action,
emphasize creative problem solving, seeking to find “win-win”
alternatives in which everyone’s interests are protected. Here we must
identify each stakeholder’s objectives; how many methods are available to
achieve those objectives; and what advantages and disadvantages attach
to each?
1In describing this method, I have drawn on an ethics assessment tool devised by Dr. Courtney
Campbell, Philosophy Department, Oregon State University, and presented at the Oregon State Uni-
versity Bioethics Institute in Corvallis, OR, Summer 1998.
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4. What ethical principles should guide us? There are at least three secular
ethical traditions:
• Rights theory holds that we ought always to act so that we treat human
beings as autonomous individuals, and not as mere means to an end.
• Utilitarian theory holds that we ought always to act so that we
maximize good consequences and minimize harmful consequences.
• Virtue theory holds that we ought always act as would a just, fair, good
person.
Ethical theorists are divided about which of these three is best. We manage
this uncertainty through the following procedure. Pick one of the three
principles. Using it as a basis, determine its implications for the decision at
hand. Then, adopt a second principle. Determine what it implies for the
decision at hand. Repeat the procedure with the third principle. Should all three
principles converge on the same conclusion, then we have good reasons for
thinking our conclusion morally justifiable.
How do we achieve moral closure? Does the decision we have reached allow
all stakeholders either to participate in the decision or to have their views
represented? If a compromise solution is deemed necessary in order to manage
otherwise intractable differences, has the compromise been reached in way that
has allowed all interested parties to have their interests articulated, understood,
and considered? If so, then the decision may be justifiable on ethical grounds.
There is a difference between consensus and compromise. Consensus means
that the vast majority of people agree about the right answer to a question. If
the group cannot reach a consensus, but must, nevertheless, take some decision
or other, then a compromise position may be necessary. But neither consensus
nor compromise should be confused with the right answer to an ethical
question. It is possible that a society might reach a consensus position that
is unjust. For example, some societies have held that women should not be
allowed to own property. That may be a consensus position, or even a
compromise position, but it should not be confused with the truth of the
matter. Moral closure is a sad fact of life; we sometimes must decide to
undertake some course of action even though we know that, ethically, it
may not be the right decision, all things considered.
ETHICAL ISSUES INVOLVED IN THE USE OF GENETIC TECHNOLOGY
IN AGRICULTURE
Discussions of the ethical dimensions of agricultural biotechnology are
sometimes confused by a conflation of two quite different sorts of objections
to GM technology: intrinsic and extrinsic. It is critical not only that we
distinguish these two classes, but keep them distinct throughout the ensuing
discussion of ethics.
Extrinsic objections focus on the potential harms consequent upon the
adoption of GMOs. Extrinsic objections hold that GM technology should not
be pursued because of its anticipated results. Briefly stated, the extrinsic
objections go as follows. GMOs may have disastrous effects on animals,
ecosystems, and humans. Possible harms to humans include perpetuation of
social inequities in modern agriculture, decreased food security for women
and children on subsistence farms in developing countries, a growing gap
between well capitalized economies in the northern hemisphere and less
capitalized peasant economies in the south, risks to the food security of
future generations, and the promotion of reductionistic and exploitative
science. Potential harms to ecosystems include possible environmental
catastrophe, inevitable narrowing of germplasm diversity, and irreversible loss
or degradation of air, soils, and waters. Potential harms to animals include
unjustified pain to those used in research and production.
These are valid concerns, and nation-states must have in place testing
mechanisms and regulatory agencies to assess the likelihood, scope, and
distribution of potential harms through a rigorous and well funded risk-
assessment procedure. For this reason, I contend that GM technology must
be developed responsibly and with appropriate caution. However, these
extrinsic objections cannot by themselves justify a moratorium, much less
a permanent ban, on GM technology, because they admit the possibility that
the harms may be minimal and outweighed by the benefits. How can one decide
whether the potential harms outweigh potential benefits unless one conducts
the research, field tests, and data analysis necessary to make a scientifically
informed assessment?
In sum, extrinsic objections raise important questions about GMOs, and each
country using GMOs ought to have in place the organizations and research
structures necessary to ensure their safe use.
There is, however, an entirely different sort of objection to GM technology,
which, if it is sound, would indeed justify a permanent ban.
Intrinsic objections allege that the process of making GMOs is objectionable
in itself. This belief is defended in several ways, but almost all of the formula-
tions are related to one central claim—the “unnaturalness objection” (UE):
It is unnatural to genetically engineer plants, animals, and foods.
If UE is true, then we ought not to engage in bioengineering, however
unfortunate may be the consequences of halting the technology. Were a nation
to accept UE as the conclusion of a sound argument, then much agricultural
research would have to be terminated and potentially significant benefits from
the technology sacrificed. A great deal is at stake.
In Vexing Nature? On Ethical Case Against Agricultural Biotechnology, I discuss
fourteen ways in which UE has been defended (Comstock, 2000). For present
purposes, those fourteen objections can be summarized as follows:
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• To engage in ag biotech is to play God.
• To engage in ag biotech is to invent world-changing technology.
• To engage in ag biotech is illegitimately to cross species boundaries.
• To engage in ag biotech is to commodify life.
Let us consider each claim in turn.
To engage in ag biotech is to play God. In a western theological framework,
humans are creatures, subjects of the Lord of the Universe, and it would be
impious for them to arrogate to themselves roles and powers appropriate only
for the Creator. Shifting genes around between individuals and species is taking
on a task not appropriate for us, subordinate beings. Therefore, to engage in
bioengineering is to play God.
There are several problems with this argument. First, there are different
interpretations of God. Absent the guidance of any specific religious tradition, it
is logically possible that God is a Being who wants to turn over to us all divine
prerogatives; or explicitly wants to turn over to us at least the prerogative of
engineering plants; or who does not care what we do. If God is any of these
beings, then the argument fails because playing God in this instance is not a
bad thing.
The argument seems to assume, however, that God is not like any of the gods
just described. Assume that the orthodox Jewish and Christian view is correct,
that God is the only personal, perfect, necessarily existing, all-loving, all-
knowing, and all-powerful being. In this traditional western theistic view, finite
humans should not aspire to infinite knowledge and power. To the extent that
bioengineering is an attempt to control nature itself, the argument is that
bioengineering is an unacceptable attempt to usurp God’s dominion.
The problem with this argument is that not all traditional Jews and
Christians think that this God would rule out genetic engineering. I am a
practicing evangelical Christian and the chairperson of my local Church
Council. In my tradition, God is thought to endorse creativity, scientific and
technological development, including genetic improvement. Other traditions
have similar views. In the mystical writings of the Jewish Kabbalah, God is
understood as One who expects humans to be co-creators, technicians working
with God to improve the world. At least one Jewish philosopher, Baruch Brody
(personal communication), has suggested that biotechnology may be a vehicle
ordained by God for the perfection of nature.
Personally, I hesitate to think that humans can “perfect” nature. However, I
have become convinced that GM might help humans to rectify some of the
damage we have already done to nature. And I believe God may endorse such
an aim. For humans are made in the divine image. God desires that we exercise
the spark of divinity within us. Inquisitiveness in science is part of our nature.
Creative impulses are not found only in the literary, musical, and plastic arts.
They are part of molecular biology, cellular theory, ecology, and evolutionary
genetics, too. It is unclear why the desire to investigate and manipulate the
chemical bases of life should not be considered as much a manifestation of our
god-like nature as the writing of poetry and the composition of sonatas. As a
way of providing theological content for UE, then, this argument is unsatisfac-
tory because it is ambiguous and contentious.
To engage in ag biotech is to invent world-changing technology, an activity
that should be reserved to God alone. Let us consider this in conjunction with
a similar objection: to engage in ag biotech is to arrogate historically unprece-
dented power to ourselves. The latter argument here is not the strong one, that
biotech gives us divine power, but the more modest one, that it gives us a
power we have not had previously. Also it would be counterintuitive to judge
an action wrong simply because it has never been performed. In this view, it
would have been wrong to prescribe a new herbal remedy for menstrual
cramps, or to administer a new anesthetic. But that seems absurd. More
argumentation is needed to call historically unprecedented actions morally
wrong. What is needed is to know to what extent our new powers will
transform society, whether we have witnessed prior transformations of this
sort, and whether those transitions are morally acceptable.
We do not know how extensive the ag biotech revolution will be, but let us
assume that it will be as dramatic as its greatest proponents assert. Have we ever
witnessed comparable transitions? The change from hunting and gathering to
agriculture was an astonishing transformation. With agriculture came not only
an increase in the number of humans on the globe, but the first appearance of
complex cultural activities: writing, philosophy, government, music, the arts,
and architecture. What sort of power did people arrogate to themselves when
they moved from hunting and gathering to agriculture? The power of
civilization itself (McNeill, 1989).
Ag biotech is often oversold by its proponents. But suppose that they are
right, that it will bring us historically unprecedented powers. Is this a reason
to oppose it? Not if we accept agriculture and its accompanying advances,
for when we accepted agriculture we arrogated to ourselves historically
unprecedented powers.
In sum, these objections are not convincing.
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I hesitate to think that humans can “perfect” nature.
However, I have become convinced that GM might help
humans to rectify some of the damage we have already
done to nature. And I believe God may endorse such an aim.
To engage in ag biotech is illegitimately to cross species boundaries. The
problems with this argument are both theological and scientific. I will leave
it to others to argue the scientific case that nature gives ample evidence of
generally fluid boundaries between species. The argument assumes that species
boundaries are distinct, rigid and unchanging, whereas, in fact, species now
appear to be messy, plastic, and mutable. To proscribe the crossing of species
borders on the grounds that it is unnatural seems scientifically indefensible.
It is also difficult to see how this objective could be defended on theological
grounds. None of the scriptural writings of the western religions proscribe
genetic engineering, of course, because genetic engineering was undreamt of
at the time the holy books were written. Now, one might argue that such a
proscription may be derived from Jewish or Christian traditions of scriptural
interpretation. Talmudic laws against mixing “kinds,” for example, might be
taken to ground a general prohibition against inserting genes from “unclean”
species into clean species. Here is one way the argument might go: for an
observant Jew to do what scripture proscribes is morally wrong; Jewish oral and
written law proscribe the mixing of kinds (e.g., eating milk and meat from the
same plate; yoking donkeys and oxen together); bioengineering is the mixing
of kinds; therefore, for a Jew to engage in bioengineering is morally wrong.
But this argument fails to show that bioengineering is intrinsically objection-
able in all of its forms for everyone. The argument might prohibit Jews from
engaging in certain kinds of biotechnological activity but not all; it would not
prohibit, for example, the transferring of genes within a species, nor, apparently,
the transfer of genes from one clean species to another clean species. Inciden-
tally, it is worth noting that the Orthodox community has accepted transgenesis
in its food supply. Eighty to ninety percent of cheese produced in the United
States is made using a GM product, chymosin. This cheese has been accepted
as kosher by Orthodox rabbis (Gressel, 1998).
In conclusion, it is difficult to find a persuasive defense for this objection
either on scientific or on religious grounds.
To engage in ag biotech is to commodify life. The argument here is that
genetic engineering treats life in a reductionistic manner, reducing living
organisms to little more than machines. Life is sacred and not to be treated as
a good of commercial value only, to be bought and sold to the highest bidder.
Could we apply this principle uniformly? Would not objecting to the
products of GM technology on these grounds also require that we object to
the products of ordinary agriculture on the same grounds? Is not the very act
of bartering or exchanging crops and animals for cash vivid testimony to the
fact that every culture on earth has engaged in the commodification of life for
centuries? If one accepts commercial trafficking in non-GM wheat and pigs,
then why should we object to commercial trafficking in GM wheat and GM
pigs? Why should it be wrong for us to treat DNA the way we have previously
treated animals, plants, and viruses (Nelkin and Lindee, 1995)?
Although this objection may be true, it is not a sufficient reason to object
to GM technology because our values and economic institutions have long
accepted the commodification of life. Now, one might object that various
religious traditions have never accepted commodification, and that genetic
engineering presents us with an opportunity to resist, to reverse course. Leon
Kass (1988, 1998), for example, has argued that we have gone too far down the
road of dehumanizing ourselves and treating nature as a machine, and that
we should pay attention to our emotional reactions against practices such as
human cloning. Even if we cannot defend these feelings in rational terms, our
revulsion at the very idea of cloning humans should carry great weight. Mary
Midgley (2000) has argued that moving genes across species boundaries is not
only “yukky” but, perhaps, a monstrous idea, a form of playing God.
Kass and Midgley have eloquently defended the relevance of our emotional
reactions to genetic engineering but, as both admit, we cannot simply allow
our emotions to carry the day. As Midgley writes, “Attention to . . . sympathetic
feelings [can stir] up reasoning that [alters] people’s whole world view”
(Midgely, 2000, p. 10). But as much hinges on the reasoning as on the
emotions.
Are the intrinsic objections sound?Are they clear, consistent, and logical?
Do they rely on principles we are willing to apply uniformly to other parts of
our lives? Might they lead to counter-intuitive results?
We hesitate to accept counter-intuitive results because they run counter to
widely-shared considered moral intuitions. If a moral rule or principle leads to
counter-intuitive results, then we have a strong reason to reject it. For example,
consider the following moral principle, which we might call the doctrine of
naïve consequentialism (NC): always improve the welfare of the most people.
Were we to adopt NC, then we would be not only permitted but required to
sacrifice one healthy person if by doing so we could save many others. If six
people need organ transplants (two need kidneys, one needs a liver, one needs
a heart, and two need lungs) then NC instructs us to sacrifice the life of the
healthy person so as to transplant their six organs to the other six. But this
result, that we are obliged to sacrifice innocent people to save strangers, is
wildly counter-intuitive. This result gives us a strong reason to reject NC.
I have argued that the four formulations of the unnaturalness objection
considered above are unsound insofar as they lead to counter-intuitive results.
I do not take this position lightly. Twelve years ago, I wrote an article, The Case
Against bGH (Comstock, 1988), which, I have been told, was one of the first
papers by a philosopher to object to ag biotech on explicitly ethical grounds.
I then wrote a series of other articles objecting to GM herbicide-resistant crops,
transgenic animals, and, indeed, all of agricultural biotechnology (reprinted in
Comstock, 2000). I am acquainted with worries about GM foods. But, for
reasons that include the weakness of the intrinsic objections, I have come to
change my mind. The sympathetic feelings on which my anti-GMO worldview
was based did not survive the stirring up of reasoning.
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WHY ARE WE CAREFUL WITH GM FOODS?
I do not pretend to know anything like the full answer to this question, but I
would like to be permitted the luxury of brief speculation about it. The reason
we are careful with GM foods may have to do with a natural, completely
understandable, and wholly rational tendency to take precautions with what
goes into our mouths. When we are in good health and happy with the foods
available to us, we have little to gain from experimenting with a new food, and
no reason to take a chance on a potentially unsafe food. We may think of this
disposition as the precautionary response.When faced with two contrasting
opinions about issues related to food safety, consumers place great emphasis on
negative information. The precautionary response is particularly strong when a
consumer sees little to gain from a new food technology. When a given food is
plentiful, it is rational to place extra weight on negative information about any
particular piece of that food.It is rational to do so, as my colleague Dermot
Hayes has pointed out, even when the source of the negative information is
known to be biased.
There are several reasons to take a precautionary approach to new foods.
First, under conditions in which nutritious tasty food is plentiful, we have
nothing to gain from trying a new food if, from our perspective, it is in other
respects identical to our current foods. Suppose, on a rack in front of me, there
are eighteen dozen maple-frosted Krispy Kreme doughnuts, all baked to a
golden brown, all weighing three ounces. If I am invited to take one of them, I
have no reason to favor one over the other. Suppose, however, that a naked man
runs into the room with wild-hair flying behind him yelling that the sky is
falling. He approaches the rack and points at the third doughnut from the left
on the fourth shelf from the bottom and exclaims, “This doughnut will cause
cancer! Avoid it at all costs, or die!” There is no reason to believe this man’s
claim and yet, since there are so many doughnuts freely available, why take a
chance? It is rational to select other doughnuts, since all are alike. Now,
perhaps one of us is a mountain climber who loves taking risks. They might be
tempted to say, “Heck, I’ll try that doughnut.” In order to focus on the right
question here, the risk-takers should ask themselves whether they would select
the tainted doughnut to take home to feed to their two-year-old daughter. Why
impose any risk on your loved ones when there is no reason to do so?
The Krispy Kreme example is meant to suggest that food tainting is both a
powerful and an extraordinarily easy social act. It is powerful because it
virtually determines consumer behavior. It is easy, because the tainter does not
have to offer any evidence of the food’s danger at all. Under conditions of
plentiful food, rational consumers do and should take precautions, avoiding
possibly tainted food no matter how untrustworthy the information source.
Our tendency to take precautions with our food suggests that a single person
with a negative view of GM foods will be much more influential than many
people with a positive view. The following experiment lends credibility to this
hypothesis. In a willingness-to-pay experiment, Hayes and colleagues (in press)
gave eighty-seven primary food shoppers $40 each. Each participant was
assigned to a group ranging in size from a half-dozen to a dozen members. Each
group was then seated at a table at lunch-time and given one pork sandwich. In
the middle of each table was one additional food item, an irradiated pork
sandwich. Each group of participants was given one of three different
treatments: (a) the Pro-irradiation treatment; (b) the Anti-irradiation treatment;
or (c) the Balanced treatment.
Each treatment began with all of the participants at a table receiving the
same, so-called “neutral” description of an irradiated pork sandwich. The
description read, in part:
The United States Food and Drug Administration has recently approved
the use of ionizing radiation to control Trichinella in pork products.
This process results in a 10,000-fold reduction in Trichinella organisms
in meat. The process does not induce measurable radioactivity in food.
After the participants read this description, they would proceed to conduct
a silent bid in order to purchase the right to exchange their non-irradiated
sandwich for the irradiated sandwich. Whoever bid the highest price would be
able to buy the sandwich for the price bid by the second-highest bidder. In
order to provide participants with information about the opinions of the others
at their table so that they could factor this information into their future bids,
the lowest and highest bids of each round were announced before the next
round of bidding began. At the end of the experiment, one of the ten bidding
rounds would be selected at random, and the person bidding the highest
amount in that round would have to pay the second-highest price bid during
that round for the sandwich.
After five rounds of bidding, the second-highest bids in all three groups
settled rather quickly at an equilibrium point, roughly, twenty cents. That is,
someone at every table was willing to pay twenty cents for the irradiated pork
sandwich, but no one in any group would pay more than twenty cents. The
bidding was repeated five times in order to give participants the opportunity
to respond to information they were getting from others at the table, and to
ensure the robustness of the price.
After five rounds of bidding, each group was given additional information.
Group (a), the so-called Pro group, was provided with a description of the
sandwich that read, in part:
Each year, 9,000 people die in the United States from food-borne illness.
Some die from Trichinella in pork. Millions of others suffer short-term
illness. Irradiated pork is a safe and reliable way to eliminate this
pathogen. The process has been used successfully in twenty countries
since 1950.
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The Pro-group participants were informed that the source of this positive
description was a pro-irradiation food-industry group. After the description was
read, five more rounds of bidding began. The price of the irradiated sandwich
quickly shot upward, reaching sixty cents by the end of round ten. A ceiling
price was not reached, however, as the bids in every round, including the last,
were significantly higher than in the preceding round—the price was still going
up when the experiment was stopped (Figure 1).
After its first five rounds of bidding, Group (b), was provided with a different
description. It read, in part:
In food irradiation, pork is exposed to radioactive materials. It receives
300,000 rads of radiation—the equivalent of thirty million chest X-
rays. This process results in radiolytic products in food. Some radiolytic
products are carcinogens, and linked to birth defects. The process was
developed in the 1950s by the Atomic Energy Commission.
The source of this description was identified to the bidders as “Food and
Water,” an anti-irradiation activist group in England. After Group (b) read this
description, it began five more rounds of bidding. The bid went down, quickly
reaching zero. After the first five rounds produced a value of twenty cents in
Group (b) for the pork sandwich described in a “neutral” way, no one in this
group would pay a penny for the irradiated sandwich described in a “negative”
way. This result obtained even though the description was clearly identified as
coming from an activist, non-scientific group.
After five rounds of bidding on the neutral description, the third group,
Group (c), received both the positive and negative descriptions. One might
expect that this group’s response would be highly variable, with some
participants scared off by the negative description and others discounting it
for its unscientific source. Some participants might be expected to bid nothing
while others would continue to bid highly. However, the price of the sandwich
in the third, so-called Balanced group, also fell quickly. Indeed, the price
reached zero almost as quickly as it did in Group (b), the negative group.
That is, even though the third group had both the neutral and the positive
Figure 1. Effect of information on average bid for irradiated pork
[reprinted from Hayes et al. (in press)].
description in front of them, no one exposed to the negative description would
pay two cents for the irradiated sandwich.
Hayes’ study illuminates the precautionary response, and carries implications
for the GM debate. These implications are that, given neutral or positive
descriptions of GM foods, consumers initially will pay more for them. Given
negative descriptions of GM foods, consumers initially will not pay more for
them. Finally, and this is the surprising result, given both positive and negative
descriptions of GM foods, consumers initially will not pay more for them. Both
sides in the GM food debate should be scrupulous in providing reasons for all
of their claims, especially negative claims.
In a worldwide context, the precautionary response of those facing food
abundance in developed countries may lead us to be insensitive to the
conditions of those in less fortunate situations. Indeed, we may find ourselves
in the following ethical dilemma.
Comstock
For purposes of argument, let us make the following three assumptions, none
of which is implausible. First, assume that GM food is safe. Second, assume that
some GM foods, such as rice enhanced with iron or vitamin A, virus-resistant
cassava, or aluminum-tolerant sweet potato, may be of great potential benefit to
millions of poor children. Third, assume that widespread anti-GM information
and sentiment, no matter how unreliable on scientific grounds, could shut
down the GM infrastructure in the developed world.
Under these assumptions, consider the possibility that by condemning GM
foods in the countries best suited to conduct GM research safely, activists could
bring to a halt the range of money-making GM foods marketed by multina-
tional corporations. This result might be a good or a bad thing. However, an
unintended side-effect would be that the new GM crops mentioned above might
not be forthcoming, assuming that their development and commercialization
depends upon the addressing of fundamental questions in plant science and
molecular biology that will be answered only if research in private industry is
allowed to progress along with that in public research institutions.
Our precautionary response to new food may put us in an uncomfortable
position. On the one hand, we want to tell “both sides” of the GM story, letting
people know both about the benefits and the risks of the technology. On the
other hand, some of the people touting the benefits of the technology make
outlandish claims that it will feed the world while some of the people decrying
In a worldwide context, the precautionary response of
those facing food abundance in developed countries may
lead us to be insensitive to the conditions of those in less
fortunate situations.
the technology make unsupported claims that it will ruin the world. In this
situation, however, those with unsupported negative stories to tell carry greater
weight than those with unsupported positive stories. Our precautionary
response, then, may well lead, in the short term at least, to the rejection of GM
technology. Yet, this rejection could indirectly harm those children most in
need.
Are we being forced to choose between two fundamental values, the value of
free speech versus the value of children’s lives?
On the one hand, open conversation and transparent decision-making
processes are critical to the foundations of a liberal democratic society. We must
reach out to include everyone in the debate, and allow people to state their
opinions about GM foods, whatever those opinions happen to be, whatever the
level of acquaintance with the science and technology happens to be. Free
speech is a value not to be compromised lightly.
On the other hand, simply stating negative opinions about GM food can
clearly have a tainting effect, a powerful and extraordinarily easy consequence
of free speech. Tainting the technology might result in the loss of this
potentially useful tool. Should we, then, draw some boundaries around the
conversation, insisting that each contributor bring some measure of scientific
data to the table, especially when negative claims are being made? Or are we
collectively prepared to leave the conversation wide open? That is, in the name
of protecting free speech, are we prepared to risk losing an opportunity to help
some of the world’s most vulnerable?
RELIGION AND ETHICS
Religious traditions provide an answer to the question, “How, overall, should
I live my life?” Secular ethical traditions provide an answer to the question,
“What is the right thing to do?” When in a pluralistic society a particular
religion’s answers come into genuine conflict with the answers arrived at
through secular ethical deliberation, we must ask how deep is the conflict.
If the conflict is so deep that honoring the religion’s views would entail
dishonoring another religion’s views, then we have a difficult decision to make.
In such cases, the conclusions of secular ethical deliberation must over-ride
the answers of the religion in question. The reason is that granting privileged
status to one religion will inevitably discriminate against another religion.
Individuals must be allowed to follow their conscience in matters theological.
But if one religion is allowed to enforce its values on others in a way that
restricts the others’ ability to pursue their values, then individual religious
freedom has not been protected.
Moral theorists refer to this feature of nonreligious ethical deliberation as the
overridingness of ethics. If a parent refuses a lifesaving medical procedure for a
minor child on religious grounds, the state is justified in overriding the parent’s
religious beliefs in order to protect what secular ethics regards as a value higher
than religious freedom: the life of a child.
The overridingness of ethics applies to our discussion only if a religious
group claims the right to halt GM technology on purely religious grounds. The
problem here is the confessional problem, of one group attempting to enforce
its beliefs on others. I mean no disrespect to religion; as I have noted, I am a
religious person, and I value religious traditions other than my own. Religious
traditions have been the repositories and incubators of virtuous behavior. Yet
each of our traditions must in a global society learn to coexist peacefully with
competing religions, and with nonreligious traditions and institutions.
If someone objects to GM technology on purely religious grounds, we must
ask on what authority they speak for their tradition, whether there are other,
conflicting, views within their tradition, and whether acting on their views will
entail disrespecting the views of people from other religions. It is, of course, the
right of each tradition to decide its attitude about genetic engineering. But in
the absence of other good reasons, we must not allow someone to ban GM
technology for narrowly sectarian reasons alone. To allow such an action would
be to disrespect the views of people who believe, on equally sincere religious
grounds, that GM technology is not necessarily inconsistent with God’s desires
for us.
MINORITY VIEWS
When, in a pluralistic society, the views of a particular minority come into
genuine conflict with the views of the majority, we must ask a number of
questions. How deep is the conflict? How has the minority been treated in the
past? If the minority has been exploited, have reparations been made? If the
conflict is so deep that honoring the minority’s views would entail overriding
the majority’s views, then we have a difficult decision to make. In such cases,
the conclusions of the state must be just, taking into account the question of
past exploitation and subsequent reparations, or lack thereof. This is a question
of justice.
The question of justice would arise in the discussion of GM technology if the
majority favored GM technology while the minority claimed the right to halt
GM technology. If the minority cited religious arguments to halt GMOs, yet the
majority believed that halting GMOs would result in loss of human life, then
the state faces a decision very similar to the one discussed in the prior section.
In this case, secular policy decisions may be justified in overriding the
minority’s religious arguments insofar as society deems that human life has a
value higher than that of religious freedom.
However, should the minority cite past oppression as the reason that their
values ought to predominate over the majority’s, then a different question
must be addressed. Here, the relevant issues have to do with the nature of past
exploitation, its scope and depth, and the sufficiency of efforts—if there have
there been any—to rectify the injustice and compensate victims. If the problem
is long-standing and has not been addressed, then imposing the will of the
majority would seem a sign of an unjust society insensitive to its past misdeeds.
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If, on the other hand, the problem has been carefully addressed by both sides
and, for example, just treaties—arrived at through fair procedures and
enforced—are rectifying past wrongs and are preventing new forms of
exploitation, then the minority’s arguments would seem to be far weaker.
This conclusion would be especially compelling if it could be shown that the
lives of other disadvantaged peoples might be put at risk by honoring a
particular minority’s wish to ban GMOs.
CONCLUSION
Earlier I described a method for reaching ethically sound judgments. On the
basis of that method I personally came to change my mind about the moral
acceptability of GM crops. My opinion changed as I took full account of three
considerations: (a) the rights of people in various countries to choose to adopt
GM technology (a consideration falling under the human rights principle);
(b) the balance of likely benefits over harms to consumers and the environment
from GM technology (a utilitarian consideration); and (c) the wisdom of
encouraging discovery, innovation, and careful regulation of GM technology
(a consideration related to virtue theory).
Is it ethically justifiable to pursue genetically modified crops and foods? I have
come to believe that three of our most influential ethical traditions converge on
a common answer. Assuming we proceed responsibly and with appropriate
caution, the answer is yes.
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audience in Wellington, New Zealand (sponsored by the New Zealand Life
Sciences Network, and Francis Wevers); and St. John’s College, Auckland,
NZ (Graham Redding), November 2000.
• The “Plant Sciences Institute Colloquium,” Iowa State University, February
2001 (Stephen Howell).
• “Biotech Issues 2001,” an Extension In-Service conference at Colorado
State University (Bob Zimdahl and Pat Kendall); and a seminar in the CSU
Philosophy Department (Phil Cafaro and Holmes Rolston); both in
February.
• The 2001 Annual Meeting of the American Association for the Advance-
ment of Science, San Francisco, in February (Katherine R. Smith and
Nicole Ballenger).
• A seminar at the Center for International Development and Science, the
Technology and Public Policy Program, and the Belfer Center for Science
and International Affairs, Harvard University, March, 2001 (Calestous
Juma and Derya Honca).
• The Center for Judaism and the Environment, and Center for Business
Ethics, Jerusalem College for Technology, Israel (Akiva Wolff, Pinchas
Rosenstein, and Jacqueline Rose); and “Symposium 2001: Plant Biotech-
nology, Its Benefits Versus Its Risks,” Tel Aviv University, Israel, May 2001
(Bernie Epel and Roger Beachy).
“Ethical Issues Involved in the Use of Genetic Technology in Agriculture” is
reprinted from pp. 182–195 of Comstock (2000), with the kind permission of
the publisher.
Other portions of the paper were written with support of the Cooperative
State Research, Education, and Extension Service, U.S. Department of
Agriculture, under Agreement No. 00-52100-9617.
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Q: I have a background as an ethicist, and I have yet to hear an ethical
principle enunciated clearly, such that it has clear practical implications that are
not subject to some clear counter example. Exactly how seriously should we
take the claim that intrinsic objections are really supposed to provide an
absolute bedrock for morality, as opposed to just one of the many values we
have to take into account and balance with lots of other values?
A: As I understand it, your question is exploring a defense of the
intrinsic objections along the following lines—look, no one bases their
objections to GMOs just on the fact that they think it is playing God, or just on
the fact that it is tinkering with nature. Rather, all of these go together to form a
package, and the cumulative result of worrying about all of them is the basis of
their view. Is that close enough?
Q: Something like that. But also, just from an epistemological or an
ethical perspective, we don’t know yet of any fundamental ethical theory that
is not counter-intuitive. So, isn’t your method going to basically prove that all
ethical principles are wrong, if your method is correct? Take one of the
principles that you enunciated at the end. Ensure that all stakeholders are
heard—do you really want to endorse that as stated, that every single
stakeholder has to be heard? We are going to be sitting around for thousands
of years waiting for everybody to finish.
A: Yes, it’s a good question. Let me answer the one that I articulated
before, then I’ll try to respond to that one. It is appealing to me to think that
the whole is greater than the sum of the parts, but I just don’t think that is true.
In this case, what we have to do, if we want to think responsibly about these
objections, is to look at each one. And if each one turns out to be radically
counter-intuitive then the whole is less than the sum of the parts. On the
question of whether we have any principles that don’t lead to counter-intuitive
results, I am much more optimistic than you are about that. I agree that ethical
theorists haven’t yet articulated such a theory, but, in terms of secular ethics,
we haven’t been at it very long—less than three or four decades by my
reckoning—and I think we will get closer to it than you seem to think. And
finally, notice that these really aren’t ethical principles that lead to counter-
intuitive results, they are more like rules of thumb—how shall we act in this
or that case—and there you are probably right, that we can find a counter
example to any such rule of thumb. But I am less certain that real principles
are subject to defeat so easily.
Q: I think it is fair to say that at least some critics do take their
principles to be absolute, in the sense that they think that saying that suffices
to show that these things are wrong. And so, if you do get a single counter
example, then I think that does cause trouble for them. I think I agree with
you on that point.
A: I am impressed, by the way, by how quickly critics run from these
principles. That is, once they are enunciated—I have had this happen to me—
someone always stands up and says, “That’s not why we are opposed to GMOs!”
And I say, “Okay, good. What are the reasons?” And then they typically turn to
the ones that NABC addresses in depth—safety, environmental consequences,
and so on—which is where the attention should be, in my view.
Q: As I understood your talk, you said that you have changed your
view, from being more anti to pro genetically engineered crops. When you held
your previous view, was it based in any way on these intrinsic objections, or
was it solely based on extrinsic considerations of the risks and benefits?
A: I think I had the intrinsic objections in the back of my mind. But,
in my writings, my objections were typically more consequentialist. I was
concerned about the effects of the new technology on family farmers,
primarily—extrinsic concerns about economic and social dislocating effects.
I was concerned about animal welfare, and still am; that’s an extrinsic concern.
Does that address your question?
Q: Yes. I was curious if it was based on an intrinsic one, what changed
your mind on that. It sounds like what changed your mind was a broader look
at the technology and its potential benefits. I wanted to confirm that.
A: Yes, thank you.
Q: Your previous writings, when you were an opponent of biotechnol-
ogy, have been used by people to back up their beliefs. Now that you have
changed your views, do you have to become more of an activist for the other
side? Or do I have to read the book?
A: Reading the book is a good start! Given the consequences of
negative information that I just showed you, I have a duty now to be as active
for my current views as I used to be for my old views. Which is why I try to
get out as much as I can, and talk.
Q: I appreciate the talk. But you leave nothing of nature standing.
People want to distinguish between the natural and the unnatural, and one way
they do it is to talk about species boundaries. And your entire argument against
those who would not cross species boundaries is, “That would rule out mules.”
So be it. I’ll accept that consequence. But the more important question: is there
any way we can use the concept, or the idea of nature and the natural, in ethical
or esthetic discourse, if we accept biotechnology as natural? And if we don’t
accept it as natural, then it would seem that the people who criticize it on the
grounds that it is against nature may be right.
A: The questioner, Mark Sagoff, has done more than perhaps anyone in
the world to think about what is natural and unnatural, so I hesitate to try to
respond quickly. I do have arguments to offer other than if you accept mules
you must accept GMOs, which I didn’t have time to go through. But, in general,
I am very skeptical about the natural/unnatural distinction. I don’t think it will
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cut much ice in the end, once we try to sort out what is natural and what is
unnatural. There are so many different places to cut the joints. In the end, there
are better conceptual categories to use, such as sentient or non-sentient, living
or non-living, humanly influenced or not humanly influenced, wild or
domesticated, and those, I suspect, in the long run will get us further faster.
And I learned that from Mark.
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The Food Industry
SUSAN HARLANDER
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Since their commercial introduction in 1996, genetically modified (GM) crops
have been rapidly adopted in the United States. Because the Food and Drug
Administration (FDA) considers them “substantially equivalent” to their
traditional counterparts, GM crops require no special labeling and are managed
as commodities with no segregation or identity preservation. This is not the
case in other parts of the world where products containing genetically modified
ingredients must be labeled if their content exceeds specified threshold levels.
This dichotomy creates challenges for the food industry in complying with
various labeling guidelines in the countries in which they conduct business.
Compliance with such guidelines requires the availability of identity-
preservation systems and robust, accurate, specific, reliable, standardized, and
validated testing methods to ensure compliance with established threshold
levels for GM ingredients. Some food companies have indicated that they will
avoid the use of some or all GM ingredients in their products, although the
majority have not followed suit. Various consumer-interest groups are calling
for labeling of all products containing GM ingredients. The implications of such
labeling will be discussed. The food industry has been monitoring the opinions
of their consumers on the GM issue for the past several years, and the results of
these surveys will be shared.
ACCEPTANCE OF GM
Genetically modified crops are ubiquitous in the United States. In 2001, it is
predicted that 26% of the corn, 68% of the soybeans, and 69% of the cotton
grown in this country will be GM varieties. They have gone through rigorous
food- and environmental-safety tests; the FDA has reviewed fifty-nine GM
crops. Numerous scientific organizations and United States and international
regulatory agencies have endorsed their safety.
Examples of GM crops include insect-resistant (Bt) corn, cotton, potato, and
tomato; herbicide-tolerant soybean, corn, rice, sugar beet, flax and canola; and
virus-resistant squash, papaya, and potato. Advantages of insect- and virus-
resistant crops include improved yields and reduced use of pesticides.
Advantages of herbicide-tolerant crops include improved weed control, reduced
crop injury, use of short-lived herbicide, reduction in foreign matter, reduced
fuel use, and significant reduction in soil erosion. For these reasons, GM has
become the most rapidly adopted technology in the history of agriculture.
Genetically modified crops are managed as commodities in the United States,
and thus have made their way through commodity-distribution channels into
thousands of ingredients used in processed foods. Examples of soy-derived
ingredients include oil, lecithin, protein isolates, and mono- and diglycerides.
Examples of corn-derived ingredients include oil, starch, flour, meal, dextrose,
and high-fructose syrup. It has been estimated that 70 to 85% of processed
foods contain one or more ingredients potentially derived from GM crops.
Acceptance of GM products varies throughout the world, creating a challenge
for multinational food companies that have made commitments to take into
account consumer preferences when making decisions regarding the ingredients
in their products. Many countries have or are developing mandatory GM-
labeling guidelines. Retailers in the United Kingdom have banned the use of
GM ingredients in their private label products, causing major food companies
to respond in kind. GM-labeling guidelines differ throughout the world,
creating a complex situation for food manufacturers.
LABELING OF GM FOODS
Most food manufacturers are avoiding the use of GM ingredients in those
countries that have instituted mandatory GM-labeling, because consumers
perceive a label as a warning. To avoid such labeling requires the use of
ingredients derived from non-GM varieties that have been identity-preserved
throughout the entire supply chain: from seed to final product. Identity-
preservation (IP) systems add cost and complexity to the supply chain, and are
reliant upon adequate chain-of-custody documentation and GM-testing
systems. Unfortunately, there are few good estimates on the cost of IP
ingredients, but they may range from 5% to 150% over farm-gate prices. Food
manufacturers must develop new specifications for non-GM ingredients, and
audit systems to ensure compliance by ingredient suppliers. Manufacturers
must understand the complete profile of all primary and secondary ingredients
used in their products. For example, cornstarch is frequently used as a carrier
of vitamins in fortified products, but may not be identified as an ingredient in
the vitamin mix.
Mandatory labeling also demands the availability of robust standardized and
validated sampling and GM-testing systems that are quantitative, reliable,
accurate, and reproducible. Adventitious contamination due to cross-
pollination is inevitable; therefore, quantitative assays will be required for
setting tolerances or threshold levels of contamination. Tests must be simple,
inexpensive, and capable of detecting GM contamination in the range of
products in the marketplace. Unfortunately, validated and standardized
sampling and testing methods do not exist, except for a protein test for
Roundup Ready® soybean. Authenticated reference standards are not available,
and testing protocols vary from laboratory to laboratory. False-positive and
false-negative rates are unacceptably high. There is no standardization on how
the results are reported to food companies. The food matrix has a dramatic
impact on extractability of DNA and protein, and protocols will need to be
developed to take this into account. Since labeling is not required in the United
States, detection methods have not developed as rapidly has as GM technology.
This deficiency will cause significant issues as disputes arise about GM status of
foods.
Most food companies have decided to remove GM ingredients from products
marketed in countries with mandatory GM-labeling laws. Some companies are
sourcing raw agricultural commodities from countries (e.g. Brazil) that have not
yet approved the commercial cultivation of GM crops. However, this does not
provide adequate assurance of non-GM status, since it has been estimated that
13% (some estimates are as high as 25%) of Brazil’s 7.5 million acres of soybean
are planted to GM varieties, even though their use is not approved in that
country. Some companies (e.g. Gerber and Heinz) have decided to remove GM
ingredients from baby foods marketed in the United States. Frito Lay has
instructed its farmers not to grow GM corn varieties, and McDonald’s will avoid
GM potatoes. Neither Frito-Lay nor McDonald’s has said that it will avoid other
GM ingredients in its products, or that it will advertise or label its products as
non-GM.
The FDA recently published draft guidance on the voluntary labeling of
foods containing or not containing GM ingredients. In this document, the FDA
affirmed that mandatory labeling is not required for bioengineered food, unless
the food is “materially different.” Since the majority of bioengineered foods
reviewed by the FDA are substantially equivalent, no labeling is required in the
United States. For manufacturers who wish to voluntarily label their products,
the agency provides the following guidance: labels must be truthful and non-
misleading, therefore, data are required to substantiate label claims. The FDA
provided advice on terminology; “genetically modified” is not recommended
since it is not technically accurate; all food has been genetically modified
through conventional plant breeding. “Genetically modified organisms” is also
misleading as most foods do not contain viable organisms. The FDA believes
that it would be misleading to label a food as “GM-free” due to the potential for
adventitious contamination due to cross-pollination. They did not establish a
threshold level of contamination because accurate and reliable testing methods
do not exist. A statement that a food is not bioengineered nor does it contain
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bioengineered ingredients may be misleading if it implies the food is superior
to foods that are not so labeled. Further, to make a “non-bioengineered” claim,
all ingredients in the product must be from non-GM varieties, and if no
bioengineered varieties of that category of foods or ingredients are marketed,
such a claim would be misleading. Some companies are overtly labeling their
products as GMO-free or non-GM. They procure ingredients from suppliers
who certify that non-GM varieties have been used for ingredient manufacture.
However, a recent study by the Wall Street Journal reported that, of twenty
products labeled “non-GM,” sixteen contained measurable quantities of GM
DNA. Therefore, even under best-case scenarios, it is very difficult to guarantee
that the “non-GM” label is truthful.
“ORGANIC” AND OTHER CONCERNS
Organic growers have expressed concern that cross-pollinating GM crops such
as corn can jeopardize their crops. The USDA Organic Guidelines preclude
the use of genetic modification for anything to be labeled as organic. Since it
is impossible to prevent cross-pollination, it may be necessary to establish a
tolerance or threshold level for adventitious contamination.
Genetically modified foods do not appear to be as big a consumer issue in
the United States as in other parts of the world. Food manufacturers have been
monitoring their 800 numbers for an indication of how their consumers feel
about GM foods. To date, the number of calls on biotechnology remains very
small (0.1% to 0.2%) for most major food companies in this country. Awareness
has increased slightly over the past 18 months, and consumers are evenly
divided between support and opposition. Calls increase during periods of
intense media coverage. Companies targeted by activist groups report periodic
increases in numbers of calls. If a brief explanation of biotechnology is
provided, acceptance increases significantly, indicating that education is an
important factor in consumer acceptance.
Most food companies in the United States are not avoiding bioengineered
ingredients for domestic production. In general, the food-processing industry
has confidence in the safety of bioengineered foods. Because GM crops have
been readily adopted in the United States, availability of non-GM crops has
been limited and these ingredients are more expensive. Even when efforts are
Most food companies in the United States are not
avoiding bioengineered ingredients for domestic
production. In general, the food-processing industry
has confidence in the safety of bioengineered foods.
made to procure non-GM ingredients, adventitious contamination is an issue,
and IP systems have not been perfected as was illustrated with the StarLink™
incident in 2000. The food industry would need to be able to accurately
forecast their supply needs for non-GM ingredients so farmers could be
instructed on the quantities required. In addition, the food industry lacks
separate storage, processing, labeling and transportation capabilities required
to ensure separation of GM and non-GM raw materials and final products.
There is little confidence in the adequacy of current GM sampling and testing
methodology to substantiate label claims and there is substantial liability if
label claims are inaccurate. Finally, the food industry hopes that the next
generation of bioengineered products will deliver compelling consumer
benefits.
The food industry hopes that the next generation
of bioengineered products will deliver compelling
consumer benefits.
FUTURE OF AG AND FOOD BIOTECH
The next generation of bioengineered foods will focus on “output traits”
that provide processing advantages and tangible consumer-relevant benefits.
Biotechnology can be used to remove allergens, natural toxicants and
antinutritional factors from foods like peanuts, soybeans, rice, and wheat.
Taste, texture, aroma, ripening time and shelf life of fresh fruits and vegetables
can be improved. It will be possible to improve the nutritional quality of foods.
Examples include modification of the saturation level of oils to produce
products high in mono-unsaturated fatty acids that are more stable, resist
oxidation, do not require hydrogenation and reduce cholesterol levels when
consumed. It is possible to increase the content of vitamin E and other
antioxidants, and to insert the capability of producing plant-based omega-3
fatty acids into oil seeds. Biotechnology can be used to elevate levels of vitamins
A, C, and D, and folate, and enhance iron bioavailability in vegetables, fruits
and grains. It is also possible to increase levels of various phytochemicals in
plants that have been associated with disease prevention, e.g. lycopene in
tomatoes and sulfurofane in broccoli for reducing cancer risk, and lutein in
vegetables for reducing risk of macular degeneration. The advancing fields of
human and plant genomics and proteomics will identify additional plant-based
compounds that could have positive effects on human health. These are the
kinds of products that excite food companies and ultimately will excite
consumers.
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The future of agricultural and food biotechnology will depend on a number
of factors including continued grower support, food-industry and retailer
unanimity on policies regarding the use of GM ingredients, government
consistency, documentation of tangible consumer benefits without undue risk,
and consumer education and acceptance. Additionally, until there is interna-
tional harmonization on GM foods, turmoil in the marketplace will continue.
Without consumer acceptance and a coordinated approach across all segments
of the food-supply chain, the promises of agricultural and food biotechnology
could be limited.
The advancing fields of human and plant genomics and
proteomics will identify additional plant-based compounds
that could have positive effects on human health. These
are the kinds of products that excite food companies and
ultimately will excite consumers.
With little understanding of how food, feed and fiber products are developed
and produced, and even less knowledge of the science of genetics, most
consumers are ill prepared to sift through the deluge of misinformation
bombarding them on a daily basis. Members of NABC have a unique oppor-
tunity to help set the record straight and challenge the myths that are circulated
by those who oppose, or question the use of, agricultural biotechnology.
Representatives of land-grant universities and other research institutes have
a deservedly high degree of credibility. Without being advocates, they can play a
vital role in educating the public, government officials, and the media, on basic
agricultural practices and scientific concepts that are critical to an objective
analysis of agricultural biotechnology.
Looking to the future, and in light of the rapid rate of adoption of crop
biotechnology and the diversity and complexity of products in the development
pipeline, I believe that product stewardship and regulation will play an
increasingly important role in promoting public confidence in the products of
biotechnology. Technology providers, growers, processors, and researchers all
have key roles to play in supporting strong governmental oversight of crop
biotechnology and implementing proactive product-stewardship programs.
A Legal View: Promoting Product
Stewardship and Regulation
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Six key arguments are commonly raised in opposition to
the use of biotechnology-derived crops. None of them
withstand close scrutiny.
WHAT WE REALLY KNOW ABOUT THE SAFETY AND BENEFITS OF
BIOTECHNOLOGY CROPS
Six key arguments are commonly raised in opposition to the use of biotechnol-
ogy-derived crops. None of them withstand close scrutiny.
Myth #1: Lack of regulation—products are rushed to market with little or no
government oversight. The reality: unprecedented regulation of plants and plant
products. Products are reviewed by at least two federal agencies, the United
States Department of Agriculture (USDA) and the Food and Drug Administra-
tion (FDA) and often by three, i.e. including the Environmental Protection
Agency (EPA) (US, 2001) These reviews take place over a period of several
years while carefully controlled and monitored greenhouse and field tests are
conducted. All of this must occur before a product can ever enter the
marketplace. There is no comparable oversight for conventional hybrids and
cultivars. The jurisdiction of the regulatory agencies has been exercised since
1986 and universally recognized by regulated parties. The National Institutes of
Health (NIH) research guidelines have been followed since 1976 for laboratory
and greenhouse research.
Myth #2: No data. The reality: volumes of data. Health, safety and environmen-
tal data representing years of laboratory, greenhouse, and field research are
routinely submitted to and reviewed by the USDA, EPA, and FDA (NAS, 2000).
New data are requested by the agencies as needed.
Myth #3: No public participation. The reality: multiple public participation
opportunities. Multiple public participation opportunities have been provided
over the past 25 years by EPA, USDA and FDA, including via public meetings,
public comment on proposed rules and policies, agency web sites, scientific
peer review, and in response to published data.
Myth #4: No benefits. The reality: established benefits. Products have shown
clear agronomic, environmental, and health benefits, including high-oleic
soybean; slower ripening fruits and vegetables; improved protection from
insects and disease (reduced use of chemical insecticides and fungicides, fewer
acres cultivated, and less fuel, water, and fertilizer used); and improved
tolerance to herbicides (reduced need for chemical applications, promotion of
reduced tillage, control of soil erosion, and use of reduced-risk herbicides)
(Alliance, 2001; USDA, 2001).
Myth #5: Harm to health and environment. The reality: no evidence of actual
harm. With intensive governmental, academic, and commercial oversight for
the past 15 years, not a single instance of actual harm to health, safety, or the
environment has ever been confirmed for biotechnology crops on the market
today (EPA, 2000).
Myth #6: No labeling. The reality: health and safety labeling is required. Federal
labeling requirements are identical for all foods. Labeling solely for consumer
choice is not required by government in the United States (Federal Register,
1992, 2001).
KEY ISSUES IN PROMOTING PRODUCT STEWARDSHIP AND REGULATION
• To the producer of biotechnology-derived products and others in the chain
of commerce, government regulation provides assurance that appropriate
safety standards have been met in bringing a product to market. But even
the best efforts of regulators may prove inadequate, particularly when
dealing with a new technology, without the development and implementa-
tion of proactive product-stewardship programs.
• In its broadest terms, product stewardship can be thought of as the legal,
ethical and moral obligation to assess products and technologies to ensure
that they are safe as well as socially and environmentally responsible.
Stewardship includes the assessment—based on sound scientific
principles—of the potential impact of a particular product or technology
on human health and the environment, as well as those actions and
principles necessary to protect the integrity and viability of a particular
product or technology.
• Not all stewardship efforts are necessarily confined to individual
companies, nor should they be. Many activities are more appropriately
industry-wide responsibilities, which are necessary or appropriate for the
protection of products or technologies as a class. Many industries operate
on the basis of voluntary consensus standards, including a broad array of
standards developed by nationally and internationally recognized standard-
setting organizations. Government agencies routinely recognize such
standards, and federal law requires agencies to use technical standards that
are developed or adopted by voluntary consensus standards bodies, unless
it would be inconsistent with applicable law or otherwise impractical.
• From a legal perspective, the organizational unit responsible for oversight
of product stewardship must be empowered to ensure compliance with the
letter and spirit of applicable regulatory requirements and to prevent
potential product-related liabilities. Legal obligations in the United States
include the submission of applications, notifications, data, and information
in order to obtain the appropriate approvals and clearances from the
USDA, FDA and EPA under the Coordinated Framework for Regulation of
Biotechnology. Those obligations also extend to the post-market
surveillance of agricultural biotechnology and crop-derived products and
to compliance with appropriate reporting requirements, such as those
imposed by EPA for plant-incorporated protectants.
• In addition to biodiversity, examples of crop biotechnology stewardship
issues include: risk assessment and risk management plans; seed quality
and purity; protein safety, including potential for allergenicity; protein
levels in food and feed; insect-resistance-management plans for certain
plant-incorporated protectants; outcrossing and open pollination; identity
preservation, product channeling and trade.
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• A successful risk-management process should be a fundamental part of the
product-stewardship program, incorporated into each phase of product
development and commercialization. Key elements of the risk-management
process include: identifying every potential source of harm (hazard);
assessing the probability of occurrence of that harm (exposure); assessing
the risk, if any, resulting from the potential combination of hazard and
exposure; and the development of alternatives for the minimization and
management of the assessed risks.
• For products of agricultural biotechnology, the risks and risk-management
alternatives must be evaluated in the context of factors such as health,
safety, and environmental and agricultural impacts; regulatory acceptance;
public acceptance; market acceptance; and civil liability. Prior to
commercialization of any new plant-biotechnology product, the developer
would conduct a full, science-based risk assessment to identify and, to the
extent possible, quantify every risk presented. Each risk would be reviewed
in all relevant contexts and an appropriate management plan would be
established, including an effective strategy to mitigate any risk that
becomes a reality.
• Regulatory oversight and industry stewardship of crop-biotechnology
products, both pre-market and post-market, have occurred notwithstand-
ing the fact that new conventionally bred varieties of food, feed, and fiber
crops receive virtually no governmental oversight in the United States or
any other nation. Moreover, the National Academy of Sciences (NAS) has
repeatedly held—most recently in an April 2000 report on pest-protected
plants—that being a product of biotechnology does not make a plant
hazardous. Specifically, the NAS has found: (1) no evidence that unique
hazards exist either in the use of rDNA techniques or the movement of
genes between unrelated organisms; (2) that the risks associated with the
introduction of rDNA engineered organisms are the same in kind as those
associated with the introduction of unmodified organisms and organisms
modified by other methods; and (3) that assessment of the risks of
introducing rDNA-engineered organisms into the environment should be
based on the nature of the organism and the environment into which it is
introduced, not on the method by which it was produced.
• Rigorous, science-based safety assessments must be conducted for each
new product or product category, first by the product developers and then
by agency scientists. Conditions carefully tailored to address identified
risks should be placed on approvals where warranted, and approvals
should always be subject to review based on new data and information
from any credible source.
• It is the very nature of oversight of a rapidly developing technology that
regulation and stewardship must be dynamic processes, always subject to
reevaluation and modification based on new information and understand-
ing.
• Proactive product stewardship together with strong regulatory oversight
will be critical to the minimization of liability and, ultimately, to domestic
and global acceptance of products of modern biotechnology.
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The mock debate was presented to introduce the theme and structure of the
upcoming workshop sessions to the assembly of NABC 2001 attendees. The
participants were:
• Moderator, Ralph Hardy, NABC President
• The affirmative team, both portrayed by Mary Ann Smith
— Professor Norton, land grant university faculty member and proponent
of GM technology,
— Ms. Braun, corporate representative for a major biotech firm, and
proponent of GM technology
• The negative team, both portrayed by Colin Scanes
— An incognito aristocratic English gentleman/organic farmer, and
opponent of GM technology
— Damon Proudon, founder of an anti-technology activist group, and
opponent of GM technology
Appendix I
Script for the Mock Debate
MARY ANN LILA SMITH
University of Illinois,
Urbana, IL
COLIN SCANES
Iowa State University,
Ames, IA
Moderator: Good morning. I am Ralph Hardy, President of the NABC, and I
will be acting as the moderator this morning for a brief mock debate that will
set the scene for the workshop breakout sessions to follow.
Let me make the following disclaimer before we begin: although we are, in
fact, dealing with real issues and controversies here, the following presentation
is a mock debate, between fictitious characters. Any resemblance of any of the
participants to real people, dead or alive, is purely coincidental. Let me tell you,
I cannot imagine that any of you could ever mistake any of these characters for
real people, but I just wanted to make this crystal clear.
We are gathered today to hear informed arguments on both sides of the issue
in The Great Agricultural Biotechnology Debate. The resolution is:
Be it resolved: that GM technology is a sound and safe innovation, and
should be permitted in the food chain without restrictions.
We will feature two opposing teams. Our first spokesperson is Professor
Norton, a member of the faculty at a large land grant university. She is a strong
proponent of GM technology and a long-time researcher in molecular
techniques for improvement of vegetable crops. Professor Norton will speak in
favor of the resolution.
Our first negative spokesperson this morning is a distinguished gentleman
from the United Kingdom who wishes to remain anonymous. However, I will
say that he is a part-time organic farmer, and a member of a very prominent,
upper-crust family. His Highness—excuse me, I meant to say—our anonymous
gentleman is strongly opposed to the resolution, and will give arguments why
biotechnology must not be permitted into the food chain.
Professor Norton will begin with a statement in favor of GM technology.
Professor Norton (in white lab coat, latex gloves, and safety goggles): Good
morning. As a seasoned member of the scientific community, I can tell you that
recombinant DNA techniques are nothing to be alarmed about. There is
nothing remotely dangerous about this simple, straightforward technique that
careful scientists like myself use brilliantly to improve your foods, and
contribute substantially to your quality of life! I really don’t understand what all
the fuss is about!
There seems to be a lot of confusion about agricultural biotechnology, and
I’m sure that I can help by explaining the basics of the science in simple, easy-
to-comprehend terms that will make it clear to all of you. Surely once you
realize how harmless this process is, all your fears will disappear!
Lets go to a few slides please—
Moderator: But professor, this is a formal debate, we weren’t planning on
showing slides.
Professor Norton: Pay attention, son. I’m a university professor. Of course I’m
going to show slides. If you’d just dim the lights please…
We begin with deoxyribonucleic acid, or you can call it DNA for short. In
plants and animals, genes are packaged here in chromosomes that carry the
DNA—all the genetic information.
(slide: a DNA molecule)
Quite simply, we take a valuable, good slice of DNA from one organism, and
transfer it to another organism, in order to give the wholesome qualities of one
plant to another. Let’s just say we’ve taken a valuable gene from a healthy wild
weedy plant, and use it to transform a garden vegetable or fruit. Usually we
insert the gene of interest into the new plant with a nifty little device called a
“gene gun.”
(slide: a bullet passing through an apple)
Then we go through a simple series of steps to ensure that the gene of interest
is present in the new and improved fruit or vegetable—this involves a series of
specific steps—
(slides: a series of a dozen rapid-fire, highly complex figures from molecular
genetics journals)
—I really don’t have the time to go into the specifics here—you wouldn’t
understand it anyway—just trust us. We are scientists and are trained to do
these steps flawlessly. Really very little could go wrong here. It is really quite
marvelous. And after the process is completed, the final product is a dramati-
cally improved fruit or vegetable variety for the betterment of mankind!
(slide: a truck-sized tomato)
Thank you very much.
Moderator: Thank you, professor. Next, we’ll give our incognito gentleman a
brief opportunity to question the professor’s argument: your highness?
Anonymous gentleman organic farmer (in designer suit with cravat, and with an
obvious regal bearing): Professor, I really must take issue with your statements.
There is a sacred trust between mankind and our Creator, under which we
accept a duty of stewardship for the earth! The task of growing food must not
take place in the laboratory, but must be left where it belongs, in the hands of
the Almighty helped by the traditional farmer!
Professor Norton: I assure you that the farmers are quite happy to be growing
our improved GM vegetable crops!
(slide: happy farmer with large tomato)
Smith and Scanes
Anonymous gentleman: Professor, if literally nothing is held sacred, what is
there to prevent us treating our entire world as some “great laboratory of life,”
with potentially disastrous results? We want some control over the changes you
are proposing! We want some assurance that indeed this process is safe! We
want testing, and we want labeling of genetically altered products!
Professor Norton: Well, we can’t always have just what we want, can we?
(slide: Harrison Ford)
Moderator: All right, it’s time to move on. Next, we’ll hear counter arguments
from the anonymous regal gentleman.
Anonymous gentleman: My good people, it is a very distinct pleasure to be in
this august body. I am going to speak on areas of belief and faith. I am going to
advocate a dismissal of this (disdainfully) “biotechnology.” I am greatly
distressed by this frivolous, artificial and uncontained transfer of genes between
species of plants and animals. I advocate a return to the tried and true methods
of our past.
In the area of medical biotechology, pharmaceutical companies spend vast
sums on the manufacture and testing of synthetic drug products that can yield
even vaster profits. Complementary and alternative medicine are as good as
orthodox medicine, or, even in some instances, are better.
Similarly in agriculture, the future will need people who understand that
sustainable development is not re-engineering Nature in an extension of global
industrialization, but a reconnection with Nature—re-discovery of the essential
unity and order of the living and spiritual world as in the case of organic
agriculture and integrative medicine.
I happen to believe that if a fraction of the money currently being invested in
developing genetically manipulated crops were applied to understanding and
improving traditional systems of agriculture—which have stood the all-
important test of time—results would be remarkable.
One of the most commonly raised arguments by those in favor of GMOs is
that they are necessary to feed the world. No one in their right mind would
resist a technology that would solve the world’s food shortages, if that were the
one way forward. But where people are starving, lack of food is rarely the
underlying cause. It is likely lack of money to buy food, distribution problems
or geopolitical issues.
Agricultural research stations, all over the world, have begun to concentrate
almost exclusively on biotech approaches. I can see why this is happening. To a
researcher, such work is new, it is modern, it is exciting, and it attracts lucrative
commercial sponsorship.
The best place to start looking for sustainability is in the traditional farming
systems that have stood the test of time. But, of course, they can be improved
by the application of new knowledge and modern equipment. The common
features of sustainable approaches include making the best possible use of
natural and regenerative processes and human ingenuity and teamwork.
Of course, whether sufficient surpluses can be generated to feed the teeming
millions in the world’s cities is another matter.
There is a sacred trust between mankind and our Creator, under which we
accept the duty of stewardship for the earth. I oppose the artificial and
uncontained transfer of genes between species of plants and animals. We
should show greater respect for the genius of Nature’s designs—rigorously
tested over millions of years.
In summary, I wholeheartedly advocate that we scorn and abandon this GM
technology in its entirety, and move back into a pure, wholesome, organic
method of farming.
Moderator: Next, our second affirmative speaker has a chance to briefly
question this gentleman’s arguments. Ms. Braun is, in fact, an executive in a
major commercial biotech industry. Ms. Braun, you may proceed with questions
for your opponent.
Ms. Braun (in business suit, with a briefcase and a pocket bulging with cash):
Well, I had intended to offer rebuttal comments to refute the arguments of my
obviously arrogant opponent here, but shoot—that accent of his—I couldn’t
understand half of what he said, could you? In any case, I do not believe that
his lame arguments have any real validity. They do not deserve a response. Who
is he to question what we are doing? He’s just another scientific illiterate.
I would rather just deliver my counter-arguments in favor of GMOs now, Mr.
Hardy.
Moderator: Very well. Ms. Braun will now provide rebuttal statements, and
provide additional evidence to make a case for GM adoption. Ms. Braun, please
proceed.
Ms. Braun: I would like to point out to this audience that we in the
biotechnology industry are on a mission of great consequence to help meet the
demands for food and fiber in this rapidly expanding global economy.
Our sales in the US of bioengineered crops are $200 million a year, and
growing. These products—all thoroughly and rigorously tested—are now
everywhere on your supermarket shelves.
The campaign of fear now being waged against genetic modification is based
largely on fantasy and a complete lack of respect for science and logic. Genetic
modification can reduce the chemical load in the environment, reduce the
impact on non-target species, and reduce the amount of land required for food
crops. There are so many real benefits from genetic modification, compared to
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the largely hypothetical and contrived risks, that it would be foolish to ban
genetic modification.
Farmers across the country know that the benefits of biotechnology are real
and very significant—not just for agriculture, but for consumers as well. For
example, the Bt trait provides corn and cotton crops with natural resistance to
pests that can cause tremendous damage. This in-plant protection provides a
terrific environmental benefit because it lets farmers use less pesticide and in a
more precise manner. Herbicide resistance in certain corn hybrids, and in some
varieties of cotton and soybean, gives farmers the opportunity to effectively
control weeds with fewer applications of more-benign products. These are just a
few of the reasons why American farmers strongly support continued access to
products of biotechnology, including all of those produced by our company.
This reduced use of chemicals and the fact that we now make a lot fewer trips
over our fields with equipment are big pluses for the environment. These
products also improve our efficiency tremendously. Economically and
environmentally, American farmers and consumers cannot afford to lose access
to the products of biotechnology. Those are the facts, pure and simple, in black
and white, and in dollars and cents. I am sure that my opponent will be unable
to find any way to disagree with the value biotech adds to our lives.
Moderator: And now a rebuttal and further opposition case-building from our
second negative spokesperson, Damon Proudon, who is a founding member of
an activist organization opposed to all technology and globalization.
Mr. Proudon (in tie-dyed shirt, with long, wild hair, and a placard stating Ban the
Genes): I don’t know why I’m here. I guess it’s a token gesture. The establish-
ment always plays these games. Well I can play the game as well as anyone.
I’m going to defend my position that GMOs need to be banned from this
earth. I even wrote stuff down from the web. A teacher at Hunter College in
New York described it for real:
We are rolling to ecological collapse: rapid climate change and rising
seas; ozone holes; loss of species and habitat; accelerated cancer rates;
terminal forms of air, water, and soil pollution, as well as social,
political and personal alienation and despair. All are rooted in the
excesses of technology.
In the era of economic globalization, the problems are magnified a million-
fold. All-powerful global bureaucracies, such as the World Trade Organization,
are preventing communities and nation-states from slowing the rate at which
global corporations freely exploit the planet, dominate social systems, destroy
local economies, and deploy the most powerful and dangerous technologies in
history.
Why have there been no referenda on the most dangerous technological
trends: nuclear, biotechnology, transport, the globalization of industrial
agriculture, corporate power, and global media concentration?
Ralph Nader—who spoke to this group last year during his heroic campaign
for the presidency—is very clear about biotech:
Genetic engineering has far outrun the science that must be its
governing discipline…unknowns beg for investigation, before biotech
corporations or their indentured researchers introduce unintended
hazards into the environment.
Corporate greed has eclipsed sound science and the humility and
caution that should be manifest. The result has been a rush to introduce
genetically altered seed into the environment without adequate testing; a
frenzy to patent genes, seeds and life forms and to extend monopolistic
control over the very material of life (and) to foist genetically food on
an unknowing public who would reject biotech food if notified and given
alternatives.
These genetically modified crops are such a con. Farmers have to buy seed
every year. They can’t just keep their seed. They have to buy pesticide—more
and more of it—and it gets in my food. They’ve even come up with a way of
making seeds that won’t grow. The so-called terminator technology. I call it
robbing poor farmers.
You say you’ll feed the world, but biotechnology will increase hunger as
farmers will be forced off their land or become serfs to the global ag-business
monopolies.
Genetic engineering destroys the fragile environment; look at the monarch
butterfly! I bet the scientists involved have felt pressure from the corporations!
A scientist in Scotland got kicked out for coming up with the wrong results!
Why should farmers in Africa and India be forced to buy genetically altered
seed? You get monocultures and low yields unless they buy pesticides and
artificial fertilizer from the same corporations.
I read somewhere that organic food can have much higher yields than these
GMOs and hybrids, but farmers don’t believe it because of the conspiracy
between the monopoly corporations and the government—most of whom come
out of big corporations and then go back to them with lots of money—and
those supposed universities with all their corporate dollars. “Frankenfoods” are
the result of corporate greed.
You scientists are in league with these global corporations and their
governments. You want science based policy, yet when it comes to global
warming caused by the same monopolies, what happens? I’ll tell what happens:
nothing! Kyoto scrapped! Surprised?
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Why should we have hidden genes lurking in our food? “Frankenfoods” are
being forced on us. If the “frankenfoods” are so good and safe why don’t you
label them? Give me an answer! What are you so afraid of? What are you
hiding?
Why are you experimenting with my food? Tampering—playing around? You
just can’t trust corporations who brought us global warming, nuclear power and
bombs, pesticide-laden food, and high gas prices. Again we see evidence for a
conspiracy between the multinational corporations and the government.
Moderator: We can now entertain cross-examination questions from our two
teams: Ms. Braun? Mr. Proudon?
(They throw jibes and taunts at each other and argue out of format.
Eventually the exchange ends with hotel security escorting Mr.
Proudon from the room.)
Moderator: (to the audience) This brief mock debate was intended to
demonstrate that in the raging controversy over GMOs, there are strong
positions ‘for’ and ‘against,’ but often the proponents are not on the same
wavelength and don’t address the same sets of facts or beliefs.
Our task in the workshops will be to examine the GM debate from a number
of different viewpoints. We will have the opportunity to explore the debate
arguments—those we think are valid, and those we may think are frivolous—in
greater detail, and will have the chance to thoughtfully develop arguments and
counter-arguments on the issues from the distinct perspective of a particular
camp: consumer advocate, European politician, developing country farmer,
corporate biotech spokesperson, university scientist, environmentalist,
government regulatory agency, and so on. Hopefully, no matter which side you
are asked to take, you will be able to develop arguments that are at least as
cogent as those managed by the spokepersons we just heard.
Appendix II
Partisan Assessments of Information
Concerning Genetically Modified Foods:
Preliminary Results
ALBERT C. GUNTHER AND KATHLEEN SCHMITT
University of Wisconsin
Madison, WI
The hostile-media perception—the tendency for partisans on an issue to judge
mass media coverage of that issue as hostile to their own point of view—has
been vividly demonstrated, but not well explained. This is a particularly
intriguing and important question because this perceptual bias seems to
contradict a robust literature on assimilation biases: the tendency to find
information more supportive, rather than more opposed, to one’s own position.
We attempted to verify this bias as a media effect and reconcile it with
assimilation biases by presenting identical information in both a mass-media
and a student-essay context, something no research has previously attempted.
(We also tested several processing explanations, but those tests are not
included in these results.)
Attendees at High Anxiety and Biotechnology: Who’s Buying, Who’s Not, and
Why? and attendees at an annual meeting of an organic food cooperative were
invited to take part in a survey. Responses of those who indicated that they
held a strongly partisan position—either as GM-food proponents (some of the
participants at NABC meeting) or as GM-food opponents (at the organic food
cooperative meeting)—were selected for analysis (N=153).
Participants were randomly assigned to read identical information presented
as either a news article or a college student’s essay. They answered a question-
naire about their perceptions of bias in the article/essay: whether the article/
essay was
• biased in its portrayal of GM foods,
• biased in portrayals of supporters or opponents of GM foods,
• biased in the percentage of favorable vs. unfavorable content,
and whether the author was personally biased.
We found that partisans on opposing sides of the issue generally saw the
same information as disagreeably biased in a news-story format, but as neutral
or even favorably biased in the student-essay format. In addition, there was
suggestive evidence that the media aspect of the hostile-media perception can
be explained by the perceived reach of the information source.
The data will be published in full elsewhere.
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